STRATEGY TO ACTION
A N N U A L R E P O R T 2 0 2 2
A MESSAGE FROM THE CHAIRMAN OF THE BOARD AND CHIEF EXECUTIVE OFFICER
To My Fellow Stakeholders,
Accelerating BOLD+1
In 2022, we were pleased to celebrate Henry Schein’s
90th anniversary, a milestone that we do not take for
granted. Most companies, full of energy and enthusiasm
at their founding, do not endure to see such a momentous
occasion. We are humbled and inspired to have done so.
Many companies fade away because they run out of ideas.
That is not the case at Henry Schein. We have a history
of transformation that is brought to life in a new strategic
plan every three years. We are brimming with ideas and
opportunities for growth, as reflected in the 2022–2024
BOLD+1 Strategic Plan we unveiled last year. Our challenge
now — and it’s the kind of challenge we live for — is to put
the best ideas into action. That was the work of 2022 and
the theme of this year’s report, Strategy to Action.
The 2022–2024 strategic plan, as a brief reminder, is as
follows: BOLD+1 means building complementary software,
specialty, and services businesses for high growth;
operationalizing our One Distribution approach to deliver
exceptional customer experience, increased efficiency,
and growth; leveraging all the businesses and solutions
that comprise Henry Schein to broaden and deepen
relationships with our customers; and driving digital
transformation for our customers and for Henry Schein. In
doing so, we help our customers operate more effectively
and efficiently while generating value for all stakeholders
— that’s the +1. Together, we make the world healthier.
BUILD
E
G
A
R
E
V
E
L
DRIVE
DIGITAL
It’s not enough, of course, to have a great plan, as we do.
The magic is in the tactical execution. To that end, our
Company took a series of actions in 2022 to accelerate the
plan’s implementation.
DRIVE
BUILD
DIGITAL
E
G
A
R
E
V
E
L
We created a Global Customer Experience Organization
that is focused on further driving an exceptional customer
experience across all of the Company’s sales channels
as well as our global brand marketing strategy, including
the Henry Schein corporate brand. This function is led by
Trinh Clark, who was named Senior Vice President and
Chief Global Customer Experience Officer. We also created
a Global eCommerce Transformation Organization that
will focus on accelerating the adoption of digital
commerce technologies across our Company, driving the
transformation of our business strategy and operations
using digital technology, and enabling the rapid growth of
digital sales revenue for the organization. This group is led
by Leigh Benowitz, who was named Senior Vice President
and Chief Global Digital Transformation Officer. Both
Ms. Clark and Ms. Benowitz were appointed to our
Company’s Executive Management Committee as a
demonstration of the strategic importance of this work.
In addition, Mark Hillebrandt was named Vice President
and Chief Digital Revenue Officer, leading the Company’s
new Digital Revenue Team in support of our strategic plan.
The Digital Revenue Team will be responsible for engaging
customers online to drive digital transactions while also
securing a significant pipeline of digitally sourced leads
and new prospects to be delivered to the Company’s
sales organization.
3
2022 was a very good year in which we continued to
effectively execute on our strategy and achieved our
financial goals despite unanticipated macroeconomic and
foreign exchange headwinds. This is not only a testament
to our plan but also to our ability to execute on the strategy.
We recorded net sales in 2022 of $12.6 billion, up from
$12.4 billion in 2021, despite sales declines in personal
protective equipment (PPE), reflecting lower prices for
gloves and lower demand for COVID-19 test kits. Excluding
PPE and COVID-19 test kits, our internal sales in local
currencies grew 5%. Non-GAAP diluted EPS for 2022
increased $0.33, or an increase of 6.5%*. Henry Schein
delivered full-year operating cash flow from continuing
operations of $602 million versus $710 million in 2021,
of which we invested $158 million in acquisitions and
$485 million in stock repurchases.
* GAAP diluted EPS for 2022 decreased $0.54, a decrease of 12.1%.
See reconciliation of GAAP and non-GAAP measures on page 9.
OPERATIONALIZEOPERATIONALIZE As part of the effort to operationalize our One Distribution
initiative, Dirk Benson joined Henry Schein as Vice
President and Chief Commercial Officer of our North
America Distribution Group. In this new position,
Mr. Benson will play a key role in further integrating the
management of Henry Schein’s North America distribution
businesses while fully leveraging the functions, talent,
processes, and systems of those businesses to enhance
the customer experience and maximize efficiency
and performance. One example of this work was the
creation last year of the North America Strategic Account
management team, which extends our success serving
large medical accounts into the dental market, where large
group practices are becoming increasingly prevalent. We
are also pursuing the benefits of tighter integration of our
distribution business outside of North America under the
leadership of Andrea Albertini, who was named CEO of
our International Distribution Group.
Supporting all of this work is an enhanced effort to
streamline the collection and aggregation of data, led
by Sara Dillon, who joined the Company in 2022 in the
newly created role of Chief Data Officer. Ms. Dillon is
responsible for organizing, capturing, and processing the
vast amounts of data that Henry Schein gathers across its
businesses globally to provide insights and solutions for
the Company and our customers.
Beyond these organizational changes, our Company
advanced last year a number of imperatives that
are essential to our continued success, including
strengthening our dental market position by utilizing our
One Schein sales approach, through which we leverage
our wide range of offerings to provide customers all they
need; advancing our One Distribution effort by acquiring
and integrating Midway Dental Supply, a full-service dental
distributor that bolstered our presence among dental
offices and dental laboratories across the Midwestern
United States; and readying for launch in 2023 our new
Global E-Commerce Platform (GEP).
Adopting Enabling Technologies
As we noted at the outset of this report, we are
brimming with ideas. Of the many ideas we pursued in
2022, two stand out in particular — the incorporation
of artificial intelligence for greater clinical support into
Dentrix, our leading practice management software,
and the announcement of a definitive agreement with
the shareholders of Biotech Dental S.A.S. to acquire a
majority ownership stake in a rapidly growing provider of
innovative clinical software, oral surgery and orthodontic
products based in Salon-de-Provence, France. These
two actions fulfill two critical strategic imperatives—
building complementary software, specialty, and
services businesses for high growth, and driving digital
transformation for our customers and for Henry Schein.
4
The promise of artificial intelligence became more real in
2022 as many companies began to understand the utility
of this revolutionary technology. In our case, through our
Henry Schein One software subsidiary, we introduced
Dentrix Detect AI™, powered and manufactured by
VideaHealth, a leading dental AI platform. The technology
is an AI-enabled X-ray analysis tool that integrates directly
into Dentrix® practice management systems to provide
real-time clinical decision support to dentists. Every
X-ray image is automatically analyzed in the software,
helping dentists more quickly identify and localize caries.
As a result, dentists can provide greater transparency to
patients, making treatment recommendations chairside
and helping to improve case acceptance.
The partnership between Henry Schein and Biotech
Dental represents another step in the journey to bring
the latest technology to customers. Biotech Dental has a
full line of high-quality software, products, and services,
including dental prostheses, clear aligners, dental
implants, regenerative solutions, and biomaterials. Of
particular note are several important software solutions
from Biotech Dental, including a product named Nemotec,
which is an integrated suite of planning and diagnostic
software using open architecture that connects disparate
devices to create a comprehensive digital view of
the patient’s oral health condition. This offers greater
diagnostic accuracy and an improved patient experience.
By integrating Nemotec with Dentrix, and making the
open-architecture clinical workflow a simple, end-to-end
solution, we expect to provide multiple positive benefits
to our customers, including greater efficiency and
productivity.
Biotech Dental is also one of the fastest-growing implant
and custom abutment brands in France, as well as the
manufacturer of the Smilers® brand of clear aligners.
In addition, Biotech Dental has launched LaGalaxy®, a
comprehensive, open, and secure software platform
where both clinical and administrative tasks can be
performed. Within a single platform, dentists and
dental laboratories benefit from end-to-end integrated
digital solutions that help improve case outcomes while
speeding up treatment time, shortening case completion,
and lowering the costs of implants, and orthodontic and
prosthetic treatments.
We expect our business development activity to continue
to contribute to a portfolio that we call Dental Specialty
Products, which encompasses oral surgery, implant and
bone regeneration products; endodontic and orthodontic
products; and our Technology & Value-Added Services
business, including Henry Schein One, a leading provider of
integrated software and services to the dental profession.
Progress on ESG Disclosures
2022 marked another milestone in the history of
Henry Schein, when our Company issued a series of
inaugural disclosures related to Environment, Social, and
Governance metrics. As part of the Company’s work to
enhance its ESG transparency, Henry Schein reported for
the first time on its sustainability efforts in accordance
with Sustainability Accounting Standards Board and
Global Reporting Initiative Standards. The Company
also issued its first Task Force on Climate-Related
Financial Disclosures Report, outlining Henry Schein’s
governance and related strategies to address climate
risks and opportunities. Among other work highlighted
in the Report, Henry Schein took the following steps to
strengthen its ESG commitment:
• Expanded our Team Schein Values to include a value
specific to Diversity and Inclusion as a testament to
our inclusive culture and commitment to D&I. We also
continue to expand our Employee Resource Groups
(ERGs), which serve as cultural drivers and played a
particularly important role in connecting our teams
across the globe during the pandemic and times
of social unrest. We continue to be committed to
significantly increasing the representation of women
in senior leadership during the coming decade, and in
2022 we expanded this commitment with an enhanced
focus on increasing the diversity of all underrepresented
groups in senior leadership at the manager-level and
above roles.
• Continued to launch new Employee Resource Groups
for Team Schein Members, including the elevASIAN
ERG for Pan-Asian Team Schein Members, and the
VET — Veterans Engagement Team ERG for those who
have served or are current serving in the military. We
announced last year, and will complete this year, the
formation of our seventh ERG, which is focused on
individuals with disabilities and their allies. As with
every ERG, membership is open to all TSMs. We also
ensured that our board members are directly engaged
with the activity of our ERGs.
• Signed the Business Ambition for 1.5°C Initiative,
committing to set science-based targets to guide the
pathway seeking to achieve net-zero emissions by
2050, and joined the World Economic Forum Alliance
of CEO Climate Leaders and the National Academy of
Medicine Action Collaborative on Decarbonization of
the Health Care Sector.
• Furthered our mission to support the equitable
distribution of health care services to underserved
and underrepresented populations by donating more
than $21.5 million in health care product and cash
in 2021 through Henry Schein Cares and the Henry
Schein Cares Foundation, Inc., thereby advancing the
Company’s five-year, $50 million commitment to health
equity announced last year.
Our commitment to the success of our stakeholders
— our customers, TSMs, supplier partners, shareholders,
and society at large — has long been the foundation of
our purpose-driven approach to corporate citizenship and
commercial engagement, and continues to inform our
bold efforts to create a healthier world.
People and Performance
In a year of milestones, Henry Schein also experienced
notable changes in corporate executive leadership that
reflect the effectiveness of our succession planning. At
the end of April 2022, Steven Paladino retired as Chief
Financial Officer after 35 years of dedicated service at
Henry Schein, including 29 years as CFO. During his
tenure, our sales have grown at a compound annual rate of
approximately 12.5% since Henry Schein became a public
company in 1995. Mr. Paladino’s many accomplishments
included the building of an exceptional team, which is
now led by Ronald N. South, our new CFO. Mr. South,
who joined Henry Schein in 2008 and had been our
Chief Accounting Officer, was succeeded in that role by
Olga Timoshkina, who joined the Company in 2021. The
leadership of our financial team includes Graham Stanley,
Vice President, Investor Relations and Strategic Financial
Project Officer, and Pete Tawadros, Vice President, Global
Financial Planning, Treasury and Analysis.
In July, Gerald A. Benjamin retired as Executive Vice
President and Chief Administrative Officer, after 34 years
with the Company. Mr. Benjamin, who also retired from
our Board of Directors, was responsible for developing
and expanding the Company’s world-class supply chain
system as well as serving as the steward of our “Team
Schein” culture. His work contributed immeasurably to
the success of the Company. Mr. Benjamin was succeeded
by Michael S. Ettinger, who was promoted to the role of
Executive Vice President and Chief Operating Officer.
Mr. Ettinger joined Henry Schein in 1994 and has served
as Senior Vice President, Corporate & Legal Affairs
5
and Secretary and Chief of Staff. As Chief Operating
Officer, he oversees the Office of the CEO, including
Henry Schein Cares, the Company’s global corporate
social responsibility program, along with the Company’s
corporate affairs, corporate communications, legal,
compliance and regulatory, global human resources,
global security, global supply chain, and information
technology functions.
I would also like to take this opportunity to note the
tragic passing in August 2022 of E. Dianne Rekow, DDS,
Ph.D., a member of the Company’s Board of Directors
since 2014 and a pioneer in the development of digital
dentistry. Dianne was an extraordinary board member
and an internationally known authority on aesthetic and
restorative dentistry whose contributions to our board
have been many and impactful, including serving as a
member of our Strategic Advisory Committee. We will
miss her probing spirit, expertise, and camaraderie.
This has been a momentous year for Henry Schein,
and we look forward to an exciting future, driven by
the exceptional individuals of Team Schein. Along with
the entire Henry Schein Board of Directors, I extend
my sincerest thanks to Team Schein Members for their
dedication and hard work. It is because of Team Schein
that I remain confident in Henry Schein’s future and in
our ability to deliver on our commitments to customers,
supplier partners, and investors. We look forward to
rewarding you yet again for your faith and trust in us.
Sincerely,
Stanley M. Bergman
Chairman of the Board and Chief Executive Officer
March 2023
Forward-looking statements made in this report are subject to
the risks specified in the Safe Harbor statement in the Company’s
Form 10-K filing and forward-looking statement language in our
press release filed on Form 8-K on February 16, 2023.
COMMON STOCK
FORM 10-K
LEGAL COUNSEL
Henry Schein Common Stock trades
on the Nasdaq® Stock Market under
Our Annual Report on Form 10-K for the
fiscal year ended December 31, 2022 has
Proskauer Rose LLP
Eleven Times Square,
the symbol “HSIC.”
been filed with the SEC and is available
New York, New York 10036
STOCKHOLDER REPORTS
AND INVESTOR INQUIRIES
For stockholder inquiries,
including requests for quarterly
and annual reports, contact our
Investor Relations department at
(631) 843-5500, or e-mail your request
to investor@henryschein.com.
Printed materials can also be
requested through the
Company’s Website.
free of charge through our Internet
Website, www.henryschein.com.
Stockholders may also obtain
a copy of the Form 10-K
upon request via email at
investor@henryschein.com.
In response to such request, the
Company will furnish without charge
the Form 10-K, including financial
statements, financial schedules,
and a list of exhibits.
INDEPENDENT AUDITORS
BDO USA, LLP
100 Park Avenue,
New York, New York 10017
STOCK TRANSFER AGENT
For address changes, account
cancellation, registration changes,
and lost stock certificates, please
contact:
Continental Stock
Transfer & Trust Company
1 State Street, 30th Floor
New York, New York 10004
(212) 509-4000
6
BOARD OF DIRECTORS
Stanley M. Bergman
Chairman of the Board
and Chief
Executive Officer
Mohamad Ali
Chief Executive Officer
of IDG, Inc.
James P. Breslawski
Vice Chairman of the
Board and President
Deborah Derby
Former President,
Horizon Group USA, Inc.
Joseph L. Herring
Former Chief Executive
Officer, Covance Inc.
Kurt P. Kuehn
Former Chief Financial
Officer, United Parcel
Service, Inc.
Philip A. Laskawy
Lead Director, Henry
Schein, Inc.; and Retired
Chairman, Ernst & Young,
LLP (now known as EY LLP)
Anne H. Margulies
Former Vice President
and Chief Information
Officer, Harvard
University
Mark E. Mlotek
Executive Vice President,
Chief Strategic Officer
Steven Paladino
Former Executive Vice
President, Chief Financial
Officer, Henry Schein, Inc.
Carol Raphael
National Advisor, Manatt
Health Solutions;
and Former President and
Chief Executive Officer,
Visiting Nurse Service
of New York
Scott Serota
Former President and
Chief Executive Officer
of Blue Cross Blue
Shield Association
Bradley T. Sheares, Ph.D.
Former Chief Executive
Officer, Reliant
Pharmaceuticals, Inc.;
and Former President
of U.S. Human Health,
Merck & Co.
Reed V. Tuckson,
M.D., FACP
Managing Director
of Tuckson Health
Connections, LLC;
and Founder, Black
Coalition Against COVID-19
7
EXECUTIVE MANAGEMENT
Stanley M. Bergman*
Chairman of the Board
and Chief
Executive Officer
Andrea Albertini
Chief Executive Officer,
International
Distribution Group
Leigh Benowitz
Senior Vice President,
Chief Global Digital
Transformation Officer
James P. Breslawski*
Vice Chairman of the
Board and President
David Brous*
Chief Executive Officer,
Strategic Business Group
Trinh Clark
Senior Vice President,
Chief Global Customer
Experience Officer
Brad Connett*
Chief Executive Officer,
North America
Distribution Group
Michael S. Ettinger*
Executive Vice President,
Chief Operating Officer
Lorelei McGlynn*
Senior Vice President,
Chief Human
Resources Officer
Mark E. Mlotek*
Executive Vice President,
Chief Strategic Officer
James Mullins
Senior Vice President,
Global Supply Chain
Kelly Murphy
Senior Vice President,
General Counsel
Christopher Pendergast
Senior Vice President,
Chief Technology Officer
Michael Racioppi
Senior Vice President,
Chief Merchandising
Officer
Walter Siegel*
Senior Vice President,
Chief Legal Officer
Ronald N. South*
Senior Vice President,
Chief Financial Officer
René Willi, Ph.D.
Chief Executive Officer,
Global Oral
Reconstruction Group
8
*Executive Officers
NON-GAAP DISCLOSURES
The following table sets forth, for the applicable periods, a reconciliation of operating
income and net income from continuing operations attributable to Henry Schein, Inc.,
and diluted earnings per share from continuing operations presented following
generally accepted accounting principles in the United States (“GAAP”) to these
measures adjusted to reflect the effects of restructuring costs, impairment of
intangible assets, acquisition intangible amortization and other adjustments.
USE OF NON-GAAP MEASURES
The information in the table includes financial measures that are not calculated and
presented in accordance with GAAP. The table reconciles differences between each of
operating income from continuing operations, net income from continuing operations
attributable to Henry Schein, Inc., and diluted earnings per share from continuing
operations attributable to Henry Schein, Inc., each as presented in accordance with
GAAP, and comparable non-GAAP amounts.
We eliminated the effect of the items listed below to assist in evaluating the
underlying operational performance of our business, excluding such costs, over the
periods presented. Management believes that non-GAAP financial measures provide
investors with useful supplemental information about the financial performance
of our business, enable comparison of financial results between periods where
certain items may vary independent of business performance and allow for greater
transparency with respect to key metrics used by management in operating our
business. These non-GAAP financial measures are presented solely for informational
and comparative purposes and should not be regarded as a replacement for
corresponding, similarly captioned, GAAP measures.
NOTES
(1) During 2022, we recorded restructuring and integration costs of $131 million, pre-
tax ($103 million net of tax and noncontrolling interests). During 2021, we recorded
restructuring costs of $8 million, pre-tax ($5 million net of tax and noncontrolling
interests). During 2020, we recorded restructuring costs of $32 million pre-tax ($24
million net of tax and noncontrolling interests). The effect that these charges had
on 2022, 2021, and 2020 earnings per diluted share from continuing operations
attributable to Henry Schein, Inc. was ($0.74), ($0.03), and ($0.17), respectively.
(2) During 2021, we recorded a pre-tax charge of $16 million, net of $1 million of
noncontrolling interests, related to settlement and litigation costs, net of a tax
benefit of $4 million, resulting in a net after-tax charge of $11 million. The effect that
this charge had on earnings per diluted share from continuing operations attributed
to Henry Schein, Inc. was ($0.08).
(3) During 2022, 2021, and 2020, we recorded impairment charges on certain
intangible assets of $34 million, pre-tax ($23 million net of tax and noncontrolling
interests), $1 million, pre-tax ($0 million net of tax and noncontrolling interests) and
$20 million, pre-tax ($11 million, net of tax and noncontrolling interests), respectively.
The effect that these charges had on 2022, 2021, and 2020 earnings per diluted
share from continuing operations attributable to Henry Schein, Inc. was ($0.16),
($0.00), and ($0.08), respectively.
(4) During 2021 and 2020, we received contingent proceeds of $10 million and $2
million, respectively from the 2019 sale of Hu-Friedy resulting in the recognition of
an additional after-tax gain of $7 million and $2 million respectively. The effect that
these transactions had on 2021 and 2020 earnings per diluted share from continuing
operations attributable to Henry Schein, Inc. was $0.05 and $0.01, respectively.
(5) During 2022, 2021, and 2020, we recorded amortization expense from acquired
intangible assets of $126 million, pre-tax ($78 million net of tax and noncontrolling
interests), $123 million, pre-tax ($76 million net of tax and noncontrolling interests)
and $102 million, pre-tax ($69 million net of tax and noncontrolling interests),
respectively. The effect that these charges had on 2022, 2021, and 2020 earnings per
diluted share from continuing operations attributable to Henry Schein, Inc. was ($0.57),
($0.54), and ($0.48), respectively.
Year Ended
December 31,
2022
Year Ended
December 26,
2021
Year Ended
December 28,
2020
(in millions, except per share data)
Operating income from continuing operations (GAAP) $
Operating margin from continuing operations (GAAP)
747
5.9%
$
Non-GAAP Adjustments:
Restructuring and integration costs (1)
Litigation settlements (2)
Impairment of intangible assets (3)
Acquisition intangible amortization (5)
Adjusted operating income
from continuing operations (Non-GAAP)
Adjusted operating margin
from continuing operations (Non-GAAP)
Net income from continuing operations attributable
to Henry Schein, Inc. (GAAP)
Adjustments, net of tax and attribution
to noncontrolling interests:
Restructuring and integration costs (1)
Litigation settlements (2)
Impairment of intangible assets (3)
Gain on sale of equity investments (4)
Acquisition intangible amortization (5)
Adjusted net income from continuing operations
attributable to Henry Schein, Inc. (Non-GAAP)
Diluted earnings per share from continuing operations
attributable to Henry Schein, Inc. (GAAP)
Diluted earnings per share from continuing operations
attributable to Henry Schein, Inc. (Non-GAAP)
Diluted weighted-average
common shares outstanding
Note: Amounts may not sum due to rounding.
$
$
$
$
$
$
$
$
$
$
$
$
$
$
131
--
34
126
1,038
8.2%
538
103
--
23
--
78
741
3.91
5.38
$
$
$
$
$
$
$
$
$
$
$
$
$
$
852
6.9%
8
16
1
123
999
8.1%
631
5
11
--
(7)
76
716
4.45
5.05
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
535
5.3%
32
--
20
102
690
6.8%
403
24
--
11
(2)
69
505
2.81
3.52
137,756
141,773
143,404
9
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2022
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____________ to ____________
Commission file number 0-27078
HENRY SCHEIN, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
11-3136595
(I.R.S. Employer Identification No.)
135 Duryea Road
Melville, New York
(Address of principal executive offices)
11747
(Zip Code)
(631) 843-5500
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Trading Symbol(s)
HSIC
Securities registered pursuant to Section 12(g) of the Act: None
Title of each class
Common Stock, par value $.01 per share
Name of each exchange on which registered
The Nasdaq Global Select Market
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
YES: ☒ NO: ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
YES: ☐ NO: ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
YES: ☒ NO: ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
YES: ☒ NO: ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an
emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company”
in Rule 12b-2 of the Exchange Act.
Large accelerated filer: ☒ Accelerated filer: ☐ Non-accelerated filer: ☐
Emerging growth company: ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal
control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared
or issued its audit report. YES: ☒ NO: ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the
filing reflect the correction of an error to previously issued financial statements. ☐
Smaller reporting company: ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received
by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES: ☐ NO: ☒
The aggregate market value of the registrant’s voting stock held by non-affiliates of the registrant, computed by reference to the closing sales price as
quoted on the Nasdaq Global Select Market on June 25, 2022, was approximately $10,463,590,000.
As of February 7, 2023, there were 131,283,515 shares of registrant’s Common Stock, par value $.01 per share, outstanding.
Portions of the Registrant’s definitive proxy statement to be filed pursuant to Regulation 14A not later than 120 days after the end of the fiscal year
(December 31, 2022) are incorporated by reference in Part III hereof.
Documents Incorporated by Reference:
TABLE OF CONTENTS
PART I
ITEM 1.
ITEM 1A.
ITEM 1B.
ITEM 2.
ITEM 3.
ITEM 4.
Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures
PART II
ITEM 5.
Market for Registrant's Common Equity, Related Stockholder Matters
ITEM 6.
ITEM 7.
and Issuer Purchases of Equity Securities
[Reserved]
Management's Discussion and Analysis of Financial Condition
and Results of Operations
ITEM 7A.
ITEM 8.
ITEM 9.
Quantitative and Qualitative Disclosures About Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting
and Financial Disclosure
ITEM 9A.
ITEM 9B.
ITEM 9C.
Controls and Procedures
Other Information
Disclosure Regarding Foreign Jurisdictions that Prevent Inspection
PART III
ITEM 10.
ITEM 11.
ITEM 12.
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management
and Related Stockholder Matters
ITEM 13.
ITEM 14.
Certain Relationships and Related Transactions, and Director Independence
Principal Accounting Fees and Services
PART IV
ITEM 15.
ITEM 16.
Exhibits and Financial Statement Schedules
Form 10-K Summary
Signatures
Page
Number
3
25
40
40
40
40
41
42
43
58
60
116
116
118
118
118
118
119
119
119
119
127
128
2
ITEM 1. Business
General
PART I
Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and
technology. We believe we are the world’s largest provider of health care products and services primarily to office-
based dental and medical practitioners, as well as alternate sites of care. Our philosophy is grounded in our
commitment to help customers operate a more efficient and successful business so the practitioner can provide
better clinical care.
With more than 90 years of experience distributing health care products, we have built a vast set of small, mid-sized
and large customers in the dental and medical markets, serving more than one million customers worldwide across
dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government,
institutional health care clinics and other alternate care clinics.
We are headquartered in Melville, New York and employ more than 22,000 people. Approximately 50% of our
workforce is based in the United States and approximately 50% is based outside of the United States. We have
operations or affiliates in 32 countries and territories. Our broad global footprint has evolved over time through our
organic success as well as through contribution from strategic acquisitions.
We offer a comprehensive selection of more than 300,000 branded products and Henry Schein corporate brand
products through our distribution centers. Our infrastructure, including over 3.8 million square feet of space in 29
strategically located distribution and 19 manufacturing facilities around the world, enables us to historically provide
rapid and accurate order fulfillment, better serve our customers and increase our operating efficiency. This
infrastructure, together with broad product and service offerings at competitive prices, and a strong commitment to
customer service, enables us to be a single source of supply for our customers’ needs.
We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and
value-added services. These segments offer different products and services to the same customer base. Our dental
businesses serve office-based dental practitioners, dental laboratories, schools, government and other
institutions. Our medical businesses serve physician offices, urgent care centers, ambulatory care sites, emergency
medical technicians, dialysis centers, home health, federal and state governments and large enterprises, such as
group practices and integrated delivery networks, among other providers across a wide range of specialties.
The health care distribution reportable segment, combining our global dental and medical businesses, distributes
consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded
and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic
and endodontic products), diagnostic tests, infection-control products, personal protective equipment products
(“PPE”) and vitamins. While our primary go-to-market strategy is in our capacity as a distributor, we also market
and sell under our own corporate brand portfolio of cost-effective, high-quality consumable merchandise products,
and manufacture certain dental specialty products in the areas of oral surgery, implants, orthodontics and
endodontics.
The technology and value-added services reportable segment provides software, technology and other value-added
services to health care practitioners. Henry Schein One, the largest contributor of sales to this category, offers
dental practice management solutions for dental and medical practitioners. In addition, we offer dentists and
physicians a broad suite of electronic health records, patient communication services including electronic marketing
and web-site design, analytics and patient demand generation. Finally, our value-added practice solutions include
practice consultancy, education, integrated revenue cycle management and the facilitation of financial service
offerings (on a non-recourse basis) to help dentists and physicians operate and expand their business operations.
We believe our hands-on consultative approach to provide solutions to support practice decision-making is a key
differentiator for our business.
3
Recent Developments
See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Recent
Developments” herein for a discussion related to the COVID-19 pandemic and recent corporate transactions.
Industry
The global health care distribution industry, as it relates to office-based health care practitioners, is fragmented and
diverse. The industry ranges from sole practitioners working out of relatively small offices to mid-sized and large
group practices ranging in size from a few practitioners to several hundred practices owned or operated by dental
support organizations (DSOs), medical group purchasing organizations (GPOs), hospital systems or integrated
delivery networks (IDNs).
Due in part to the limited capacity of office-based health care practitioners to store and manage large quantities of
supplies in their offices, the distribution of health care supplies and small equipment to office-based health care
practitioners has been characterized by frequent, small quantity orders, and a need for rapid, reliable and
substantially complete order fulfillment. The purchasing decisions within an office-based health care practice are
typically made by the practitioner, hygienist or office manager. Supplies and small equipment are generally
purchased from more than one distributor, with one generally serving as the primary supplier.
The health care distribution industry continues to experience growth due to demand driven by the aging population,
increased health care awareness and the importance of preventative care, an increasing understanding of the
connection between good oral health and overall health, improved access to care globally, the proliferation of
medical technology and testing, new pharmacology treatments and expanded third-party insurance coverage,
partially offset by the effects of unemployment on insurance coverage and technological improvements, including
the advancement of software and services, prosthetic solutions and telemedicine. In addition, the non-acute market
continues to benefit from the shift of procedures and diagnostic testing from acute care settings to alternate-care
sites, particularly physicians’ offices and ambulatory surgery centers.
We believe that consolidation within the industry will continue to result in a number of distributors, particularly
those with limited financial, operating and marketing resources, seeking to combine with larger companies that can
provide growth opportunities. This consolidation also may continue to result in distributors seeking to acquire
companies that can enhance their current product and service offerings or provide opportunities to serve a broader
customer base.
In addition, customer consolidation will likely lead to multiple locations under common management and the
movement of more procedures from the hospital setting to the physician or alternate care setting as the health care
industry is increasingly focused on efficiency and cost containment. This trend has benefited distributors capable
of providing a broad array of products and services at low prices. It also has accelerated the growth of health
maintenance organizations (“HMOs”), group practices, other managed care accounts and collective buying groups,
which, in addition to their emphasis on obtaining products at competitive prices, tend to favor distributors capable
of providing specialized management information support. We believe that the trend towards cost containment has
the potential to favorably affect demand for technology solutions, including software, which can enhance the
efficiency and facilitation of practice management.
Competition
The distribution and manufacture of health care supplies and equipment is highly competitive. Many of the health
care products we sell are available to our customers from a number of suppliers. In addition, our competitors could
obtain exclusive rights from manufacturers to market particular products. Manufacturers also could seek to sell
directly to end-users, and thereby eliminate or reduce our role and that of other distributors. In certain parts of the
dental end market, such as those related to dental specialty products, and medical end market manufacturers already
sell directly to end customers.
In North America, we compete with other distributors, as well as several manufacturers, of dental and medical
products, primarily on the basis of price, breadth of product line, e-commerce capabilities, customer service and
4
value-added products and services. In the dental market, our primary competitors in the U.S. are the Patterson
Dental division of Patterson Companies, Inc. and Benco Dental Supply Company. In addition, we compete against
a number of other distributors that operate on a national, regional and local level. Our primary competitors in the
U.S. medical market, which accounts for the large majority of our global medical sales, are McKesson Corporation
and Medline Industries, Inc., which are national distributors. We also compete with a number of regional and local
medical distributors, as well as a number of manufacturers that sell directly to physicians. With regard to our dental
software, we compete against numerous companies, including the Patterson Dental division of Patterson
Companies, Inc., Carestream Health, Inc., Carestream Dental LLC, Centaur Software Development Co Pty Ltd.
(d.b.a. dental4windows, dental4web), Open Dental Software, Inc., PlanetDDS LLC, Good Methods Global Inc.
(d.b.a. CareStack) and Curve Dental, LLC. In other software end markets, including revenue cycle management,
patient relationship management and patient demand generation, we compete with companies such as Vyne
Therapeutics Inc., EDI-Health Group, Inc. (d.b.a. Dental X Change, Inc.), Weave Communications, Inc., and
Solutionreach, Inc. The medical practice management and electronic medical records market is fragmented and we
compete with numerous companies such as the NextGen division of Quality Systems, Inc., eClinicalWorks,
Allscripts Healthcare Solutions, Inc. and Epic Systems Corporation.
Outside of the U.S., we believe we are the only global distributor of supplies and equipment to dental practices and
our competitors are primarily local and regional companies. We also face significant competition internationally,
where we compete on the basis of price and customer service against several large competitors, including the
GACD Group, Proclinic SA, Lifco AB, Planmeca Oy and Billericay Dental Supply Co. Ltd., as well as a large
number of other dental and medical product distributors and manufacturers in international countries and territories
we serve.
Competitive Strengths
We have more than 90 years of experience in distributing products to health care practitioners resulting in strong
awareness of the Henry Schein® brand. Our competitive strengths include:
A focus on meeting our customers’ unique needs. We are committed to providing customized solutions to our
customers that are driven by our understanding of the end markets we serve and reflect the technology-driven
products and services best suited for their practice needs. We are committed to continuing to enhance these
offerings through organic investment in our products and our teams, as well as through the acquisition of new
products and services that may help us better serve our customers.
Direct sales and marketing expertise. Our sales and marketing efforts are designed to establish and solidify
customer relationships through personal or virtual visits by field sales representatives, frequent direct marketing and
telesales contact, emphasizing our broad product lines, including exclusive distribution agreements, competitive
prices and ease of order placement, particularly through our e-commerce platforms. The key elements of our direct
sales and marketing efforts are:
• Field sales consultants. Our field sales consultants, including equipment sales specialists, covering major
North American, European and other international markets. These consultants complement our direct
marketing and telesales efforts and enable us to better market, service and support the sale of more
sophisticated products and equipment.
• Marketing. We market to existing and prospective office-based health care providers through a
combination of owned, earned and paid digital channels, tradeshows, as well as through catalogs, flyers,
direct mail and other promotional materials. Our strategies include an emphasis on educational content
through webinars and content marketing initiatives. We continue to enhance our marketing technology to
improve our targeting capability and the relevance of messaging and offers.
• Telesales. We support our direct marketing effort with inbound and outbound telesales representatives,
who facilitate order processing, generate new sales through direct and frequent contact with customers and
stay abreast of market developments and the hundreds of new products, services and technologies
introduced each year to educate practice personnel.
5
• Electronic commerce solutions. We provide our customers and sales teams with innovative and
competitive e-commerce solutions. We continue to invest in our e-commerce platform to offer enhanced
content management so customers can more easily find the products they need and to enable an engaging
purchase experience, supported by excellent customer service.
• Social media. Our operating entities and employees engage our customers and supplier partners through
various social media platforms, which are an important element of our communications and marketing
efforts. We continue to expand our social media presence to raise awareness about issues, engage
customers beyond a sale and deliver services and solutions to specialized audiences.
Broad product and service offerings at competitive prices. We offer a broad range of products and services to our
customers, at competitive prices, in the following categories:
• Consumable supplies and equipment. We distribute consumable products, small equipment, laboratory
products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, dental
specialty products, diagnostic tests, infection-control products and vitamins. We offer over 300,000 branded
products, through our distribution centers, to our customers. We also market and sell our own corporate
brand portfolio of cost-effective, high-quality consumable merchandise products and manufacture certain
dental specialty products in the areas of implants, orthodontics and endodontics.
• Technology and other value-added products and services. We sell practice management, business
analytics, patient engagement and patient demand creation software solutions to our dental customers. Our
practice management solutions provide practitioners with electronic medical records, patient treatment
history, analytics, billing, accounts receivable analyses and management, appointment calendars, electronic
claims processing and word processing programs, network and hardware services, e-commerce and
electronic marketing services, sourcing third party patient payment plans, transition services and training
and education programs for practitioners. We also sell medical software for practice management, certified
electronic health records (“EHR”) and e-Prescribe medications and prescription solutions through
MicroMD®. We have technical representatives supporting customers using our practice management
solutions and services. As of December 31, 2022, we had an active user base of approximately 110,000
practices and 380,000 consumers, including users of AxiUm, Dentally®, Dentrix Ascend®, Dental
Vision®, Dentrix® Dental Systems, Dentrix® Enterprise, Easy Dental®, EndoVision®, Evolution® and
EXACT®, Gesden®, Jarvis Analytics™, Julie® Software, Oasis, OMSVision®, Orisline®, PBS Endo®,
PerioVision®, Power Practice® Px, PowerDent, and Viive® and subscriptions for Demandforce®, Sesame,
and Lighthouse360® for dental practices and DentalPlans.com® for dental patients; and MicroMD® for
physician practices.
• Repair services. We have over 130 equipment sales and service centers worldwide that provide a variety of
repair, installation and technical services for our health care customers. Our technicians provide
installation and repair services for: dental handpieces, dental and medical small equipment, table-top
sterilizers and large dental equipment.
• Financial services. We offer our customers solutions in operating their practices more efficiently by
providing access to a number of financial services and products provided by third party suppliers (including
non-recourse financing for equipment, technology and software products, non-recourse practice financing
for leasehold improvements, business debt consolidation and commercial real estate, non-recourse patient
financing and credit card processing) at rates that we believe are generally lower than what our customers
would be able to secure independently. We also provide staffing services, dental practice valuation and
brokerage services.
Commitment to superior customer service. We maintain a strong commitment to providing superior customer
service. We frequently monitor our customer service through customer surveys, focus groups and statistical
reports. Our customer service policy primarily focuses on:
6
• Exceptional order fulfillment. We ship an average of approximately 157,000 cartons daily. Historically,
approximately 99% of items have been shipped without back-ordering and were shipped on the same
business day the order is received. Due to supply chain disruptions during the year ended December 31,
2022, approximately 96% of items ordered were shipped without back-ordering. As supply chains continue
to stabilize, we expect our percentage of items shipped without back-ordering and shipped on the same day
to return to historical levels.
• Comprehensive ordering process. Customers may place orders 24 hours a day, 7 days a week via e-
commerce solutions, telephone, fax, e-mail and mail.
Integrated management information systems. Certain of our information systems generally allow for centralized
management of key functions, including accounts receivable, inventory, accounts payable, payroll, purchasing,
sales, order fulfillment and financial and operational reporting. These systems allow us to manage our growth,
deliver superior customer service, properly target customers, manage financial performance and monitor daily
operational statistics.
Cost-effective purchasing. We believe that cost-effective purchasing is a key element to maintaining and enhancing
our position as a competitively priced provider of health care products. We continuously evaluate our purchase
requirements and suppliers’ offerings and prices in order to obtain products at the lowest possible cost. In 2022,
our top 10 health care distribution suppliers and our single largest supplier accounted for approximately 28% and
4%, respectively, of our aggregate purchases.
Efficient distribution. We distribute our products from our 29 strategically located distribution centers. We strive
to maintain optimal inventory levels in order to satisfy customer demand for prompt delivery and complete order
fulfillment. These inventory levels are managed on a daily basis with the aid of our management information
systems. Once an order is entered, it is electronically transmitted to the distribution center nearest the customer’s
location for order fulfillment.
Products and Services
The following table sets forth the percentage of consolidated net sales by principal categories of products and
services offered through our health care distribution and technology and value-added services reportable segments:
Health care distribution:
Dental products (1)
Medical products (2)
Total health care distribution
Technology and value-added services:
Software and related products and
other value-added products (3)
Total excluding Corporate TSA net sales
Corporate TSA net sales (4)
Total
December 31,
December 25,
2022
2021
December 26,
2020
59.1 %
35.2
94.3
5.7
100.0
-
100.0
60.8 %
34.0
94.8
5.2
100.0
-
100.0
58.4 %
35.8
94.2
5.1
99.3
0.7
100.0
(1)
(2)
Includes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants,
gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, PPE products,
equipment repair and high-tech and digital restoration equipment.
Includes branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray
products, equipment, PPE products and vitamins.
(3) Consists of practice management software and other value-added products, which are distributed primarily to health care providers,
and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other
services.
(4) Corporate TSA net sales represents sales of certain products to Covetrus under the transition services agreement entered into in
connection with the Animal Health Spin-off, which ended in December 2020. See Note-23 Related Party Transactions for further
information.
7
Business Strategy
Our mission is to provide innovative, integrated health care products and services; and to be trusted advisors and
consultants to our customers - enabling them to deliver the best quality patient care and enhance their practice
management efficiency and profitability. Our BOLD+1 Strategic Plan consists of the following:
• Build (“B”) Complementary software, specialty, and services businesses for high growth
• Operationalize (“O”) One Distribution to deliver exceptional customer experience, increased efficiency,
and growth
• Leverage (“L”) One Schein to broaden and deepen relationships with our customers
• Drive (“D”) Drive digital transformation for our customers and for Henry Schein
• +1 Create Value for our stakeholders
To accomplish this, we apply our competitive strengths in executing the following strategies:
• Increase penetration of our existing customer base. We have over 1 million customers worldwide and we
intend to increase sales to our existing customer base and enhance our position as their primary supplier.
We believe our offering of a broad range of products, services and support, including software solutions
that can help drive improved workflow efficiency and patient communications for practices, coupled with
our full-service value proposition, helps us to retain and grow our customer base.
• Increase the number of customers we serve. This strategy includes increasing the productivity of our field
sales consultants and telesales team, as well as using our customer database to focus our marketing efforts
in all of our operating segments. In the dental business, we provide products and services to independent
practices, mid-market groups, and large DSOs as well as community health centers and government sites of
care. Leveraging our broad array of assets and capabilities, we offer solutions to address these new
markets. In the medical business, we have expanded to serve customers located in settings outside of the
traditional office, such as urgent care clinics, retail, occupational health and home health settings. As
settings of health care shift, we remain committed to serving these practitioners and providing them with
the products and services they need.
• Leverage our value-added products and services. We continue to increase cross-selling efforts for key
product lines utilizing a consultative selling process. In the dental business, we have significant cross-
selling opportunities between our dental software users and our dental customers. In the medical business,
we have opportunities to expand our vaccine, injectables and other pharmaceuticals sales to health care
practitioners, as well as cross-selling EHR systems and software when we sell our core products. Our
strategy extends to providing health systems, integrated delivery networks and other large group and multi-
site health care organizations, including physician clinics, these same value added products and services.
As physicians and health systems closely align, we have increased access to opportunities for cross-
marketing and selling our product and service portfolios.
• Pursue strategic acquisitions and joint ventures. Our acquisition strategy is focused on investments in
companies that add new customers and sales teams, increase our geographic footprint (whether entering a
new country, such as emerging markets, or building scale where we have already invested in businesses),
and finally, those that enable us to access new products and technologies.
Markets Served
Demographic trends indicate that our markets are growing, as an aging U.S. population is increasingly using health
care services. According to the U.S. Census Bureau’s International Database, between 2022 and 2032, the 45 and
older population is expected to grow by approximately 11%. Between 2022 and 2042, this age group is expected to
grow by approximately 21%. This compares with expected total U.S. population growth rates of approximately 6%
between 2022 and 2032 and approximately 12% between 2022 and 2042.
In the dental industry, there is predicted to be a rise in oral health care expenditures as the 45-and-older segment of
the population increases. There is increasing demand for new technologies that allow dentists to increase
8
productivity, and this is being driven in the U.S. by lower insurance reimbursement rates. At the same time, there is
an expected increase in dental insurance coverage.
In the medical market, there continues to be a migration of procedures from acute-care settings to physicians’
offices and home health settings, a trend that we believe provides additional opportunities for us. There also is the
continuing use of vaccines, injectables and other pharmaceuticals in alternate-care settings. We believe we have
established a leading position as a vaccine supplier to the office-based physician practitioner.
We support our dental and medical professionals through the many SKUs that we offer, as well as through
important value-added services, including practice management software, electronic claims processing, financial
services and continuing education, all designed to help maximize a practitioner’s efficiency.
Additionally, we seek to expand our dental full-service model and medical offerings in countries where
opportunities exist. We do this through both direct sales and by partnering with local distribution and
manufacturing companies.
For information on revenues and long-lived assets by geographic area, see Note 3 – Segment and Geographic Data
of “Notes to Consolidated Financial Statements.”
Seasonality and Other Factors Affecting Our Business and Quarterly Results
We experience fluctuations in quarterly earnings. As a result, we may fail to meet or exceed the expectations of
securities analysts and investors, which could cause our stock price to decline.
Our business is subject to seasonal and other quarterly fluctuations. Sales and profitability generally have been
higher in the third and fourth quarters due to the timing of sales of seasonal products (including influenza vaccine)
purchasing patterns of office-based health care practitioners for certain products (including equipment and
software) and year-end promotions. Sales and profitability may also be impacted by the timing of certain annual
and biennial dental tradeshows where equipment promotions are offered. In addition, some dental practices delay
equipment purchases in the U.S. until year-end due to tax incentives. We expect our historical seasonality of sales
to continue in the foreseeable future.
Governmental Regulations
We strive to be compliant in all material respects with the applicable laws, regulations and guidance described
below, and believe we have effective compliance programs and other controls in place to ensure substantial
compliance. However, compliance is not guaranteed either now or in the future, as certain laws, regulations and
guidance may be subject to varying and evolving interpretations that could affect our ability to comply, as well as
future changes, additions and enforcement approaches, including political changes. When we discover situations of
non-compliance we seek to remedy them and bring the affected area back into compliance. President Biden’s
administration (the “Biden Administration”) has indicated that it will be more aggressive in its pursuit of alleged
violations of law, and has revoked certain guidance that would have limited governmental use of informal agency
guidance to pursue potential violations, and has stated that it is more prepared to pursue individuals for corporate
law violations, including an aggressive approach to anti-corruption activities. Changes to applicable laws,
regulations and guidance described below, as well as related administrative or judicial interpretations, may require
us to update or revise our operations, services, marketing practices and compliance programs and controls, and may
impose additional and unforeseen costs on us, pose new or previously immaterial risks to us, or may otherwise have
a material adverse effect on our business.
Government
Certain of our businesses involve the distribution, manufacturing, importation, exportation, marketing and sale of,
and/or third party payment for, pharmaceuticals and/or medical devices, and in this regard, we are subject to
extensive local, state, federal and foreign governmental laws and regulations, including as applicable to our
wholesale distribution of pharmaceuticals and medical devices, manufacturing activities, and as part of our
specialty home medical supply business that distributes and sells medical equipment and supplies directly to
9
patients. Federal, state and certain foreign governments have also increased enforcement activity in the health care
sector, particularly in areas of fraud and abuse, anti-bribery and corruption, controlled substances handling, medical
device regulations and data privacy and security standards.
Government and private insurance programs fund a large portion of the total cost of medical care, and there have
been efforts to limit such private and government insurance programs, including efforts, thus far unsuccessful, to
seek repeal of the entire United States Patient Protection and Affordable Care Act, as amended by the Health Care
and Education Reconciliation Act, each enacted in March 2010 (as amended, the “ACA”). In addition, activities to
control medical costs, including laws and regulations lowering reimbursement rates for pharmaceuticals, medical
devices and/or medical treatments or services, are ongoing. Many of these laws and regulations are subject to
change and their evolving implementation may impact our operations and our financial performance.
Our businesses are generally subject to numerous laws and regulations that could impact our financial performance,
and failure to comply with such laws or regulations could have a material adverse effect on our business.
Operating, Security and Licensure Standards
Certain of our businesses are subject to local, state and federal governmental laws and regulations relating to the
distribution of pharmaceuticals and medical devices and supplies. Among the United States federal laws applicable
to us are the Controlled Substances Act, the Federal Food, Drug, and Cosmetic Act, as amended (“FDC Act”),
Section 361 of the Public Health Service Act and Section 401 of the Consolidated Appropriations Act of the Social
Security Act, as well as laws regulating the billing of and reimbursement from government programs, such as
Medicare and Medicaid, and from commercial payers. We are also subject to comparable foreign regulations.
The FDC Act, the Controlled Substances Act, their implementing regulations, and similar foreign laws generally
regulate the introduction, manufacture, advertising, marketing and promotion, sampling, pricing and
reimbursement, labeling, packaging, storage, handling, returning or recalling, reporting, and distribution of, and
record keeping for, pharmaceuticals and medical devices shipped in interstate commerce, and states may similarly
regulate such activities within the state. Furthermore, Section 361 of the Public Health Service Act, which provides
authority to prevent the introduction, transmission or spread of communicable diseases, serves as the legal basis for
the United States Food and Drug Administration’s (“FDA”) regulation of human cells, tissues and cellular and
tissue-based products, also known as “HCT/P products.”
The Federal Drug Quality and Security Act of 2013 brought about significant changes with respect to
pharmaceutical supply chain requirements. Title II of this measure, known as the Drug Supply Chain Security Act
(“DSCSA”), was first implemented in November 2014 and will be phased in over a period of ten years. DSCSA is
intended to build a national electronic, interoperable system by November 27, 2023, that will identify and trace
certain prescription drugs as they are distributed in the United States. The law’s track and trace requirements
applicable to manufacturers, wholesalers, third-party logistics providers (e.g., trading partners), repackagers and
dispensers (e.g., pharmacies) of prescription drugs took effect in January 2015, and continues to be implemented.
The DSCSA product tracing requirements replace the former FDA drug pedigree requirements and pre-empt certain
state requirements that are inconsistent with, more stringent than, or in addition to, the DSCSA requirements.
The DSCSA also establishes certain requirements for the licensing and operation of prescription drug wholesalers
and third-party logistics providers (“3PLs”), and includes the eventual creation of national wholesaler and 3PL
licenses in cases where states do not license such entities. The DSCSA requires that wholesalers and 3PLs
distribute drugs in accordance with certain standards regarding the recordkeeping, storage and handling of
prescription drugs. The DSCSA requires wholesalers and 3PLs to submit annual reports to the FDA, which include
information regarding each state where the wholesaler or 3PL is licensed, the name and address of each facility and
contact information. According to FDA guidance, states are pre-empted from imposing any licensing requirements
that are inconsistent with, less stringent than, directly related to, or covered by the standards established by federal
law in this area. Current state licensing requirements concerning wholesalers will remain in effect until the FDA
issues new regulations as directed by the DSCSA. In addition, with respect to our specialty home medical supply
business, we are subject to certain state licensure laws (including state pharmacy laws), and also certain
accreditation standards, including to qualify for reimbursement from Medicare and other third-party payers.
10
The Food and Drug Administration Amendments Act of 2007 and the Food and Drug Administration Safety and
Innovation Act of 2012 amended the FDC Act to require the FDA to promulgate regulations to implement a unique
device identification (“UDI”) system. The UDI rule phased in the implementation of the UDI regulations,
generally beginning with the highest-risk devices (i.e., Class III medical devices) and ending with the lowest-risk
devices. Most compliance dates were reached as of September 24, 2018, with a final set of requirements for low
risk devices being reached on September 24, 2022, which completed the phase in. However, in May 2021, the
FDA issued an enforcement policy stating that it does not intend to object to the use of legacy identification
numbers on device labels and packages for finished devices manufactured and labeled prior to September 24, 2023.
The UDI regulations require “labelers” to include unique device identifiers (“UDIs”), with a content and format
prescribed by the FDA and issued under a system operated by an FDA-accredited issuing agency, on the labels and
packages of medical devices (including, but not limited to, certain software that qualifies as a medical device under
FDA rules), and to directly mark certain devices with UDIs. The UDI regulations also require labelers to submit
certain information concerning UDI-labeled devices to the FDA, much of which information is publicly available
on an FDA database, the Global Unique Device Identification Database. On July 22, 2022, the FDA posted the
final guidance regarding the Global Unique Device Identification Database called Unique Device Identification
Policy Regarding Compliance Dates for Class I and Unclassified Devices, Direct Marketing, and Global Unique
Device Identification Database Requirements for Certain Devices. The UDI regulations and subsequent FDA
guidance regarding the UDI requirements provide for certain exceptions, alternatives and time extensions. For
example, the UDI regulations include a general exception for Class I devices exempt from the Quality System
Regulation (other than record-keeping requirements and complaint files). Regulated labelers include entities such
as device manufacturers, repackagers, reprocessors and relabelers that cause a device’s label to be applied or
modified, with the intent that the device will be commercially distributed without any subsequent replacement or
modification of the label and include certain of our businesses.
Under the Controlled Substances Act, as a distributor of controlled substances, we are required to obtain and renew
annually registrations for our facilities from the United States Drug Enforcement Administration (“DEA”)
permitting us to handle controlled substances. We are also subject to other statutory and regulatory requirements
relating to the storage, sale, marketing, handling, reporting, record-keeping and distribution of such drugs, in
accordance with the Controlled Substances Act and its implementing regulations, and these requirements have been
subject to heightened enforcement activity in recent times. We are subject to inspection by the DEA. Certain of
our businesses are also required to register for permits and/or licenses with, and comply with operating and security
standards of, the DEA, the FDA, the United States Department of Health and Human Services (“HHS”), and
various state boards of pharmacy, state health departments and/or comparable state agencies as well as comparable
foreign agencies, and certain accrediting bodies, depending on the type of operations and location of product
distribution, manufacturing or sale. These businesses include those that distribute, manufacture, relabel, and/or
repackage prescription pharmaceuticals and/or medical devices and/or HCT/P products, or own pharmacy
operations, or install, maintain or repair equipment.
In addition, Section 301 of the National Organ Transplant Act, and a number of comparable state laws, impose civil
and/or criminal penalties for the transfer of certain human tissue (for example, human bone products) for valuable
consideration, while generally permitting payments for the reasonable costs incurred in procuring, processing,
storing and distributing that tissue. We are also subject to foreign government regulation of such products. The
DEA, the FDA and state regulatory authorities have broad inspection and enforcement powers, including the ability
to suspend or limit the distribution of products by our distribution centers, seize or order the recall of products and
impose significant criminal, civil and administrative sanctions for violations of these laws and regulations. Foreign
regulations subject us to similar foreign enforcement powers.
EU Regulation of Medicinal and Dental Products
European Union (“EU”) member states regulate their own healthcare systems, as does EU law. The latter regulates
certain matters, most notably medicinal products and medical devices. Medicinal products are defined, broadly, as
substances or combinations of substances having certain functionalities and may not include medical devices. EU
“regulations” apply in all member states, whereas “directives” are implemented by the individual laws of member
states.
11
On medicines for humans, we are regulated under Directive No. 2001/83/EC of 6 November 2001, as amended by
Directive 2003/63/EC of 25 June 2003, and EU Regulation (EC) No. 726/2004 of 31 March 2004. These rules
provide for the authorization of products, and regulate their manufacture, importation, marketing and distribution.
It implements requirements which may be implemented without warning, as well as a national pharmacovigilance
system under which marketing authorizations may be withdrawn, and includes potential sanctions for breaches of
the rules, and on other bases such as harmfulness or lack of efficacy.
EU Regulation No. 1223/2009 of 30 November 2009 on cosmetic products requires that cosmetic products (which
includes dental products) be safe for human health when used under normal or reasonably foreseeable conditions of
use and comply with certain obligations which apply to manufacturer, importer and distributor. It includes market
surveillance, and non-compliance may result in the recall or withdrawal of products, along with other sanctions.
In the EU, the EU Medical Device Regulation No. 2017/745 of 5 April 2017 (“EU MDR”) covers a wide scope of
our activities, from dental material to X-ray machines, and certain software. It was meant to become applicable
three years after publication (i.e., May 26, 2020). However, on April 23, 2020, to allow European Economic Area
(“EEA”) national authorities, notified bodies, manufacturers and other actors to focus fully on urgent priorities
related to the COVID-19 pandemic, the European Council and Parliament adopted Regulation 2020/561,
postponing the date of application of the EU MDR by one year (to May 26, 2021).
The EU MDR significantly modifies and intensifies the regulatory compliance requirements for the medical device
industry as a whole. Among other things, the EU MDR:
strengthens the rules on placing devices on the market and reinforces surveillance once they are available;
•
• establishes explicit provisions on manufacturers’ responsibilities for the follow-up of the quality,
•
•
•
•
performance and safety of devices placed on the market;
improves the traceability of medical devices throughout the supply chain to the end-user or patient through
a unique identification number;
sets up a central database to provide patients, healthcare professionals and the public with comprehensive
information on products available in the EU;
strengthens rules for the assessment of certain high-risk devices, such as implants, which may have to
undergo an additional check by experts before they are placed on the market; and
identifies importers and distributors and medical device products through registration in a database
(EUDAMED, which is not fully functional for the time being and might not be so before the end of 2024 at
the earliest; therefore, the use of this database is only possible through a voluntary basis and, by a way of
consequence, is currently not mandatory).
In particular, the EU MDR imposes strict requirements for the confirmation that a product meets the regulatory
requirements, including regarding a product’s clinical evaluation and a company’s quality systems, and for the
distribution, marketing and sale of medical devices, including post-market surveillance. Medical devices that have
been assessed and/or certified under the Directive No. 93/42/EEC of 14 June 1993 concerning medical devices
(“EU Medical Device Directive”) may for the moment continue to be placed on the market until 2024 (or until the
expiry of their certificates, if applicable and earlier). However, on January 6, 2023, the EU Commission submitted a
proposed amendment to extend the MDR transitional periods until December 31, 2027 for higher risk devices and
December 31, 2028, for other medical devices to ensure continued access to medical devices for patients and to
allow medical devices already placed on the market in accordance with the current legal framework to remain on
the market. We continue to monitor developments and whether the proposed amendment and new deadlines will be
approved by the European Parliament and Council. Nevertheless, EU MDR requirements regarding the distribution,
marketing and sale including quality systems and post-market surveillance have to be observed by manufacturers,
importers and distributors as of the application date (i.e., since May 26, 2021).
Other EU regulations that may apply under appropriate circumstances include EU Regulation No. 1907/2006 of 18
December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals, which
requires importers to register substances or mixtures that they import in the EU beyond certain quantities, and the
EU Regulation No. 1272/2008 of 16 December 2008 on classification, labelling and packaging of substances and
mixtures, which sets various obligations with respect to the labelling and packaging of concerned substances and
mixtures.
12
Furthermore, compliance with legal requirements has required and may in the future require us to delay product
release, sale or distribution, or institute voluntary recalls of, or other corrective action with respect to products we
sell, each of which could result in regulatory and enforcement actions, financial losses and potential reputational
harm. Our customers are also subject to significant federal, state, local and foreign governmental regulation, which
may affect our interactions with customers, including the design and functionality of our products.
Certain of our businesses are subject to various additional federal, state, local and foreign laws and regulations,
including with respect to the sale, transportation, storage, handling and disposal of hazardous or potentially
hazardous substances, and safe working conditions. In addition, certain of our businesses must operate in
compliance with a variety of burdensome and complex billing and record-keeping requirements in order to
substantiate claims for payment under federal, state and commercial healthcare reimbursement programs. One of
these businesses was suspended in October 2021 by CMS from receiving payments from Medicare, although it was
permitted to continue to perform and bill for Medicare services. On September 30, 2022, CMS terminated the
suspension of Medicare payments. As a result of the termination of the suspension, we recognized $4 million of
previously deferred revenue during the year ended December 31, 2022.
Certain of our businesses also maintain contracts with governmental agencies and are subject to certain regulatory
requirements specific to government contractors.
Antitrust and Consumer Protection
The federal government of the United States, most U.S. states and many foreign countries have antitrust laws that
prohibit certain types of conduct deemed to be anti-competitive, as well as consumer protection laws that seek to
protect consumers from improper business practices. At the U.S. federal level, the Federal Trade Commission
oversees enforcement of these types of laws, and states have similar government agencies. Violations of antitrust
or consumer protection laws may result in various sanctions, including criminal and civil penalties. Private
plaintiffs may also bring civil lawsuits against us in the United States for alleged antitrust law violations, including
claims for treble damages. EU law also regulates competition and provides for detailed rules protecting consumers.
The Biden Administration has indicated increased antitrust enforcement and has been more aggressive in
enforcement activities, including investigation and challenging non-compete restrictions and other restrictive
contractual terms that it believes harm workers and competition.
Health Care Fraud
Certain of our businesses are subject to federal and state (and similar foreign) health care fraud and abuse, referral
and reimbursement laws and regulations with respect to their operations. Some of these laws, referred to as “false
claims laws,” prohibit the submission or causing the submission of false or fraudulent claims for reimbursement to
federal, state and other health care payers and programs. Other laws, referred to as “anti-kickback laws,” prohibit
soliciting, offering, receiving or paying remuneration in order to induce the referral of a patient or ordering,
purchasing, leasing or arranging for, or recommending, ordering, purchasing or leasing of, items or services that are
paid for by federal, state and other health care payers and programs. Certain additional state and federal laws, such
as the federal Physician Self-Referral Law, commonly known as the “Stark Law,” prohibit physicians and other
health professionals from referring a patient to an entity with which the physician (or family member) has a
financial relationship, for the furnishing of certain designated health services (for example, durable medical
equipment and medical supplies), unless an exception applies. Violations of Anti-Kickback Statutes or the Stark
Law may be enforced as violations of the federal False Claims Act.
The fraud and abuse laws and regulations have been subject to heightened enforcement activity over the past few
years, and significant enforcement activity has been the result of “relators” who serve as whistleblowers by filing
complaints in the name of the United States (and if applicable, particular states) under applicable false claims laws,
and who may receive up to 30% of total government recoveries. Penalties under fraud and abuse laws may be
severe, including treble damages and substantial civil penalties under the federal False Claims Act, as well as
potential loss of licenses and the ability to participate in federal and state health care programs, criminal penalties,
or imposition of a corporate integrity agreement or corporate compliance monitor which could have a material
adverse effect on our business. Also, these measures may be interpreted or applied by a prosecutorial, regulatory or
13
judicial authority in a manner that could require us to make changes in our operations or incur substantial defense
and settlement expenses. Even unsuccessful challenges by regulatory authorities or private relators could result in
reputational harm and the incurring of substantial costs. Most states have adopted similar state false claims laws,
and these state laws have their own penalties, which may be in addition to federal False Claims Act penalties, as
well as other fraud and abuse laws.
With respect to measures of this type, the United States government (among others) has expressed concerns about
financial relationships between suppliers on the one hand and physicians, dentists and other healthcare
professionals on the other. As a result, we regularly review and revise our marketing practices as necessary to
facilitate compliance.
We also are subject to certain United States and foreign laws and regulations concerning the conduct of our foreign
operations, including the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, German anti-corruption laws
and other anti-bribery laws and laws pertaining to the accuracy of our internal books and records, which have been
the focus of increasing enforcement activity globally in recent years.
While we believe that we are substantially compliant with applicable fraud and abuse laws and regulations, and
have adequate compliance programs and controls in place to ensure substantial compliance, we cannot predict
whether changes in applicable law, or interpretation of laws, or changes in our services or marketing practices in
response to changes in applicable law or interpretation of laws, or failure to comply with applicable law, could have
a material adverse effect on our business.
Affordable Care Act and Other Insurance Reform
The ACA increased federal oversight of private health insurance plans and included a number of provisions
designed to reduce Medicare expenditures and the cost of health care generally, to reduce fraud and abuse, and to
provide access to increased health coverage. The ACA also materially expanded the number of individuals in the
United States with health insurance.
The ACA has faced frequent legal challenges, including litigation seeking to invalidate and Congressional action
seeking to repeal some of or all of the law or the manner in which it has been implemented. In 2012, the United
States Supreme Court, in upholding the constitutionality of the ACA and its individual mandate provision requiring
that people buy health insurance or else face a penalty, simultaneously limited ACA provisions requiring Medicaid
expansion, making such expansion a state-by-state decision. In addition, one of the major political parties in the
United States remains committed to seeking the ACA’s legislative repeal, but legislative efforts to do so have
previously failed to pass both chambers of Congress. Under President Trump’s administration, a number of
administrative actions were taken to materially weaken the ACA, including, without limitation, by permitting the
use of less robust plans with lower coverage and eliminating “premium support” for insurers providing policies
under the ACA. The Tax Cuts and Jobs Act enacted in 2017, which contains a broad range of tax reform provisions
that impact the individual and corporate tax rates, international tax provisions, income tax add-back provisions and
deductions, also effectively repealed the ACA’s individual mandate by zeroing out the penalty for non-compliance.
In the most recent ACA litigation, the federal Fifth Circuit Court of Appeals found the individual mandate to be
unconstitutional, and returned the case to the District Court for the Northern District of Texas for consideration of
whether the remainder of the ACA could survive the excision of the individual mandate. The Fifth Circuit’s
decision was appealed to the United States Supreme Court. The Supreme Court issued a decision on June 17, 2021.
Without reaching the merits of the case, the Supreme Court held that the plaintiffs in the case did not have standing
to challenge the ACA. Any outcomes of future cases that change the ACA, in addition to future legislation,
regulation, guidance and/or Executive Orders that do the same, could have a significant impact on the U.S.
healthcare industry. For instance, the American Rescue Plan Act of 2021 enhanced premium tax credits, which has
resulted in an expansion of the number of people covered under the ACA. These changes are time-limited, with
some enhancements in place for 2021 only and others available through the end of 2022.
An ACA provision, generally referred to as the Physician Payment Sunshine Act or Open Payments Program (the
“Sunshine Act”), imposes annual reporting and disclosure requirements for drug and device manufacturers and
distributors with regard to payments or other transfers of value made to certain covered recipients (including
physicians, dentists, teaching hospitals, physician assistants, nurse practitioners, clinical nurse specialists, certified
14
registered nurse anesthetists, and certified nurse midwives), and for such manufacturers and distributors and for
group purchasing organizations, with regard to certain ownership interests held by covered recipients in the
reporting entity. The Centers for Medicare and Medicaid Services (“CMS”) publishes information from these
reports on a publicly available website, including amounts transferred and physician, dentist, teaching hospital, and
non-physician practitioner identities. The Sunshine Act pre-empts similar state reporting laws, although we or our
subsidiaries may be required to report under certain state transparency laws that address circumstances not covered
by the Sunshine Act, and some of these state laws, as well as the federal law, can be unclear. We are also subject to
foreign regulations requiring transparency of certain interactions between suppliers and their customers.
In the United States, government actions to seek to increase health-related price transparency may also affect our
business. For example, hospitals are currently required to publish online a list of their standard charges for all items
and services, including discounted cash prices and payer-specific and de-identified negotiated charges, in a publicly
accessible online file. Hospitals are also required to publish a consumer-friendly list of standard charges for certain
“shoppable” services (i.e., services that can be scheduled by a patient in advance) and associated ancillary services
or, alternatively, maintain an online price estimator tool. CMS may impose civil monetary penalties for
noncompliance with these price transparency requirements. Additionally, the No Surprises Act (“NSA”), generally
effective January 1, 2022, imposes additional price transparency requirements. The NSA is intended to reduce the
number of “out-of-network” patients. This will result in fewer out-of-network payments to physicians and other
providers, which may cause financial stress to those providers who are dependent on higher out-of-network fees.
Another notable Medicare health care reform initiative, the Medicare Access and CHIP Reauthorization Act of
2015 (“MACRA”), enacted on April 16, 2015, established a new payment framework, which modified certain
Medicare payments to “eligible clinicians,” including physicians, dentists and other practitioners. Under MACRA,
certain eligible clinicians are required to participate in Medicare through the Merit-Based Incentive Payment
System (“MIPS”) or Advanced Alternative Payment Models, through which Medicare reimbursement to eligible
clinicians includes both positive and negative payment adjustments that take into account quality, promoting
interoperability, cost and improvement activities. Data collected in the first MIPS performance year (2017)
determined payment adjustments that began January 1, 2019. MACRA standards and payment levels continue to
evolve, and reflect a fundamental change in physician reimbursement that is expected to provide substantial
financial incentives for physicians to participate in risk contracts, and to increase physician information technology
and reporting obligations. The implications of the implementation of MACRA are uncertain and will depend on
future regulatory activity and physician activity in the marketplace. New state-level payment and delivery system
reform programs, including those modeled after such federal programs, are also increasingly being rolled out
through Medicaid administrators, as well as through the private sector, which may further alter the marketplace and
impact our business.
Recently, in addition to other government efforts to control health care costs, there has been increased scrutiny on
drug pricing and concurrent efforts to control or reduce drug costs by Congress, the President, executive branch
agencies and various states. At the state level, several states have adopted laws that require drug manufacturers to
provide advance notice of certain price increases and to report information relating to those price increases, while
others have taken legislative or administrative action to establish prescription drug affordability boards or multi-
payer purchasing pools to reduce the cost of prescription drugs. At the federal level, several related bills have been
introduced and regulations proposed which, if enacted or finalized, respectively, would impact drug pricing and
related costs.
As a result of political, economic and regulatory influences, the health care distribution industry in the United
States is under intense scrutiny and subject to fundamental changes. We cannot predict what further reform
proposals, if any, will be adopted, when they may be adopted, or what impact they may have on us.
EU Directive on the pricing and reimbursement of medicinal products
EU law provides for the regulation of the pricing of medicinal products which are implemented by EU member
states (Directive No. 89/105/EC of 21 December 1988 relating to the transparency of measures regulating the
pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems).
Member states may, subject notably to transparency conditions and to the statement of reasons based upon
objective and verifiable criteria, regulate the price charged (or its increases) for authorized medicines and their level
15
of reimbursement, or they may freeze prices, place controls on the profitability of persons responsible for placing
medicinal products on the market, and include or exclude the medicine on the list of products covered by national
health insurance systems.
EU law does not expressly include provisions like those of the Sunshine Act in the United States, but a growing
number of EU member states (such as France in 2011 and Italy in 2022) have enacted laws to increase the
transparency of relationships in the healthcare sector. The scope of these laws varies from one member state to
another and may, for example, include the relations between healthcare industry players and physicians or their
associations, students preparing for medical professions or their associations, teachers, health establishments or
publishers of prescription and dispensing assistance software.
Regulated Software; Electronic Health Records
The FDA has become increasingly active in addressing the regulation of computer software and digital health
products intended for use in health care settings. The 21st Century Cures Act (the “Cures Act”), signed into law on
December 13, 2016, among other things, amended the medical device definition to exclude certain software from
FDA regulation, including clinical decision support software that meets certain criteria. On September 27, 2019,
the FDA issued a suite of guidance documents on digital health products, which incorporated applicable Cures Act
standards, including regarding the types of clinical decision support tools and other software that are exempt from
regulation by the FDA as medical devices, and continues to issue new guidance in this area. Certain of our
businesses involve the development and sale of software and related products to support physician and dental
practice management, and it is possible that the FDA or foreign government authorities could determine that one or
more of our products is a medical device, which could subject us or one or more of our businesses to substantial
additional requirements with respect to these products.
In addition, our businesses that involve physician and dental practice management products, and our specialty home
medical supply business, include electronic information technology systems that store and process personal health,
clinical, financial and other sensitive information of individuals. These information technology systems may be
vulnerable to breakdown, wrongful intrusions, data breaches and malicious attack, which could require us to
expend significant resources to eliminate these problems and address related security concerns and could involve
claims against us by private parties and/or governmental agencies. For example, we are directly or indirectly
subject to numerous and evolving federal, state, local and foreign laws and regulations that protect the privacy and
security of personal information, such as the federal Health Insurance Portability and Accountability Act of 1996,
as amended, and implementing regulations (“HIPAA”), the Controlling the Assault of Non-Solicited Pornography
and Marketing Act, the Telephone Consumer Protection Act of 1991, Section 5 of the Federal Trade Commission
Act, the California Privacy Act (“CCPA”), and the California Privacy Rights Act (“CPRA”) that became effective
on January 1, 2023. Additionally, Virginia, Colorado, Connecticut and Utah recently passed comprehensive
privacy legislation, and several privacy bills have been proposed both at the federal and state level that may result
in additional legal requirements that impact our business. Laws and regulations relating to privacy and data
protection are continually evolving and subject to potentially differing interpretations. These requirements may not
be harmonized, may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another or
may conflict with other rules or our practices. Our businesses’ failure to comply with these laws and regulations
could expose us to breach of contract claims, substantial fines, penalties and other liabilities and expenses, costs for
remediation and harm to our reputation. Also, evolving laws and regulations in this area could restrict the ability of
our customers to obtain, use or disseminate patient information, or could require us to incur significant additional
costs to re-design our products to reflect these legal requirements, which could have a material adverse effect on
our operations.
Also, the European Parliament and the Council of the EU adopted the pan-European General Data Protection
Regulation (“GDPR”), effective from May 25, 2018, which increased privacy rights for individuals (“Data
Subjects”), including individuals who are our customers, suppliers and employees. The GDPR extended the scope
of responsibilities for data controllers and data processors, and generally imposes increased requirements and
potential penalties on companies, such as us, that are either established in the EU and process personal data of Data
Subjects (regardless the Data Subject location), or that are not established in the EU but that offer goods or services
to Data Subjects in the EU or monitor their behavior in the EU. Noncompliance can result in penalties of up to the
greater of EUR 20 million, or 4% of global company revenues (sanction that may be public), and Data Subjects
16
may seek damages. Member states may individually impose additional requirements and penalties regarding
certain limited matters (for which the GDPR let some room of flexibility), such as employee personal data. With
respect to the personal data it protects, the GDPR requires, among other things, controller accountability, consents
from Data Subjects or another acceptable legal basis to process the personal data, notification within 72 hours of a
personal data breach where required, data integrity and security, and fairness and transparency regarding the
storage, use or other processing of the personal data. The GDPR also provides rights to Data Subjects relating
notably to information, access, rectification, erasure of the personal data and the right to object to the processing.
On August 20, 2021, China promulgated the PRC Personal Information Protection Law (“PIPL”), which took effect
on November 1, 2021. The PIPL imposes specific rules for processing personal information and it also specifies
that the law shall also apply to personal information activities carried out outside China but for the purpose of
providing products or services to PRC citizens. Any non-compliance with these laws and regulations may subject
us to fines, orders to rectify or terminate any actions that are deemed illegal by regulatory authorities, other
penalties, as well as reputational damage or legal proceedings against us, which may affect our business, financial
condition or results of operations. The PIPL carries maximum penalties of CNY50 million or 5% of the annual
revenue of entities that process personal data.
In the United States, the CCPA, which increases the privacy protections afforded California residents, became
effective January 1, 2020. The CCPA generally requires companies, such as us, to institute additional protections
regarding the collection, use and disclosure of certain personal information of California residents. Compliance
with the obligations imposed by the CCPA depends in part on how particular regulators interpret and apply them.
Regulations were released in August of 2020, but there remains some uncertainty about how the CCPA will be
interpreted by the courts and enforced by the regulators. If we fail to comply with the CCPA or if regulators assert
that we have failed to comply with the CCPA, we may be subject to certain fines or other penalties and litigation,
any of which may negatively impact our reputation, require us to expend significant resources, and harm our
business. Furthermore, California voters approved the CPRA on November 3, 2020, which amends and expands
the CCPA, including by providing consumers with additional rights with respect to their personal information, and
creating a new state agency, the California Privacy Protection Agency, to enforce the CCPA and the CPRA. The
CPRA came into effect on January 1, 2023, applying to information collected by businesses on or after January 1,
2022.
Other states, as well as the federal government, have increasingly considered the adoption of similarly expansive
personal privacy laws, backed by significant civil penalties for non-compliance. Virginia and Colorado were both
successful in passing privacy legislation in 2021, becoming effective on January 1, 2023 and July 1, 2023,
respectively. In 2022, privacy legislation passed in Connecticut, effective July 1, 2023, and Utah, effective
December 31, 2023. While we believe we have substantially compliant programs and controls in place to comply
with the GDPR, CCPA, PIPL, CPRA and state law requirements, our compliance with data privacy and
cybersecurity laws is likely to impose additional costs on us, and we cannot predict whether the interpretations of
the requirements, or changes in our practices in response to new requirements or interpretations of the
requirements, could have a material adverse effect on our business.
We also sell products and services that health care providers, such as physicians and dentists, use to store and
manage patient medical or dental records. These customers, and we, are subject to laws, regulations and industry
standards, such as HIPAA and the Payment Card Industry Data Security Standards, which require the protection of
the privacy and security of those records, and our products may also be used as part of these customers’
comprehensive data security programs, including in connection with their efforts to comply with applicable privacy
and security laws. Perceived or actual security vulnerabilities in our products or services, or the perceived or actual
failure by us or our customers who use our products or services to comply with applicable legal or contractual data
privacy and security requirements, may not only cause us significant reputational harm, but may also lead to claims
against us by our customers and/or governmental agencies and involve substantial fines, penalties and other
liabilities and expenses and costs for remediation.
Various federal initiatives involve the adoption and use by health care providers of certain electronic health care
records systems and processes. The initiatives include, among others, programs that incentivize physicians and
dentists, through MIPS, to use EHR technology in accordance with certain evolving requirements, including
regarding quality, promoting interoperability, cost and improvement activities. Qualification for the MIPS
17
incentive payments requires the use of EHRs that are certified as having certain capabilities designated in evolving
standards adopted by CMS and the Office of the National Coordinator for Health Information Technology of HHS
(“ONC”). Certain of our businesses involve the manufacture and sale of such certified EHR systems and other
products linked to government supported incentive programs. In order to maintain certification of our EHR
products, we must satisfy these changing governmental standards. If any of our EHR systems do not meet these
standards, yet have been relied upon by health care providers to receive federal incentive payments, we may be
exposed to risk, such as under federal health care fraud and abuse laws, including the False Claims Act.
Moreover, in order to satisfy our customers, and comply with evolving legal requirements, our products may need
to incorporate increasingly complex functionality, such as with respect to reporting and information blocking.
Although we believe we are positioned to accomplish this, the effort may involve increased costs, and our failure to
implement product modifications, or otherwise satisfy applicable standards, could have a material adverse effect on
our business.
Other health information standards, such as regulations under HIPAA, establish standards regarding electronic
health data transmissions and transaction code set rules for specific electronic transactions, such as transactions
involving claims submissions to third party payers. Failure to abide by these and other electronic health data
transmission standards could expose us to breach of contract claims, substantial fines, penalties, and other liabilities
and expenses, costs for remediation and harm to our reputation.
Additionally, as electronic medical devices are increasingly connected to each other and to other technology, the
ability of these connected systems to safely and effectively exchange and use exchanged information becomes
increasingly important. As a medical device manufacturer, we must manage risks including those associated with
an electronic interface that is incorporated into a medical device.
There may be additional legislative or regulatory initiatives in the future impacting health care.
E-Commerce
Electronic commerce solutions have become an integral part of traditional health care supply and distribution
relationships. Our distribution business is characterized by rapid technological developments and intense
competition. The continuing advancement of online commerce requires us to cost-effectively adapt to changing
technologies, to enhance existing services and to develop and introduce a variety of new services to address the
changing demands of consumers and our customers on a timely basis, particularly in response to competitive
offerings.
Through our proprietary, technologically-based suite of products, we offer customers a variety of competitive
alternatives. We believe that our tradition of reliable service, our name recognition and large customer base built
on solid customer relationships, position us well to participate in this significant aspect of the distribution business.
We continue to explore ways and means to improve and expand our online presence and capabilities, including our
online commerce offerings and our use of various social media outlets.
International Transactions
United States and foreign import and export laws and regulations require us to abide by certain standards relating to
the importation and exportation of products. We also are subject to certain laws and regulations concerning the
conduct of our foreign operations, including the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, German
anti-corruption laws and other anti-bribery laws and laws pertaining to the accuracy of our internal books and
records, as well as other types of foreign requirements similar to those imposed in the United States.
While we believe that we are substantially compliant with the foregoing laws and regulations promulgated
thereunder and possess all material permits and licenses required for the conduct of our business, there can be no
assurance that laws and regulations that impact our business or laws and regulations as they apply to our customers’
practices will not have a material adverse effect on our business.
18
See “Item 1A. Risk Factors.” for a discussion of additional burdens, risks and regulatory developments that may
affect our results of operations and financial condition.
Proprietary Rights
We hold trademarks relating to the “Henry Schein®” name and logo, as well as certain other trademarks. We intend
to protect our trademarks to the fullest extent practicable.
Employees and Human Capital
Environment, Social and Governance
Henry Schein has remained steadfastly committed over our nine-decade history to the core philosophy that our
purpose-driven mission of "doing good" for our stakeholders is inextricably linked to our Company "doing well" in
business through our stakeholder engagement model “our Mosaic of Success”. We balance the needs of our five
key stakeholders – Team Schein Members (TSMs), our Customers, our Suppliers, our Stockholders, and Society –
to continue to drive our sustainability and ESG efforts to foster a healthier planet and healthier people. Overseen
by the Nominating and Governance Committee of our Board of Directors with the Compensation Committee also
playing a role in ESG matters related to human capital engagement and executive compensation, key 2022
sustainability and ESG highlights included:
• With the backdrop of the ongoing COVID-19 pandemic and the humanitarian crises in Ukraine and other
regions, we continued our efforts to drive an overall culture of wellness and engagement for our TSMs as
we navigated a new hybrid work environment and ensure supply chain resiliency to support our customers
and our communities. Henry Schein was named Chair of the Private Sector Roundtable on Global Health
Security, and continued its work across sectors to support the creation of market intelligence platforms that
enable the appropriate sharing of real-time supply chain data, including through the WHO's Pandemic
Supply Chain Network and various national efforts, including the U.S. Supply Chain Control Tower.
•
(i) Publishing our annual Corporate Social Responsibility and Sustainability Report according to the Global
Reporting Initiative and Sustainability Accounting Standards Board reporting standards and issuing our
first Taskforce for Climate-related Financial Disclosures report; (ii) committing to announcing our carbon
reduction goal by the end of 2023; (iii) continued initiatives and programs to advance health equity efforts
to promote access to care for underserved and underrepresented communities, investing in diversity for
greater health equity in partnership with health care professionals, and increasing awareness of health
equity needs globally; (iv) announced the top line findings of our pay equity analysis across the U.S., which
reviews compensation across gender and ethnic groups; (v) expanding our Diversity and Inclusion (“D&I”)
learning journey, such as by educating global directors and vice presidents on more advanced topics of D&I
including privilege and equity, as well as offering education to all global TSMs below director level on the
importance of D&I; and (vi) continuing to drive a culture of wellness for our TSMs by fostering an
environment where they can feel engaged, included and psychologically safe.
At Henry Schein, our employees are our greatest asset. We employ more than 22,000 people, approximately 50%
of our workforce is based in the United States and approximately 50% is based outside of the United States.
Approximately 12% of our employees are subject to collective bargaining agreements. We believe that our
relations with our employees are excellent.
We refer to our employees as Team Schein Members, or “TSMs.” Our TSMs are the cornerstone of the Company.
We have a strong values-based culture that cultivates a meaningful employee experience that is centered around
people. We know our business success is built on the engagement and commitment of our team, which is dedicated
to meeting the needs of their fellow TSMs, our customers, supplier partners, stockholders and society. As part of
this commitment, our highlights in 2022 included:
19
• Nurturing a connected community for a happier, more engaged, collaborative work environment. We
continue to adapt to the new way of working for our TSMs by listening to their needs. With TSMs working
remotely, hybrid and in-person, our goal is to continue to create a collaborative community where every
TSM feels connected to our culture. Through various virtual and in-person programming from our
Employee Resource Groups, Wellness Committee and Team Schein Engagement team, we continue to
bring TSMs together in a meaningful way through virtual education sessions and networking events. To
help create a sense of connection and belonging amongst the team, we launched “TSM Experience Panels,”
which feature TSMs who share their authentic experiences and offer advice and best practices on specific
topics. We offer a variety of opportunities to volunteer for team-building and engaging in their local
communities in which they live and work such as through the We Care Global Challenge, Back to School,
and Holiday Cheer. In addition, they can “help health happen” by participating in key programs and
initiatives (e.g., Gives Kids A Smile, Healthy Lifestyles, Healthy Communities and Release the Pressure)
that partner with industry associations, customers, and suppliers to support access to quality health care for
underserved and underrepresented communities. We continue to evaluate the engagement of our team
through various listening mechanisms including roundtables, hosted by our CEO and Executive
Management Committee (“EMC”), and various surveys, including The Pulse, our global culture survey that
evaluates TSM engagement globally with results reviewed by senior leaders, reported to the Board of
Directors (“BOD”). Throughout 2022, we held 10 solutions-focused roundtables hosted by our EMC
members with over 100 TSMs to dive in deeper and influence our strategy on programs and processes
designed to further enhance our culture.
• Driving a culture of wellness for our team members and society. In 2020, we launched a Mental Wellness
Committee with a mission to drive a culture of wellness and empower every TSM to be their best self,
mentally, emotionally and physically. The Committee provides resources, guidance and support, and
works across our businesses to establish enhanced workplace norms to help improve and safeguard our
TSMs’ wellness. We actively engage leadership, including our CEO, EMC, BOD and TSMs alike in
conversations around the importance of wellness in the workplace. In 2022, we rolled-out an EMC video
series that focused on being more intentional in the way we work across our business. These new
workplace norms focused on meeting and technology etiquette, successful calendaring, establishing and
communicating reasonable expectations and prioritization, the importance of taking and respecting time
off, and the importance of making time for social connection. In addition to expanding education on key
mental health topics in partnership with our employee assistance vendor, we also rolled-out manager-
specific education to provide tips on how to identify signs of burnout and have conversations around
wellness with their teams. With the rise of suicide rates around the world, the Wellness Committee held
seminars for the team on suicide prevention and hosted in-person community walks that resulted in
donations to local suicide prevention organizations globally.
• Being committed to enhancing our D&I initiatives. We believe a diverse workforce fosters innovation and
cultivates an environment filled with unique perspectives. As a result, D&I helps us meet the needs of
customers around the world and provide our TSMs an inclusive environment where they feel they belong.
We measure our success in D&I through, among other things, our global culture survey, where results in
2021 showed D&I is our top strength out of 14 focus areas. To guide our efforts and education related to
D&I, our Diversity and Inclusion Council, with engagement from our BOD and EMC, drives the
Company’s overall D&I strategy. To deepen our commitment to D&I across the Company, Global
Directors and Vice Presidents each have a goal tied to their compensation to champion D&I and attend
education. We continue to expand our D&I learning journey, educating global Directors and Vice
Presidents on key D&I topics including leading inclusively, bias and equity. We also continue to educate
our global TSMs on the importance of D&I. Additionally, we promote engagement by utilizing our
Employee Resource Groups (“ERGs”), which we continue to expand, as an inclusive and diverse vehicle
for all TSMs to share, connect, learn and develop both personally and professionally. Each of our ERGs
has a sponsor from our Executive Management Committee and our BOD and our CEO engages directly in
many of our ERG programs. While inclusion continues to remain a top priority, we also understand the
importance of ensuring our internal team reflects the diversity of our customers and society. In addition to
our current gender parity by 2030 goal, we announced a new goal in 2022 with an enhanced focus on
20
increasing the diversity of all underrepresented groups in senior leadership levels through our talent
planning, compensation and recruitment processes, in alignment with our corporate strategic planning
objectives to achieve concrete results. We continue to disclose additional diversity data, with frequent
reporting to the EMC and BOD. In 2022, we published our United States Equal Employment Opportunity
Commission (“EEOC”) EEO-1 data for the U.S. for the first time. We continue to enhance our recruiting
strategy by developing and investing in strategic hires who complement our D&I mission. We believe that
these efforts will serve as a critical steppingstone as we continue to strengthen our D&I initiatives in an
effort to meet the evolving needs of our customers, supplier partners, TSMs, stockholders and society.
• Understanding that growth, recognition and purpose are key pillars to TSM fulfillment. Personal and
professional development of our TSMs is important to us. As such, we invest in our employees by
providing both formal and informal learning opportunities that are focused on growing and enhancing
knowledge, skills and abilities. TSMs globally are offered a broad suite of professional development
training programs targeted to specific learning opportunities based on their current and potential future role
within the Company. We also offer over 50 organizational and development training courses designed to
aid in the overall development and advancement of skills and competencies to enable organizational
success. Executive education, mentorship and coaching programs also form an important part of our
development and career support initiatives. Additionally, we continued to see an increase in participation
in our Organizational Development initiatives in 2022 with our TSMs reporting a high utilization of skills
learned. Talent planning efforts are also an integral part of our commitment to ensure a strong diverse
leadership pipeline across the organization. Through a formal global process, we strategically identify and
develop talent through targeted development opportunities and intentional succession plans. We
continuously identify potential management successors as part of our succession planning process.
Information derived from talent planning efforts informs curriculum design and content to help focus on the
right capabilities and help ensure alignment of career development efforts with the future needs of the
organization. Our BOD is provided with periodic updates regarding our talent and succession planning
efforts and participates in professional development activities with our TSMs. We know recognition and
purpose are also key pillars to TSM engagement, so we continue to find ways to recognize our TSMs
through our annual performance review process, and various recognition opportunities including our Teddy
Philson Team Schein Award, which highlights TSMs who exemplify our Team Schein Values. In addition,
we continue to focus on ensuring every TSM understands the importance in the role they play within the
organization, how they contribute to a larger purpose of creating a healthier world, as well as continue to
provide opportunities for TSMs to engage in meaningful ways that connect back to their own personal
purpose, such as helping the community through CSR activities.
Available Information
We make available free of charge through our Internet website, www.henryschein.com, our annual report on Form
10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, statements of beneficial ownership of
securities on Forms 3, 4 and 5 and amendments to these reports and statements filed or furnished pursuant to
Section 13(a) and Section 16 of the Securities Exchange Act of 1934 as soon as reasonably practicable after such
materials are electronically filed with, or furnished to, the United States Securities and Exchange Commission, or
SEC. Our principal executive offices are located at 135 Duryea Road, Melville, New York 11747, and our
telephone number is (631) 843-5500. Unless the context specifically requires otherwise, the terms the “Company,”
“Henry Schein,” “we,” “us” and “our” mean Henry Schein, Inc., a Delaware corporation, and its consolidated
subsidiaries.
21
Information about our Executive Officers
The following table sets forth certain information regarding our executive officers:
Name
Age
Position
Stanley M. Bergman
James P. Breslawski
David Brous
Brad Connett
Michael S. Ettinger
Lorelei McGlynn
Mark E. Mlotek
Ronald N. South
Walter Siegel
73
69
54
64
61
59
67
61
63
Chairman, Chief Executive Officer, Director
Vice Chairman, President, Director
Chief Executive Officer, Strategic Business Group
Chief Executive Officer, North America Distribution Group
Executive Vice President and Chief Operating Officer
Senior Vice President, Chief Human Resources Officer
Executive Vice President, Chief Strategic Officer, Director
Senior Vice President, Chief Financial Officer
Senior Vice President and Chief Legal Officer
Stanley M. Bergman has been our Chairman and Chief Executive Officer since 1989 and a director since 1982.
Mr. Bergman held the position of President from 1989 to 2005. Mr. Bergman held the position of Executive Vice
President from 1985 to 1989 and Vice President of Finance and Administration from 1980 to 1985.
James P. Breslawski has been our Vice Chairman since 2018, President since 2005 and a director since 1992. Mr.
Breslawski was the Chief Executive Officer of our Henry Schein Global Dental Group from 2005 to 2018. Mr.
Breslawski held the position of Executive Vice President and President of U.S. Dental from 1990 to 2005, with
primary responsibility for the North American Dental Group. Between 1980 and 1990, Mr. Breslawski held
various positions with us, including Chief Financial Officer, Vice President of Finance and Administration and
Corporate Controller.
David Brous has been our Chief Executive Officer, Strategic Business Group since 2021. Mr. Brous joined us in
2002 and has held many positions within the organization, including President, Strategic Business Units Group and
Asia Pacific & Brazil Dental, leading and managing the Corporate Business Development Group and the
International Healthcare Group (managing our International Animal Health business, International Medical
business and Australia / New Zealand Dental business).
Brad Connett has been our Chief Executive Officer, North American Distribution Group since 2021. Previously
Mr. Connett was the President of our U.S. Medical Group from 2018 to 2021. Mr. Connett joined us in 1997 and
has held a number of roles of increasing responsibility at the Company. Throughout his career, he has received
numerous industry honors, including the John F. Sasen Leadership Award from the Health Industry Distributors
Association (HIDA), in recognition of his service to the industry, and induction into the Medical Distribution Hall
of Fame by Repertoire Magazine.
Michael S. Ettinger has been our Executive Vice President and Chief Operating Officer since July 2022. Prior to
his current position, Mr. Ettinger served as Senior Vice President, Corporate & Legal Affairs, Chief of Staff and
Secretary from 2015 to July 2022, Senior Vice President, Corporate & Legal Affairs and Secretary from 2013 to
2015, Corporate Senior Vice President, General Counsel & Secretary from 2006 to 2013, Vice President, General
Counsel and Secretary from 2000 to 2006, Vice President and Associate General Counsel from 1998 to 2000 and
Associate General Counsel from 1994 to 1998. Before joining us, Mr. Ettinger served as a senior associate with
Bower & Gardner and as a member of the Tax Department at Arthur Andersen.
Lorelei McGlynn has been our Senior Vice President, Chief Human Resources Officer since 2013. Since joining
us in 1999, Ms. McGlynn has served as Vice President, Global Human Resources and Financial Operations from
2008 to 2013, Chief Financial Officer, International Group and Vice President of Global Financial Operations from
2002 to 2008 and Vice President, Finance, North America from 1999 to 2002. Prior to joining us, Ms. McGlynn
served as Assistant Vice President of Finance at Adecco Corporation.
22
Mark E. Mlotek has been our Executive Vice President and Chief Strategic Officer since 2012. Mr. Mlotek was
Senior Vice President and subsequently Executive Vice President of the Corporate Business Development Group
between 2000 and 2012. Prior to that, Mr. Mlotek was Vice President, General Counsel and Secretary from 1994 to
1999 and became a director in 1995. Prior to joining us, Mr. Mlotek was a partner in the law firm of Proskauer
Rose LLP, counsel to us, specializing in mergers and acquisitions, corporate reorganizations and tax law from 1989
to 1994.
Ronald N. South has been our Senior Vice President and Chief Financial Officer (and principal financial officer
and principal accounting officer) since April 2022. Prior to holding his current position, Mr. South was our
Corporate Finance and Chief Accounting Officer from 2013 until April 2022. Prior to joining us in 2008 as our
Vice President, Corporate Finance, Mr. South held leadership roles at Bristol-Myers Squibb, where he served as
Vice President, Finance, for the Cardiovascular and Metabolic business lines, as well as Vice President, Controller,
for its U.S. Pharmaceutical Division, and Vice President, Corporate General Auditor. Prior to Bristol-Myers
Squibb, he served as North American Director of Corporate Audit at PepsiCo, and held several roles of increasing
responsibility with PricewaterhouseCoopers LLP, where he advised clients located in the United States, Europe,
and Latin America. Mr. South is a certified public accountant.
Walter Siegel has been our Senior Vice President and Chief Legal Officer since 2021. Previously, Mr. Siegel was
our Senior Vice President and General Counsel from 2013 until 2021. Prior to joining us, Mr. Siegel was employed
with Standard Microsystems Corporation, a publicly traded global semiconductor company from 2005 to 2012,
holding positions of increasing responsibility, most recently as Senior Vice President, General Counsel and
Secretary.
Other Executive Management
The following table sets forth certain information regarding other Executive Management:
Name
Age
Position
Andrea Albertini
Leigh Benowitz
Trinh Clark
James Mullins
Kelly Murphy
Christopher Pendergast
Michael Racioppi
René Willi, Ph.D.
52
55
49
58
42
60
68
55
Chief Executive Officer, International Distribution Group
Senior Vice President and Chief Global Digital Transformation Officer
Senior Vice President and Chief Global Customer Experience Officer
Senior Vice President, Global Supply Chain
Senior Vice President and General Counsel
Senior Vice President and Chief Technology Officer
Senior Vice President, Chief Merchandising Officer
Chief Executive Officer, Global Oral Reconstruction Group
Andrea Albertini has been Chief Executive Officer, International Distribution Group since 2023. Mr. Albertini
joined us in 2013 and has held several positions within the organization including President, International
Distribution Group, President of our EMEA Dental Distribution Group, and Vice-President of International Dental
Equipment. Prior to joining Henry Schein, Mr. Albertini held leadership positions at Cefla Dental Group and
Castellini.
Leigh Benowitz has been our Senior Vice President and Chief Global Digital Transformation Officer since August
2022. Ms. Benowitz joined us in 2017 and has held several key positions including Vice President Digital &
Customer Experience and Global eCommerce Platform Digital Transformation Officer. Prior to joining Henry
Schein, Ms. Benowitz held various positions with increasing responsibilities at Citi.
Trinh Clark has been our Senior Vice President and Chief Global Customer Experience Officer since August
2022. Ms. Clark joined us in 2007 and has served as Vice President, Technology Enablement, North American
Distribution Group. Prior to joining Henry Schein, Ms. Clark held various positions of increasing responsibilities at
eSurg.
23
James Mullins has been our Senior Vice President of Global Supply Chain since 2018. Mr. Mullins joined us in
1988 and has held a number of key positions with increasing responsibility, including Global Chief Customer
Service Officer.
Kelly Murphy has been our Senior Vice President and General Counsel since 2021. Since joining us in 2011, Ms.
Murphy has held several key positions of increasing responsibility within the legal function, most recently serving
as Deputy General Counsel.
Christopher Pendergast has been our Senior Vice President and Chief Technology Officer since 2018. Prior to
joining us, Mr. Pendergast was the employed by VSP Global from 2008 to 2018, most recently as the Chief
Technology Officer and Chief Information Officer. Prior to VSP Global, Mr. Pendergast served in roles of
increasing responsibility at Natural Organics, Inc., from 2006 to 2008, IdeaSphere Inc./Twinlab Corporation from
2000 to 2006, IBM Corporation from 1987 to 1994 and 1998 to 2000 and Rohm and Haas from 1994 to 1998.
Michael Racioppi has been our Senior Vice President, Chief Merchandising Officer since 2008. Prior to holding
his current position, Mr. Racioppi was President of the Medical Division from 2000 to 2008 and Interim President
from 1999 to 2000, and Corporate Vice President from 1994 to 2008, with primary responsibility for the Medical
Group, Marketing and Merchandising departments. Mr. Racioppi served as Senior Director, Corporate
Merchandising from 1992 to 1994. Before joining us in 1992, Mr. Racioppi was employed by Ketchum
Distributors, Inc. as the Vice President of Purchasing and Marketing. He currently serves on the board of National
Distribution and Contracting and previously served on the board of Health Distribution Management Association
and Health Industry Distributors Association (HIDA).
René Willi, Ph.D. has been our Chief Executive Officer, Global Oral Reconstruction Group since 2021.
Previously, Dr. Willi was the President of our Global Dental Surgical Group. Prior to joining Henry Schein, Dr.
Willi held senior level roles with Institut Straumann AG as Executive Vice President, Surgical Business Unit from
2005 to 2013. Prior to Straumann, he held roles of increasing responsibility in Medtronic Plc’s cardiovascular
division from 2003 to 2005 and with McKinsey & Company as a management consultant from 2000 to 2003.
24
ITEM 1A. Risk Factors
Our business operations could be affected by factors that are not presently known to us or that we currently
consider not to be material to our operations, so you should not consider the risks disclosed in this section to
necessarily represent a complete statement of all risks and uncertainties. The Company believes that the following
risks could have a material adverse impact on our business, reputation, financial results, financial condition and/or
the trading price of our common stock. The order in which these factors appear does not necessarily reflect their
relative importance or priority.
COMPANY RISKS
Our business, results of operations, cash flows, financial condition and liquidity may be negatively impacted by
the effects of disease outbreaks, epidemics, pandemics, or similar wide-spread public health concerns and other
natural disasters. The COVID-19 pandemic and the responses of governments to it had, and may again have, a
material adverse effect on our business, results of operations and cash flows and may result in a material
adverse effect on our financial condition and liquidity.
Our business, results of operations, cash flows, financial condition and liquidity may be negatively impacted by the
effects of disease outbreaks, epidemics, pandemics, similar wide-spread public health concerns and other natural
disasters. The COVID-19 pandemic has had, and continues to have, an unprecedented impact on society, worldwide
economic activity, and the health care sector (particularly, the dental market). As a global healthcare solutions
company, the COVID-19 pandemic and the governmental responses to it had, and may again have, a material
adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on
our financial condition and liquidity. Even after the COVID-19 pandemic has begun to subside, we may again
experience material adverse impacts to our business, results of operations and cash flows as a result of, among other
things, its global economic impact, including any recession that may occur in the future, or a prolonged period of
economic slowdown or the reluctance of patients to return for elective dental or medical care. The impacts and
potential impacts from the COVID-19 pandemic include, but are not limited to:
• Significant volatility in supply, demand and selling prices for personal protective equipment (PPE), COVID-19
tests and other COVID-19 related products. Available supply, customer demand and selling prices for PPE,
COVID-19 tests and other COVID-19 related products fluctuated in fiscal 2022 and we expect such volatility to
continue for the duration of the COVID-19 pandemic. This has resulted in inventory reserves, fluctuating margins
and increased revenue related to such products. The volatility in sales of COVID-19 test kits has moderated, albeit
at a significantly lower level of sales compared with 2021, resulting in us recording an inventory obsolescence
reserve of $17 million for COVID-19 test kits during the year ended December 31, 2022 and we expect further
declines in sales volumes. Our estimates for supply, demand and selling prices are inherently uncertain and if
supply, demand, selling prices or other market dynamics significantly fluctuate in the future beyond our current
assumptions, additional inventory reserves may be required, margins may be reduced and/or revenue may decline
for such products, each which could materially adversely impact our business, results of operations and cash flows.
Additionally, governmental policies designed to reduce the transmission of COVID-19 and variants thereof could
once again lead to the closure of dental offices or deferral of elective procedures and wellness exams by medical
and dental patients. Such previous closures and restrictions impacted our customers’ spending with us and had, and
if reinstated may again have, a material adverse effect on our business, results of operations and cash flows.
Although we believe that most practices currently are able to access adequate supply, we still may be unable to
supply our customers with the specific brand and/or quantity of certain PPE products, COVID-19 tests and other
COVID-19 related products they demand, which may lead to our customers seeking alternative sources of supply.
Healthcare professionals’ inability to obtain a sufficient quantity and/or brand of certain PPE, COVID-19 tests and
other COVID-19 related products would adversely impact our business, results of operations and cash flows, and
could materially adversely affect our financial condition and liquidity;
25
• Reduction in Peoples’ Ability and Willingness to be in Public. Restrictions recommended by several public health
organizations, and implemented, from time to time, by federal, state and local governments, to slow and limit the
transmission of COVID-19 and variants thereof has caused and may in the future cause some people to be less
willing to go to elective medical and dental appointments, which could again materially adversely affect demand
for our products. A lengthened period of materially suppressed demand could again cause material adverse impacts
on our business, results of operations and cash flows and could materially adversely affect our financial condition
and liquidity;
• Negative impact on our workforce and impact of adapted business practices. The spread of COVID-19 and
variants thereof caused us to modify our business practices (including employee travel, employee work locations,
and physical participation in meetings, events and conferences), and we may take further actions as may be required
by government authorities or our customers or that we determine are in the best interests of our employees. As the
COVID-19 pandemic continues to unfold, we continue to evaluate appropriate actions for our business. At the onset
of the COVID-19 pandemic, many of our office-based workers shifted abruptly to working remotely. As the
COVID-19 pandemic has evolved, we have modified our work arrangements to implement more flexible working
arrangements for our office-based workers, including permanent work from home, hybrid and office-based
arrangements. Implementing these modified business practices to include remote work arrangements could have a
negative impact on employee morale, strain our business continuity plans, introduce operational risk (including but
not limited to cybersecurity risks), and impair our ability to efficiently operate our business;
• Significant changes in political conditions. Significant changes in political conditions in markets in which we
purchase and distribute our products have occurred and are expected to continue at least during the pendency of the
pandemic, including quarantines, governmental or regulatory actions, closures or other restrictions that limit or
close our operating facilities, restrict our employees’ ability to travel or perform necessary business functions, or
otherwise constrain the operations of our business partners, suppliers or customers, which may materially adversely
affect our business, results of operations, cash flows, financial condition and liquidity;
• Volatility in the financial markets. Volatility in the financial markets may materially adversely affect the
availability and cost of credit to us;
The impact of the COVID-19 pandemic may also exacerbate other risks discussed below, any of which could have
a material adverse effect on us.
We are dependent upon third parties for the manufacture and supply of a significant volume of our products.
We obtain a significant volume of the products we distribute from third parties, with whom we generally do not
have long-term contracts. While there is typically more than one source of supply, some key suppliers, in the
aggregate, supply a significant portion of the products we sell. In 2022, our top 10 health care distribution suppliers
and our single largest supplier accounted for approximately 28% and 4%, respectively, of our aggregate purchases.
Because of our dependence upon such suppliers, our operations are subject to the suppliers’ ability and willingness
to supply products in the quantities that we require, and the risks include delays caused by interruption in
production based on conditions outside of our control, including a supplier’s failure to comply with applicable
government requirements (which may result in product recalls and/or cessation of sales) or an interruption in the
suppliers’ manufacturing capabilities. In the event of any such interruption in supply, we would need to identify
and obtain acceptable replacement sources on a timely basis. There is no guarantee that we would be able to obtain
such alternative sources of supply on a timely basis, if at all, and an extended interruption in supply, particularly of
a high sales volume product, could result in a significant disruption in our sales and operations, as well as damage
to our relationships with customers and our reputation. In addition, certain of our suppliers have had their ability to
service certain markets restricted or negatively impacted because of allegations of forced labor in their supply
chain. Forced labor legislation affecting the supply chain has increased around the world, and the United States
recently passed the Uyghur Forced Labor Prevention Act. Our supply chain could be materially disrupted if our
suppliers fail to comply with, or are unable to satisfy our demand for products, as a result of applicable forced labor
legislation and regulations.
26
Our future growth (especially for our technology and value-added services segment) is dependent upon our ability
to develop or acquire and maintain and protect new products and technologies that achieve market acceptance
with acceptable margins.
Our future success depends on our ability to timely develop (or obtain the right to sell) competitive and innovative
(particularly for our technology and value-added services segment) products and services and to market them
quickly and cost-effectively. Our ability to anticipate customer needs and emerging trends and develop or acquire
new products, services and technologies at competitive prices requires significant resources, including employees
with the requisite skills, experience and expertise, particularly in our technology segment, including dental practice
management, patient engagement and demand creation software solutions. The failure to successfully address these
challenges could materially disrupt our sales and operations. Additionally, our software and e-services products,
like software products generally, may contain undetected errors or bugs when introduced or as new versions are
released. Any such defective software may result in increased expenses related to the software and could adversely
affect our relationships with customers as well as our reputation. With respect to certain software and e-services
that we develop, we rely primarily upon copyright, trademark and trade secret laws, as well as contractual and
common law protections and confidentiality obligations. We cannot provide assurance that such legal protections
will be available, adequate or enforceable in a timely manner to protect our software or e-services products.
Risks inherent in acquisitions, dispositions and joint ventures could offset the anticipated benefits.
One of our business strategies has been to expand our domestic and international markets in part through
acquisitions and joint ventures and we expect to continue to make acquisitions and enter into joint ventures in the
future. Such transactions require significant management attention, may place significant demands on our
operations, information systems, legal, regulatory, compliance-functions and financial resources, and there is risk
that one or more may not succeed. We cannot be sure, for example, that we will achieve the benefits of revenue
growth that we expect from these acquisitions or joint ventures or that we will avoid unforeseen additional costs,
taxes or expenses. Our ability to successfully implement our acquisition and joint venture strategy depends upon,
among other things, the following:
•
•
•
•
•
•
the availability of suitable acquisition or joint venture candidates at acceptable prices;
our ability to consummate such transactions, which could potentially be prohibited due to U.S. or
foreign antitrust regulations;
the liquidity of our investments and the availability of financing on acceptable terms;
our ability to retain customers or product lines of the acquired businesses or joint ventures;
our ability to retain, recruit and incentivize the management of the companies we acquire; and
our ability to successfully integrate these companies’ operations, services, products and personnel with
our culture, management policies, legal, regulatory and compliance policies, cybersecurity systems and
policies, internal procedures, working capital management, financial and operational controls and
strategies.
Furthermore, some of our acquisitions and future acquisitions may give rise to an obligation to make contingent
payments or to satisfy certain repurchase obligations, which payments could have material adverse impacts on our
financial results individually or in the aggregate.
Additionally, when we decide to sell assets or a business, we may encounter difficulty in finding buyers or
executing alternative exit strategies on acceptable terms in a timely manner, which could delay the accomplishment
of our strategic objectives. Alternatively, we may dispose of assets or a business at a price or on terms that are less
than we had anticipated. Dispositions may also involve continued financial involvement in a divested business,
such as through transition service agreements, indemnities or other current or contingent financial obligations.
Under these arrangements, performance by the acquired or divested business, or other conditions outside our
control, could affect our future financial results.
Certain provisions in our governing documents and other documents to which we are a party may discourage
third parties from seeking to acquire us that might otherwise result in our stockholders receiving a premium
over the market price of their shares.
27
The provisions of our certificate of incorporation and by-laws may make it more difficult for a third-party to
acquire us, may discourage acquisition bids and may impact the price that certain investors might be willing to pay
in the future for shares of our common stock. These provisions, among other things require (i) the affirmative vote
of the holders of at least 60% of the shares of common stock entitled to vote to approve a merger, consolidation, or
a sale, lease, transfer or exchange of all or substantially all of our assets; and (ii) the affirmative vote of the holders
of at least 66 2/3% of our common stock entitled to vote to (a) remove a director; and (b) to amend or repeal our
by-laws, with certain limited exceptions. In addition, certain of our employee incentive plans provide for
accelerated vesting of stock options and other awards upon termination without cause within two years following a
change in control, or grant the plan committee discretion to accelerate awards upon a change of control. Further,
certain agreements between us and our executive officers provide for increased severance payments and certain
benefits if those executive officers are terminated without cause by us or if they terminate for good reason, in each
case within two years following a change in control or within ninety days prior to the effective date of the change in
control or after the first public announcement of the pendency of the change in control.
Adverse changes in supplier rebates or other purchasing incentives could negatively affect our business.
The terms on which we purchase or sell products from many suppliers may entitle us to receive a rebate or other
purchasing incentive based on the attainment of certain growth goals. Suppliers may reduce or eliminate rebates or
incentives offered under their programs, or increase the growth goals or other conditions we must meet to earn rebates
or incentives to levels that we cannot achieve. Increased competition either from generic or equivalent branded
products could result in us failing to earn rebates or incentives that are conditioned upon achievement of growth
goals. Additionally, factors outside of our control, such as customer preferences, consolidation of suppliers or supply
issues, can have a material impact on our ability to achieve the growth goals established by our suppliers, which may
reduce the amount of rebates or incentives we receive. The occurrence of any of these events could have an adverse
impact on our business, financial condition or operating results.
Sales of corporate brand products entail additional risks, including the risk that such sales could adversely affect
our relationships with suppliers.
We offer certain corporate brand products that are available exclusively from us. The sale of such products subjects
us to the risks generally encountered by entities that source, market and sell corporate brand products, including but
not limited to potential product liability risks, mandatory or voluntary product recalls, potential supply chain and
distribution chain disruptions, and potential intellectual property infringement risks. Any failure to adequately address
some or all of these risks could have an adverse effect on our business, financial condition or operating results.
In addition, an increase in the sales of our corporate brand products may negatively affect our sales of products owned
by our suppliers which, consequently, could adversely impact certain of our supplier relationships. Our ability to
locate qualified, economically stable suppliers who satisfy our requirements, and to acquire sufficient products in a
timely and effective manner, is critical to ensuring, among other things, that customer confidence is not diminished.
Any failure to develop sourcing relationships with a broad and deep supplier base could have an adverse effect on
our business, financial condition or operating results.
INDUSTRY RISKS
The health care products distribution industry is highly competitive (including, without limitation, competition
from third-party online commerce sites) and consolidating, and we may not be able to compete successfully.
We compete with numerous companies, including several major manufacturers and distributors. Some of our
competitors have greater financial and other resources than we do, which could allow them to compete more
successfully. Most of our products are available from several sources and our customers tend to have relationships
with several distributors. Competitors could obtain exclusive rights to market particular products, which we would
then be unable to market. Manufacturers also could increase their efforts to sell directly to end-users and thereby
eliminate or reduce our role in distribution. Industry consolidation among health care product distributors and
manufacturers, price competition, product unavailability, whether due to our inability to gain access to products or
to interruptions in manufacturing supply, or the emergence of new competitors, also could increase competition.
28
Consolidation has also increased among manufacturers of health care products, which could have a material
adverse effect on our margins and product availability. We could be subject to charges and financial losses in the
event we fail to satisfy minimum purchase commitments contained in some of our contracts. Additionally,
traditional health care supply and distribution relationships are being challenged by electronic online commerce
solutions. The continued advancement of online commerce by third parties will require us to cost-effectively adapt
to changing technologies, to enhance existing services and to differentiate our business (including with additional
value-added services) to address changing demands of consumers and our customers on a timely basis. The
emergence of such potential competition and our inability to anticipate and effectively respond to changes on a
timely basis could have a material adverse effect on our business.
The repeal or judicial prohibition on implementation of the Affordable Care Act could materially adversely
affect our business.
The ACA greatly expanded health insurance coverage in the United States and has been the target of litigation and
Congressional reform efforts since its adoption. The U.S. Supreme Court, in upholding the constitutionality of the
ACA and its individual mandate provision in 2012, simultaneously limited ACA provisions requiring Medicaid
expansion, making such expansion a state-by-state decision. In 2017, the U.S. Congress effectively repealed the
ACA’s individual mandate provision by eliminating the financial penalty for non-compliance. In the most recent
ACA litigation, a federal appeals court found the individual mandate to be unconstitutional, and returned the case to
a lower federal court for consideration of whether the remainder of the ACA could survive the excision of the
individual mandate. This decision was appealed to the U.S. Supreme Court, and the Supreme Court issued a
decision on June 17, 2021. Without reaching the merits of the case, the Supreme Court held that the plaintiffs in
the case did not have standing to challenge the ACA. Any outcome of future cases that change the ACA, in
addition to future legislation, regulation, guidance and/or Executive Orders that do the same, could have a
significant impact on the U.S. healthcare industry. For instance, the American Rescue Plan Act of 2021 enhanced
premium tax credits, which has resulted in an expansion of the number of people covered under the ACA. These
changes are time-limited, with some enhancements in place for 2021 only and others available through the end of
2022.
The health care industry is experiencing changes due to political, economic and regulatory influences that could
materially adversely affect our business.
The health care industry is highly regulated and subject to changing political, economic and regulatory influences.
In recent years, the health care industry has undergone, and is in the process of undergoing, significant changes
driven by various efforts to reduce costs, including, among other factors: trends toward managed care; collective
purchasing arrangements and consolidation among office-based health care practitioners; and changes in
reimbursements to customers, including increased attention to value-based payment arrangements, as well as
growing enforcement activities (and related monetary recoveries) by governmental officials. Both our profitability
and the profitability of our customers may be materially adversely affected by laws and regulations reducing
reimbursement rates for pharmaceuticals, medical supplies and devices, and/or medical treatments or services, or
changes to the methodology by which reimbursement levels are determined. If we are unable to react effectively to
these and other changes in the health care industry, our business could be materially adversely affected.
Expansion of group purchasing organizations (“GPO”), dental support organizations (“DSO”) or provider
networks and the multi-tiered costing structure may place us at a competitive disadvantage.
The health care products industry is subject to a multi-tiered costing structure, which can vary by manufacturer
and/or product. Under this structure, certain institutions can obtain more favorable prices for health care products
than we are able to obtain. The multi-tiered costing structure continues to expand as many large integrated health
care providers and others with significant purchasing power, such as GPOs and DSOs, demand more favorable
pricing terms. Additionally, the formation of provider networks, GPOs and DSOs may shift purchasing decisions
to entities or persons with whom we do not have a historical relationship and may threaten our ability to compete
effectively, which could in turn negatively impact our financial results. Although we are seeking to obtain similar
terms from manufacturers to access lower prices demanded by GPO and DSO contracts or other contracts, and to
develop relationships with existing and emerging provider networks, GPOs and DSOs, we cannot guarantee that
such terms will be obtained or contracts executed.
29
Increases in shipping costs or service issues with our third-party shippers could harm our business.
Our ability to meet our customers’ expedited delivery expectations is an integral component of our business
strategy for which our customers rely. Shipping is a significant expense in the operation of our business. We ship
almost all of our orders through third-party delivery services, and typically bear the cost of shipment. Accordingly,
any significant increase in shipping rates could have a material adverse effect on our business, financial condition
or operating results. While we have recently experienced increases in the cost of shipping, we do not expect these
additional expenses to be material to our results. However, it is possible that such costs could be material in the
future. Similarly, strikes or other service interruptions by those shippers, including at transportation centers or
shipping ports, could cause our operating expenses to rise and materially adversely affect our ability to deliver
products on a timely basis.
MACRO ECONOMIC AND POLITICAL RISKS
Uncertain global and domestic macro-economic and political conditions could materially adversely affect our
results of operations and financial condition.
Uncertain global and domestic macro-economic and political conditions that affect the economy and the economic
outlook of the United States, Europe, Asia and other parts of the world could materially adversely affect our results
of operations and financial condition. These uncertainties, include, among other things:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
election results;
changes to laws and policies governing foreign trade (including, without limitation, the United States-
Mexico-Canada Agreement (USMCA), the EU-UK Trade and Cooperation Agreement of December
2020 (that went into effect in 2021) and other international trade agreements);
greater restrictions on imports and exports;
supply chain disruptions;
changes in laws and policies governing health care or data privacy;
tariffs and sanctions;
changes to the relationship between the United States and China;
sovereign debt levels;
the inability of political institutions to effectively resolve actual or perceived economic, currency or
budgetary crises or issues;
consumer confidence;
unemployment levels (and a corresponding increase in the uninsured and underinsured population);
changes in regulatory and tax regulations;
interest rate fluctuations, and strengthening of the dollar, which have and will continue to impact our
results of operations;
availability of capital;
increases in fuel and energy costs;
the effect of inflation on our ability to procure products and our ability to increase prices over time and
pass through to our customers price increases we may receive;
changes in tax rates and the availability of certain tax deductions;
increases in labor costs;
increases in health care costs;
our aspirations, goals and disclosures related to environmental, social and governance (ESG) matters;
the threat or outbreak of war, terrorism or public unrest (including, without limitation, the war in
Ukraine and the possibility of a wider European or global conflict); and
changes in laws and policies governing manufacturing, development and investment in territories and
countries where we do business.
30
Additionally, changes in government, government debt and/or budget crises may lead to reductions in government
spending in certain countries, which could reduce overall health care spending, and/or higher income or corporate
taxes, which could depress spending overall. Recessionary or inflationary conditions and depressed levels of
consumer and commercial spending may also cause customers to reduce, modify, delay or cancel plans to purchase
our products and may cause suppliers to reduce their output or change their terms of sale. We have experienced
inflationary pressures, including higher freight costs and interest expense. Although inflation impacts both our
revenues and costs, the depth and breadth of our product portfolio often allows us to offer lower-cost national brand
solutions or corporate brand alternatives to our more price-sensitive customers who are unable to absorb price
increases, thus positioning us to protect our gross profit. The strengthening of the dollar, likewise, has impacted
our revenues and costs, but neither inflation nor exchange rates have materially impacted our results of operations
in fiscal year 2022. We generally sell products to customers with payment terms. If customers’ cash flow or
operating and financial performance deteriorate, or if they are unable to make scheduled payments or obtain credit,
they may not be able to, or may delay, payment to us. Likewise, for similar reasons suppliers may restrict credit or
impose different payment terms.
REGULATORY AND LITIGATION RISKS
Failure to comply with existing and future regulatory requirements could materially adversely affect our
business.
We strive to be compliant with the applicable laws, regulations and guidance described below in all material
respects, and believe we have effective compliance programs and other controls in place to ensure substantial
compliance. However, compliance is not guaranteed either now or in the future as certain laws, regulations and
guidance may be subject to varying and evolving interpretations that could affect our ability to comply, as well as,
future changes, additions and enforcement approaches, including in light of political changes. When we discover
situations of non-compliance we seek to remedy them and bring the affected area back into compliance. The Biden
Administration has indicated that it will be more aggressive in its pursuing alleged violations of law, and it has
revoked certain guidance that would have limited governmental use of informal agency guidance to pursue such
violations, as well as indicating it was more prepared to pursue individuals for corporate law violations, including
an aggressive approach to anti-corruption activities. Changes with respect to the applicable laws, regulations and
guidance described below may require us to update or revise our operations, services, marketing practices, and
compliance programs and controls, and may impose additional and unforeseen costs on us, pose new or previously
immaterial risks to us, or may otherwise have a material adverse effect on our business. There can be no assurance
that current and future government regulations will not adversely affect our business, and we cannot predict new
regulatory priorities, the form, content or timing of regulatory actions, and their impact on the health care industry
and on our business and operations.
Global efforts toward healthcare cost containment continue to exert pressure on product pricing. In the United
States, in addition to other government efforts to control health care costs, there has been increased scrutiny on drug
pricing and concurrent efforts to control or reduce drug costs by Congress, the President, executive branch agencies
and various states. At the state level, several states have adopted laws that require drug manufacturers to provide
advance notice of certain price increases and to report information relating to those price increases, while others
have taken legislative or administrative action to establish prescription drug affordability boards or multi-payer
purchasing pools to reduce the cost of prescription drugs. At the federal level, several related bills have been
introduced and regulations proposed which, if enacted or finalized, respectively, would impact drug pricing and
related costs.
Under the Sunshine Act, we are required to collect and report detailed information regarding certain financial
relationships we have with covered recipients, including physicians, dentists, teaching hospitals, and certain other
non-physician practitioners. We and our subsidiaries may be required to report information under certain state
transparency laws that address circumstances not covered by the Sunshine Act, and some of these state laws, as
well as the federal law, can be unclear. We are also subject to foreign regulations requiring transparency of certain
interactions between suppliers and their customers. While we believe we have substantially compliant programs
and controls in place satisfying the above laws and requirements, such compliance imposes additional costs on us
and the requirements are sometimes unclear. In the United States, government actions to seek to increase health-
related price transparency may also affect our business.
31
Our business is subject to additional requirements under various local, state, federal and international laws and
regulations applicable to the sale and distribution of, and third-party payment for, pharmaceuticals and medical
devices and HCT/P products. Among the federal laws with which we must comply are the Controlled Substances
Act, the FDC Act, the Federal Drug Quality and Security Act, including DSCSA, Section 361 of the Public Health
Services Act and Section 401 of the Consolidated Appropriations Act of the Social Security Act. Among other
things, such laws, and the regulations promulgated thereunder:
•
•
•
•
•
•
•
•
•
•
•
regulate the introduction, manufacture, advertising, marketing and promotion, sampling, pricing and
reimbursement, labeling, packaging, storage, handling, returning or recalling, reporting, and
distribution of, and record keeping for drugs, HCT/P products and medical devices, including
requirements with respect to unique medical device identifiers;
subject us to inspection by the FDA and DEA and similar state authorities;
regulate the storage, transportation and disposal of certain of our products that are considered
hazardous materials;
require us to advertise and promote our drugs and devices in accordance with applicable FDA
requirements;
require us to report average sales price (ASP) for drugs or biologicals payable under Medicare Part B to
CMS with or without a Medicaid drug rebate agreement;
require registration with the FDA and the DEA and various state agencies;
require record keeping and documentation of transactions involving drug products;
require us to design and operate a system to identify and report suspicious orders of controlled
substances to the DEA and certain states;
require us to manage returns of products that have been recalled and subject us to inspection of our
recall procedures and activities;
impose on us reporting requirements if a pharmaceutical, HCT/P product or medical device causes
serious illness, injury or death;
require manufacturers, wholesalers, repackagers and dispensers of prescription drugs to identify and
trace certain prescription drugs as they are distributed;
require the licensing of prescription drug wholesalers and third-party logistics providers; and
•
• mandate compliance with standards for the recordkeeping, storage and handling of prescription drugs,
and associated reporting requirements.
The FDA has become increasingly active in addressing the regulation of computer software and digital health
products intended for use in health care settings. The Cures Act, signed into law on December 13, 2016, among
other things, amended the medical device definition to exclude certain software from FDA regulation, including
certain clinical decision support software. On September 27, 2019, the FDA issued a suite of guidance documents
on digital health products, which incorporated applicable Cures Act standards, and on September 28, 2022, the
FDA subsequently finalized certain of these guidance documents, including regarding the types of clinical decision
support tools and other software that are exempt from regulation by the FDA as medical devices, and the FDA
continues to issue new guidance in this area. Certain of our businesses involve the development and sale of
software and related products to support physician and dental practice management, and it is possible that the FDA
or foreign government authorities could determine that one or more of our products is subject to regulation as a
medical device, which could subject us or one or more of our businesses to substantial additional requirements,
costs and potential enforcement actions or liabilities for noncompliance with respect to these products.
Applicable federal, state, local and foreign laws and regulations also may require us to meet various standards
relating to, among other things, licensure or registration, program eligibility, procurement, third-party
reimbursement, sales and marketing practices, product integrity and supply tracking to product manufacturers,
product labeling, personnel, privacy and security of health or other personal information, installation, maintenance
and repair of equipment and the importation and exportation of products. The FDA and DEA, as well as CMS
(including with respect to complex Medicare reimbursement requirements applicable to our specialty home medical
supplies business), have recently increased their regulatory and enforcement activities and, in particular, the DEA
has heightened enforcement activities due to the opioid crisis in the United States. One of our businesses was
32
suspended in October 2021 by CMS from receiving payments from Medicare, although it was permitted to continue
to perform and bill for Medicare services. On September 30, 2022, CMS terminated the suspension of Medicare
payments. As a result of the termination of the suspension, we recognized $4 million of previously deferred
revenue during the year ended December 31, 2022. Our business is also subject to requirements of similar and
other foreign governmental laws and regulations affecting our operations abroad.
The failure to comply with any of these laws or regulations, or new interpretations of existing laws and regulations,
or the imposition of any additional laws and regulations, could materially adversely affect our business. The costs
to us associated with complying with the various applicable statutes and regulations, as they now exist and as they
may be modified, could be material. Allegations by a governmental body that we have not complied with these
laws could have a material adverse effect on our businesses. While we believe that we are substantially compliant
with applicable laws and regulations, and believe we have adequate compliance programs and controls in place to
ensure substantial compliance, if it is determined that we have not complied with these laws, we are potentially
subject to warning letters, substantial civil and criminal penalties, mandatory recall of product, seizure of product
and injunction, consent decrees and suspension or limitation of payments to us, product sale and distribution. If we
enter into settlement agreements to resolve allegations of non-compliance, we could be required to make settlement
payments or be subject to civil and criminal penalties, including fines and the loss of licenses. Non-compliance
with government requirements could also adversely affect our ability to participate in important federal and state
government health care programs, such as Medicare and Medicaid, and damage our reputation.
The EU Medical Device Regulation may adversely affect our business.
The EU MDR, applicable since May 26, 2021, significantly modifies and intensifies the regulatory compliance
requirements for the medical device industry as a whole. Among other things, the EU MDR:
•
•
•
•
•
•
strengthens the rules on placing devices on the market and reinforce surveillance once they are
available;
establishes explicit provisions on manufacturers’ responsibilities for the follow-up of the quality,
performance and safety of devices placed on the market;
improves the traceability of medical devices throughout the supply chain to the end-user or patient
through a unique identification number;
sets up a central database to provide patients, healthcare professionals and the public with
comprehensive information on products available in the EU;
strengthens rules for the assessment of certain high-risk devices, such as implants, which may have to
undergo an additional check by experts before they are placed on the market; and
identifies importers and distributors and medical device products through registration in a database
(EUDAMED not due until 2024 and after as mentioned above).
In particular, the EU MDR imposes strict requirements for the confirmation that a product meets the regulatory
requirements, including regarding a product’s clinical evaluation and a company’s quality systems, and for the
distribution, marketing and sale of medical devices, including post-market surveillance. Medical devices that have
been assessed and/or certified under the EU Medical Device Directive may continue to be placed on the market
until 2024 (or until the expiry of their certificates, if applicable and earlier). However, on January 6, 2023, the EU
Commission submitted a proposed amendment to extend the MDR transitional periods until December 31, 2028,
for certain medical devices to ensure continued access to medical devices for patients and to allow medical devices
already placed on the market in accordance with the current legal framework to remain on the market. We continue
to monitor developments and whether the proposed amendment and new deadlines will be approved by the
European Parliament and Council. Nevertheless, EU MDR requirements regarding the distribution, marketing and
sale including quality systems and post-market surveillance have to be observed by manufacturers, importers and
distributors as of the application date (i.e., May 26, 2021).
The modifications created by the EU MDR may have an impact on the way we design and manufacture products
and the way we conduct our business in the European Economic Area.
33
If we fail to comply with laws and regulations relating to health care fraud or other laws and regulations, we
could suffer penalties or be required to make significant changes to our operations, which could materially
adversely affect our business.
Certain of our businesses are subject to federal and state (and similar foreign) health care fraud and abuse, referral
and reimbursement laws and regulations with respect to their operations. Some of these laws, referred to as “false
claims laws,” prohibit the submission or causing the submission of false or fraudulent claims for reimbursement to
federal, state and other health care payers and programs. Other laws, referred to as “anti-kickback laws,” prohibit
soliciting, offering, receiving or paying remuneration in order to induce the referral of a patient or ordering,
purchasing, leasing or arranging for, or recommending ordering, purchasing or leasing of, items or services that are
paid for by federal, state and other health care payers and programs. Certain additional state and federal laws, such
as the federal Physician Self-Referral Law, commonly known as the “Stark Law,” prohibit physicians and other
health professionals from referring a patient to an entity with which the physician (or family member) has a
financial relationship, for the furnishing of certain designated health services (for example, durable medical
equipment and medical supplies), unless an exception applies. Violations of Anti-Kickback statutes or the Stark
Law may be enforced as violations of the federal False Claims Act.
The fraud and abuse laws and regulations have been subject to heightened enforcement activity over the past few
years, and significant enforcement activity has been the result of “relators” who serve as whistleblowers by filing
complaints in the name of the United States (and if applicable, particular states) under applicable false claims laws,
and who may receive up to 30% of total government recoveries. Penalties under fraud and abuse laws may be
severe, including treble damages and substantial civil penalties under the federal False Claims Act, as well as
potential loss of licenses and the ability to participate in federal and state health care programs, criminal penalties,
or imposition of a corporate compliance monitor, which could have a material adverse effect on our business. Also,
these measures may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that
could require us to make changes in our operations or incur substantial defense and settlement expenses. Even
unsuccessful challenges by regulatory authorities or private relators could result in reputational harm and the
incurring of substantial costs. Most states have adopted similar state false claims laws, and these state laws have
their own penalties which may be in addition to federal False Claims Act penalties, as well as other fraud and abuse
laws.
With respect to measures of this type, the United States government (among others) has expressed concerns about
financial relationships between suppliers on the one hand and physicians, dentists and other health care providers,
on the other. As a result, we regularly review and revise our marketing practices as necessary to facilitate
compliance.
In the EU, the Directive No. 2019/1937 of October 23, 2019, on the protection of persons who report breaches of
Union law, organizes the legal protection of whistleblowers. This Directive covers whistleblowers reporting
breaches of certain EU laws, in particular as regards public health, the above-mentioned Directive No. 2001/83,
Regulation No. 726/2004 or, as regards data protection, the GDPR. The Directive protects a wide range of people
and includes former employees. All private companies with 50 or more employees are required to create effective
internal reporting channels. Though it was required before December 17, 2021, at the latest, the implementation of
this Directive by EU member states is still underway for some of them. At the end of January 2023 and according
to information available on public sources, sixteen EU member states have fully implemented it (France, Belgium,
Denmark, Finland, Latvia, The Netherlands, Ireland, Croatia, Cyprus, Greece, Lithuania, Romania, Malta, Portugal,
Sweden and Bulgaria) while the process is ongoing in the others with varying degrees of progress.
We also are subject to the requirements of the new Directive No. 2022/2464 on corporate sustainability reporting
("CSR Directive") adopted on December 14, 2022 and has to be implemented by EU members states by July 6,
2024, at the latest. By amending Directives No. 2004/109, No. 2006/43, No. 2013/34 and Regulation No. 537/2014,
the CSR Directive strengthens the existing rules on non-financial reporting by setting new requirements for large
companies to publish sustainability-related information and, in particular, disclose details about their risks and
impacts on environmental matters.
We also are subject to certain United States and foreign laws and regulations concerning the conduct of our foreign
operations, including the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, German anti-corruption laws
34
and other anti-bribery laws and laws pertaining to the accuracy of our internal books and records, which have been
the focus of increasing enforcement activity globally in recent years. Our businesses are generally subject to
numerous other laws and regulations that could impact our financial results, including, without limitation,
securities, antitrust, consumer protection, and marketing laws and regulations.
In the EU, both active and passive bribery are criminalized. The EU Council Framework Decision 2003/568/JHA
of 22 July 2003 on combating corruption in the private sector establishes more detailed rules on the liability of
legal persons and deterrent sanctions. However, the liability of legal persons is regulated at a national level.
Failure to comply with fraud and abuse laws and regulations, and other laws and regulations, could result in
significant civil and criminal penalties and costs, including the loss of licenses and the ability to participate in
federal and state health care programs, and could have a material adverse effect on our business. We may
determine to enter into settlements, make payments, agree to consent decrees or enter into other arrangements to
resolve such matters. Intentional or unintentional failure to comply with consent decrees could materially adversely
affect our business.
While we believe that we are substantially compliant with applicable fraud and abuse and other laws and
regulations, and believe we have adequate compliance programs and controls in place to ensure substantial
compliance, we cannot predict whether changes in applicable law, or interpretation of laws, or changes in our
services or marketing practices in response to changes in applicable law or interpretation of laws, could have a
material adverse effect on our business.
If we fail to comply with laws and regulations relating to the collection, storage and processing of sensitive
personal information or standards in electronic health records or transmissions, we could be required to make
significant changes to our products, or incur substantial fines, penalties or other liabilities.
Our businesses that involve physician and dental practice management products, and our specialty home medical
supply business, include electronic information technology systems that store and process personal health, clinical,
financial and other sensitive information of individuals. These information technology systems may be vulnerable
to breakdown, wrongful intrusions, data breaches and malicious attack, which could require us to expend
significant resources to eliminate these problems and address related security concerns, and could involve claims
against us by private parties and/or governmental agencies.
We are directly or indirectly subject to numerous and evolving federal, state, local and foreign laws and regulations
that protect the privacy and security of personal information, such as HIPAA, the Controlling the Assault of Non-
Solicited Pornography and Marketing Act, the Telephone Consumer Protection Act of 1991, Section 5 of the
Federal Trade Commission Act, the CCPA, and the CPRA that becomes effective on January 1, 2023. Laws and
regulations relating to privacy and data protection are continually evolving and subject to potentially differing
interpretations. These requirements may not be harmonized, may be interpreted and applied in a manner that is
inconsistent from one jurisdiction to another or may conflict with other rules or our practices. Our businesses’
failure to comply with these laws and regulations could expose us to breach of contract claims, substantial fines,
penalties and other liabilities and expenses, costs for remediation and harm to our reputation. Also, evolving laws
and regulations in this area could restrict the ability of our customers to obtain, use or disseminate patient
information, or could require us to incur significant additional costs to re-design our products to reflect these legal
requirements, which could have a material adverse effect on our operations.
In addition, the European Parliament and the Council of the EU adopted the GDPR effective from May 25, 2018,
which increased privacy rights for individuals (“Data Subjects”), including individuals who are our customers,
suppliers and employees. The GDPR extended the scope of responsibilities for data controllers and data
processors, and generally imposes increased requirements and potential penalties on companies, such as us, that are
either established in the EU and process personal data of Data Subjects (regardless the Data Subject location), or
that are not established in the EU but that offer goods or services to Data Subjects in the EU or monitor their
behavior in the EU. Noncompliance can result in penalties of up to the greater of EUR 20 million, or 4% of global
company revenues (sanction that may be public), and Data Subjects may seek damages. Member states may
individually impose additional requirements and penalties regarding certain limited matters (for which the GDPR
left some room of flexibility), such as employee personal data. With respect to the personal data it protects, the
35
GDPR requires, among other things, controller accountability, consents from Data Subjects or another acceptable
legal basis to process the personal data, notification within 72 hours of a personal data breach where required, data
integrity and security, and fairness and transparency regarding the storage, use or other processing of the personal
data. The GDPR also provides rights to Data Subjects relating notably to information, access, rectification, erasure
of the personal data and the right to object to the processing.
On August 20, 2021, China promulgated the PIPL, which took effect on November 1, 2021. The PIPL imposes
specific rules for processing personal information and it also specifies that the law shall also apply to personal
information activities carried out outside China but for the purpose of providing products or services to PRC
citizens. Any non-compliance with these laws and regulations may subject us to fines, orders to rectify or terminate
any actions that are deemed illegal by regulatory authorities, other penalties, as well as reputational damage or legal
proceedings against us, which may affect our business, financial condition or results of operations. The PIPL
carries maximum penalties of CNY50 million or 5% of the annual revenue of entities that process personal data.
In the United States, the CCPA, which increases the privacy protections afforded California residents, became
effective January 1, 2020. The CCPA generally requires companies, such as us, to institute additional protections
regarding the collection, use and disclosure of certain personal information of California residents. Compliance
with the obligations imposed by the CCPA depends in part on how particular regulators interpret and apply them.
Regulations were released in August of 2020, but there remains some uncertainty about how the CCPA will be
interpreted by the courts and enforced by the regulators. If we fail to comply with the CCPA or if regulators assert
that we have failed to comply with the CCPA, we may be subject to certain fines or other penalties and litigation,
any of which may negatively impact our reputation, require us to expend significant resources, and harm our
business. Furthermore, California voters approved the CPRA on November 3, 2020, which will amend and expand
the CCPA, including by providing consumers with additional rights with respect to their personal information, and
creating a new state agency to enforce CCPA and CPRA. The CPRA came into effect on January 1, 2023, applying
to information collected by businesses on or after January 1, 2022.
Other states, as well as the federal government, have increasingly considered the adoption of similarly expansive
personal privacy laws, backed by significant civil penalties for non-compliance. Virginia and Colorado were both
successful in passing privacy legislation in 2021, becoming effective on January 1, 2023 and July 1, 2023,
respectively. Connecticut and Utah also passed comprehensive privacy laws that will go into effect in July 1, 2023
and December 31, 2023. While we believe we have substantially compliant programs and controls in place to
comply with the GDPR, CCPA, PIPL and CPRA requirements, our compliance with data privacy and cybersecurity
laws is likely to impose additional costs on us, and we cannot predict whether the interpretations of the
requirements, or changes in our practices in response to new requirements or interpretations of the requirements,
could have a material adverse effect on our business.
We also sell products and services that health care providers, such as physicians and dentists, use to store and
manage patient medical or dental records. These customers and we are subject to laws, regulations and industry
standards, such as HIPAA and the Payment Card Industry Data Security Standards, which require the protection of
the privacy and security of those records. Our products or services may be used as part of these customers’
comprehensive data security programs, including in connection with their efforts to comply with applicable data
privacy and security laws and contractual requirements. Perceived or actual security vulnerabilities in our products
or services, or the perceived or actual failure by us or our customers who use our products or services to comply
with applicable legal or contractual data privacy and security requirements, may not only cause us significant
reputational harm, but may also lead to claims against us by our customers and/or governmental agencies and
involve substantial fines, penalties and other liabilities and expenses and costs for remediation.
Under the GDPR, health data belong to the category of “sensitive data” and benefit from specific protections.
Processing of such data is generally prohibited, except for specific exceptions.
Certain of our businesses involve the manufacture and sale of EHR systems and other products linked to
government supported incentive programs, where the EHR systems must be certified as having certain capabilities
designated in evolving standards, such as those adopted by CMS and ONC. In order to maintain certification of our
EHR products, we must satisfy the changing governmental standards. If any of our EHR systems do not meet these
standards, yet have been relied upon by health care providers to receive federal incentive payments, we may be
36
exposed to risk, such as under federal health care fraud and abuse laws, including the False Claims Act. While we
believe we are substantially in compliance with such certifications and with applicable fraud and abuse laws and
regulations and that we have adequate compliance programs and controls in place to ensure substantial compliance,
we cannot predict whether changes in applicable law, or interpretation of laws, or resulting changes in our, could
have a material adverse effect on our business.
Moreover, in order to satisfy our customers and comply with evolving legal requirements, our products may need to
incorporate increasingly complex functionality, such as with respect to reporting and information blocking.
Although we believe we are positioned to accomplish this, the effort may involve increased costs, and our failure to
implement product modifications, or otherwise satisfy applicable standards, could have a material adverse effect on
our business.
Additionally, as electronic medical devices are increasingly connected to each other and to other technology, the
ability of these connected systems to safely and effectively exchange and use exchanged information becomes
increasingly important. As a medical device manufacturer, we must manage risks including those associated with
an electronic interface that is incorporated into a medical device.
Tax legislation could materially adversely affect our financial results and tax liabilities.
We are subject to the tax laws and regulations of the United States federal, state and local governments, as well as
foreign jurisdictions. From time to time, various legislative initiatives may be proposed that could materially
adversely affect our tax positions. There can be no assurance that our effective tax rate will not be materially
adversely affected by legislation resulting from these initiatives. In addition, tax laws and regulations are extremely
complex and subject to varying interpretations. Although we believe that our historical tax positions are sound and
consistent with applicable laws, regulations and existing precedent, there can be no assurance that our tax positions
will not be challenged by relevant tax authorities or that we would be successful in any such challenge.
We face inherent risk of exposure to product liability, intellectual property infringement and other claims in the
event that the use of the products we sell results in injury.
Our business involves a risk of product liability, intellectual property infringement and other claims in the ordinary
course of business, and from time to time we are named as a defendant in cases as a result of our distribution of
products. Additionally, we own interests in companies that manufacture certain dental products. As a result, we
could be subject to the potential risk of product liability, intellectual property infringement or other claims relating
to the manufacture and distribution of products by those entities. In addition, as our corporate brand business
continues to grow, purchasers of such products may increasingly seek recourse directly from us, rather than the
ultimate product manufacturer, for product-related claims. Another potential risk we face in the distribution of our
products is liability resulting from counterfeit or tainted products infiltrating the supply chain. In addition, some of
the products that we transport and sell are considered hazardous materials. The improper handling of such
materials or accidents involving the transportation of such materials could subject us to liability or at least legal
action that could harm our reputation.
Customs policies or legislative import restrictions could hinder the Company’s ability to import goods necessary
to our operations on a timely basis and result in government enforcement actions and/or sanctions.
Government-imposed import policies and legislation regulating the import of goods and prohibiting the use of
forced labor or human trafficking could result in delays or the inability to import goods in a timely manner that are
necessary to our operations, and such policies or legislation could also result in financial penalties, other sanctions,
government enforcement actions and reputational harm. While the Company has policies against and seeks to
avoid the import of goods that are manufactured in whole or in part by forced labor or through human trafficking,
as a result of legislative and governmental policy initiatives, we may be subject to increasing potential delays,
added costs, supply chain disruption and other restrictions.
37
GENERAL RISKS
Security risks generally associated with our information systems and our technology products and services could
materially adversely affect our business, and our results of operations could be materially adversely affected if
such products, services or systems (or third-party systems we rely on) are interrupted, damaged by unforeseen
events, are subject to cyberattacks or fail for any extended period of time.
We rely on information systems (IS) in our business to obtain, rapidly process, analyze, manage and store customer,
product, supplier and employee data to, among other things:
• maintain and manage worldwide systems to facilitate the purchase and distribution of thousands of
inventory items from numerous distribution centers;
receive, process and ship orders on a timely basis;
•
• manage the accurate billing and collections for thousands of customers;
•
•
process payments to suppliers; and
provide products and services that maintain certain of our customers’ electronic medical or dental
records (including protected health information of their patients).
Information security risks have generally increased in recent years, and a cyberattack that bypasses our IS security
systems (including third-party systems we rely on) causing an IS security breach may lead to a material disruption
of our IS business systems (including third-party systems we rely on) and/or the loss of business information, as
well as claims against us by affected parties and/or governmental agencies, and involve fines and penalties, costs
for remediation, and substantial defense and settlement expenses. In addition, we develop products and provide
services to our customers that are technology-based, and a cyberattack that bypasses the IS security systems of our
products or services causing a security breach and/or perceived security vulnerabilities in our products or services
could also cause significant loss of business and reputational harm, and actual or perceived vulnerabilities may lead
to claims against us by our customers and/or governmental agencies. In particular, certain of our practice
management products and services purchased by health care providers, such as physicians and dentists, are used to
store and manage patient medical or dental records. These customers are subject to laws and regulations which
require that they protect the privacy and security of those records, and our products may be used as part of these
customers’ comprehensive data security programs, including in connection with their efforts to comply with
applicable privacy and security laws. Perceived or actual security vulnerabilities in our products or services, or the
perceived or actual failure by us or our customers who use our products to comply with applicable legal
requirements, may not only cause reputational harm and loss of business, but may also lead to claims against us by
our customers and/or governmental agencies and involve damages, fines and penalties, costs for remediation, and
substantial defense and settlement expenses. In addition, a cyberattack on a third-party that we use to manage a
portion of our information systems could result in the same effects. Additionally, legislative or regulatory action
related to cybersecurity may increase our costs to develop or implement new technology products and services.
From time to time, we have had to address immaterial security incidents (“security incidents”). There can be no
assurance that we will not experience material security incidents in the future. Security incidents can be difficult to
detect and any delay in identifying them could increase their harm. While we have implemented measures to
protect our IS systems, such measures may not prevent these events. Any such security incidents could disrupt our
operations, harm our reputation or otherwise have a material adverse effect on our business. We have various
insurance policies, including cybersecurity insurance, covering risks and in amounts that we consider adequate.
There can be no assurance that the insurance coverage we maintain is sufficient or will be available in adequate
amounts or at a reasonable cost to cover costs and expenses related to security incidents.
Furthermore, procedures and safeguards must continually evolve to meet new IS challenges, and enhancing
protections, and conducting investigations and remediation, may impose additional costs on us.
Finally, our business may be interrupted by shortfalls of IS systems providers engaged by our customers, such as
Internet-based services upon which our customers depend to access certain of our products.
38
Our global operations are subject to inherent risks that could materially adversely affect our business.
Our global operations are subject to risks that could materially adversely affect our business. The risks that our
global operations are subject to include, among other things:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
difficulties and costs relating to staffing and managing foreign operations;
difficulties and delays inherent in sourcing products, establishing channels of distribution and contract
manufacturing in foreign markets;
fluctuations in the value of foreign currencies (including, without limitation, in connection with
Brexit);
uncertainties relating to the EU-UK Trade and Cooperation Agreement of December 2020, which went
into effect in 2021, including for example potential implementation issues, potential disputes over the
interpretation of the provisions of the Agreement and possible changes to the Agreement restricting the
free movement of goods between the U.K. and the European Union;
longer payment cycles of foreign customers and difficulty of collecting receivables in foreign
jurisdictions;
repatriation of cash from our foreign operations to the United States;
regulatory requirements, including, without limitation, anti-bribery, anti-corruption and laws pertaining
to the accuracy of our internal books and records;
litigation risks, new or unanticipated litigation developments and the status of litigation matters;
unexpected difficulties in importing or exporting our products and import/export tariffs, quotas,
sanctions or penalties;
limitations on our ability under local laws to protect our intellectual property;
unexpected regulatory, legal, economic and political changes in foreign markets;
changes in tax regulations that influence purchases of capital equipment;
civil disturbances, geopolitical turmoil, including terrorism, war or political or military coups;
risks associated with climate change, including physical risks such as impacts from extreme weather
events and other potential physical consequences, regulatory and technological requirements, market
developments, stakeholder expectations and reputational risk; and
public health emergencies, including COVID-19.
Our future success is substantially dependent upon our senior management, and our revenues and profitability
depend on our relationships with capable sales personnel as well as customers, suppliers and manufacturers of
the products that we distribute.
Our future success is substantially dependent upon the efforts and abilities of members of our existing senior
management, particularly Stanley M. Bergman, Chairman and Chief Executive Officer. The loss of the services of
Mr. Bergman could have a material adverse effect on our business. We have an employment agreement with Mr.
Bergman. We do not currently have “key man” life insurance policies on any of our employees. Competition for
senior management is intense, burnout and turn-over rates are increasing workplace concerns during and after the
COVID-19 pandemic, and we may not be successful in attracting and retaining key personnel. Additionally, our
future revenues and profitability depend on our ability to maintain satisfactory relationships with qualified sales
personnel as well as customers, suppliers and manufacturers. If we fail to maintain our existing relationships with
such persons or fail to acquire relationships with such key persons in the future, our business may be materially
adversely affected.
Disruptions in the financial markets may materially adversely affect the availability and cost of credit to us.
Our ability to make scheduled payments or refinance our obligations with respect to indebtedness will depend on
our operating and financial performance, which in turn is subject to prevailing economic conditions and financial,
business and other factors beyond our control. Disruptions in the financial markets may materially adversely affect
the availability and cost of credit to us.
39
Item 1B. Unresolved Staff Comments
We have no unresolved comments from the staff of the SEC that were issued 180 days or more preceding the end of
our 2022 fiscal year.
ITEM 2. Properties
Within our health care distribution segment (for properties with more than 100,000 square feet) we lease and/or
own approximately 5.8 million square feet of properties, consisting of distribution, office, showroom,
manufacturing and sales space, in locations including the United States, Australia, Austria, Belgium, Brazil,
Canada, Chile, China, the Czech Republic, France, Germany, Hong Kong SAR, Ireland, Israel, Italy, Japan,
Liechtenstein, Luxembourg, Malaysia, Mexico, the Netherlands, New Zealand, Poland, Portugal, Singapore, South
Africa, Spain, Sweden, Switzerland, Thailand, United Arab Emirates and the United Kingdom. Lease expirations
range from 2023 to 2041.
We believe that our properties are in good condition, are well maintained and are suitable and adequate to carry on
our business. We have additional operating capacity at certain distribution center facilities.
ITEM 3. Legal Proceedings
For a discussion of Legal Proceedings, see Note 15 – Commitments and Contingencies of the Notes to the
Consolidated Financial Statements included under Item 8.
ITEM 4. Mine Safety Disclosures
Not applicable.
40
PART II
ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of
Equity Securities
Our common stock is traded on the Nasdaq Global Select Market tier of the Nasdaq Stock Market, or Nasdaq,
under the symbol HSIC.
On February 7, 2023, there were approximately 88,000 holders of record of our common stock and the last reported
sales price was $87.14. A substantially greater number of holders of our common stock are “street name” or
beneficial holders, whose shares are held by banks, brokers and other financial institutions.
Purchases of Equity Securities by the Issuer
Our share repurchase program, announced on March 3, 2003, originally allowed us to repurchase up to two million
shares pre-stock splits (eight million shares post-stock splits) of our common stock, which represented
approximately 2.3% of the shares outstanding at the commencement of the program. Subsequent additional
increases totaling $4.5 billion, authorized by our Board of Directors, to the repurchase program provide for a total
of $4.6 billion (including $400 million authorized on August 17, 2022) of shares of our common stock to be
repurchased under this program.
As of December 31, 2022, we had repurchased approximately $4.5 billion of common stock (87,180,669 shares)
under these initiatives, with $115 million available for future common stock share repurchases.
On February 8, 2023, our Board of Directors authorized the repurchase of up to an additional $400 million in shares
of our common stock.
The following table summarizes repurchases of our common stock under our stock repurchase program during the
fiscal quarter ended December 31, 2022:
Total
Number
of Shares
Fiscal Month
Purchased (1)
9/25/2022 through 10/29/2022
10/30/2022 through 11/26/2022
11/27/2022 through 12/31/2022
-
1,249,083 $
2,333,467
3,582,550
Average
Price Paid
Per Share
-
76.29
81.30
Total Number
of Shares
Purchased as Part
of Our Publicly
Maximum Number
of Shares
that May Yet
Be Purchased Under
Announced Program
Our Program (2)
-
1,249,083
2,333,467
3,582,550
5,703,693
3,741,485
1,439,841
(1) All repurchases were executed in the open market under our existing publicly announced authorized program.
(2)
The maximum number of shares that may yet be purchased under this program is determined at the end of each month based on the
closing price of our common stock at that time. This table excludes shares withheld from employees to satisfy minimum tax
withholding requirements for equity-based transactions.
Dividend Policy
We have not declared any cash or stock dividends on our common stock during fiscal years 2022 or 2021. We
currently do not anticipate declaring any cash or stock dividends on our common stock in the foreseeable future.
We intend to retain earnings to finance the expansion of our business and for general corporate purposes, including
our share repurchase program. Any declaration of dividends will be at the discretion of our Board of Directors and
will depend upon the earnings, financial condition, capital requirements, level of indebtedness, contractual
restrictions with respect to payment of dividends and other factors.
41
Stock Performance Graph
The graph below compares the cumulative total stockholder return on $100 invested, assuming the reinvestment of
all dividends, on December 30, 2017, the last trading day before the beginning of our 2018 fiscal year, through the
end of our 2022 fiscal year with the cumulative total return on $100 invested for the same period in the Dow Jones
U.S. Health Care Index and the Nasdaq Stock Market Composite Index.
COMPARISON OF 5-YEAR CUMULATIVE TOTAL RETURN
$300
$250
$200
$150
$100
$50
December
2017
December
2018
December
2019
December
2020
December
2021
December
2022
Henry Schein, Inc.
Dow Jones US Health Care Index
NASDAQ Composite Index
ASSUMES $100 INVESTED ON DECEMBER 30, 2017
ASSUMES DIVIDENDS REINVESTED
December 30, December 29, December 28, December 26, December 25, December 31,
2017
100.00
2018
111.49
$
2019
122.98
2020
121.58
2021
138.37
2022
147.48
$
$
$
$
$
Henry Schein, Inc.
Dow Jones U.S. Health
Care Index
100.00
104.72
129.31
147.48
183.33
176.40
NASDAQ Stock Market
Composite Index
100.00
96.41
133.30
191.21
235.27
158.65
ITEM 6.
[Reserved]
42
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Cautionary Note Regarding Forward-Looking Statements
In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we
provide the following cautionary remarks regarding important factors that, among others, could cause future results
to differ materially from the forward-looking statements, expectations and assumptions expressed or implied
herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of
future performance. These forward-looking statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance and achievements or industry results to be materially
different from any future results, performance or achievements expressed or implied by such forward-looking
statements. These statements are generally identified by the use of such terms as “may,” “could,” “expect,”
“intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make” or other comparable
terms. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in
this Annual Report on Form 10-K, and in particular the risks discussed under the caption “Risk Factors” in Item 1A
of this report and those that may be discussed in other documents we file with the Securities and Exchange
Commission (SEC). Forward looking statements include the overall impact of the Novel Coronavirus Disease 2019
(COVID-19) on us, our results of operations, liquidity and financial condition (including any estimates of the
impact on these items), the rate and consistency with which dental and other practices resume or maintain normal
operations in the United States and internationally, expectations regarding personal protective equipment (“PPE”)
products and COVID-19 related product sales and inventory levels, whether additional resurgences or variants of
the virus will adversely impact the resumption of normal operations, whether supply chain disruptions will
adversely impact our business, the impact of integration and restructuring programs as well as of any future
acquisitions, general economic conditions including exchange rates, inflation and recession, and more generally
current expectations regarding performance in current and future periods. Forward looking statements also include
the (i) our ability to have continued access to a variety of COVID-19 test types, expectations regarding COVID-19
test sales, demand and inventory levels, as well as the efficacy or relative efficacy of the test results given that the
test efficacy has not been, or will not have been, independently verified under normal FDA procedures and (ii)
potential for us to distribute the COVID-19 vaccines and ancillary supplies.
Risk factors and uncertainties that could cause actual results to differ materially from current and historical results
include, but are not limited to: risks associated with COVID-19 and any variants thereof, as well as other disease
outbreaks, epidemics, pandemics, or similar wide-spread public health concerns and other natural disasters; our
dependence on third parties for the manufacture and supply of our products; our ability to develop or acquire and
maintain and protect new products (particularly technology products) and technologies that achieve market
acceptance with acceptable margins; transitional challenges associated with acquisitions, dispositions and joint
ventures, including the failure to achieve anticipated synergies/benefits; legal, regulatory, compliance,
cybersecurity, financial and tax risks associated with acquisitions, dispositions and joint ventures; certain provisions
in our governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates
or other purchasing incentives; risks related to the sale of corporate brand products; effects of a highly competitive
(including, without limitation, competition from third-party online commerce sites) and consolidating market; the
repeal or judicial prohibition on implementation of the Affordable Care Act; changes in the health care industry;
risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs
for our products or other service issues with our third-party shippers; general global and domestic macro-economic
and political conditions, including inflation, deflation, recession, fluctuations in energy pricing and the value of the
U.S. dollar as compared to foreign currencies, and changes to other economic indicators, international trade
agreements, potential trade barriers and terrorism; failure to comply with existing and future regulatory
requirements; risks associated with the EU Medical Device Regulation; failure to comply with laws and regulations
relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to
the collection, storage and processing of sensitive personal information or standards in electronic health records or
transmissions; changes in tax legislation; risks related to product liability, intellectual property and other claims;
litigation risks; new or unanticipated litigation developments and the status of litigation matters; risks associated
with customs policies or legislative import restrictions; cyberattacks or other privacy or data security breaches; risks
associated with our global operations; our dependence on our senior management, employee hiring and retention,
and our relationships with customers, suppliers and manufacturers; and disruptions in financial markets. The order
in which these factors appear should not be construed to indicate their relative importance or priority.
43
We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control
or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction
of actual results. We undertake no duty and have no obligation to update forward-looking statements except as
required by law.
Where You Can Find Important Information
We may disclose important information through one or more of the following channels: SEC filings, public
conference calls and webcasts, press releases, the investor relations page of our website (www.henryschein.com)
and the social media channels identified on the Newsroom page of our website.
Recent Developments
The COVID-19 pandemic negatively impacted the global economy, disrupted global supply chains and created
significant volatility and disruption of global financial markets in 2020 and 2021. The impact of COVID-19 had a
material adverse effect on our business, results of operations and cash flows in 2020. During the year ended
December 25, 2021, patient traffic levels returned to levels approaching pre-pandemic levels. Demand for dental
products and certain medical products throughout 2021 was driven by sales of PPE and COVID-19 test kits.
During the year ended December 31, 2022 we experienced a decrease in the sales volume of PPE and COVID-19
test kits. The volatility in sales of COVID-19 test kits has moderated, albeit at a significantly lower level of sales
compared with 2021, resulting in us recording an inventory obsolescence reserve of $17 million for COVID-19 test
kits during the year ended December 31, 2022.
While the U.S. economy has recently experienced inflationary pressures and strengthening of the U.S dollar, their
impacts have not been material to our results of operations in the fourth quarter or full year ended December 31,
2022, and we currently expect moderating of inflation and foreign currency fluctuations. Though inflation impacts
both our revenues and costs, the depth and breadth of our product portfolio often allows us to offer lower-cost
national brand solutions or corporate brand alternatives to our more price-sensitive customers who are unable to
absorb price increases, thus positioning us to protect our gross profit.
Our consolidated financial statements reflect estimates and assumptions made by us that affect, among other things,
our goodwill, long-lived asset and definite-lived intangible asset valuation; inventory valuation; equity investment
valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax
contingencies; the allowance for doubtful accounts; hedging activity; supplier rebates; measurement of
compensation cost for certain share-based performance awards and cash bonus plans; and pension plan
assumptions. Due to the significant uncertainty surrounding the future impact of COVID-19, our judgments
regarding estimates and impairments could change in the future. There is an ongoing risk that the COVID-19
pandemic may again have a material adverse effect on our business, results of operations and cash flows and may
result in a material adverse effect on our financial condition and liquidity. However, the extent of the potential
impact cannot be reasonably estimated at this time.
44
Executive-Level Overview
Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and
technology. We believe we are the world’s largest provider of health care products and services primarily to office-
based dental and medical practitioners, as well as alternate sites of care. We serve more than one million customers
worldwide including dental practitioners, laboratories, physician practices, and ambulatory surgery centers, as well
as government, institutional health care clinics and other alternate care clinics. We believe that we have a strong
brand identity due to our more than 90 years of experience distributing health care products.
We are headquartered in Melville, New York, employ approximately 22,000 people (of which approximately
10,700 are based outside of the United States) and have operations or affiliates in 32 countries and territories. Our
broad global footprint has evolved over time through our organic success as well as through contribution from
strategic acquisitions.
We have established strategically located distribution centers around the world to enable us to better serve our
customers and increase our operating efficiency. This infrastructure, together with broad product and service
offerings at competitive prices, and a strong commitment to customer service, enables us to be a single source of
supply for our customers’ needs.
While our primary go-to-market strategy is in our capacity as a distributor, we also market and sell under our own
corporate brand portfolio of cost-effective, high-quality consumable merchandise products, and manufacture certain
dental specialty products in the areas of implants, orthodontics and endodontics. We have achieved scale in these
global businesses primarily through acquisitions as manufacturers of these products typically do not utilize a
distribution channel to serve customers.
We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and
value-added services. These segments offer different products and services to the same customer base. Our global
dental businesses serve office-based dental practitioners, dental laboratories, schools, government and other
institutions. Our medical businesses serve physician offices, urgent care centers, ambulatory care sites, emergency
medical technicians, dialysis centers, home health, federal and state governments and large enterprises, such as
group practices and integrated delivery networks, among other providers across a wide range of specialties.
The health care distribution reportable segment, combining our global dental and medical operating segments,
distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services,
branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant,
orthodontic and endodontic products), diagnostic tests, infection-control products, PPE products and vitamins.
Our global technology and value-added services business provides software, technology and other value-added
services to health care practitioners. Our technology business offerings include practice management software
systems for dental and medical practitioners. Our value-added practice solutions include practice consultancy,
education, revenue cycle management and financial services on a non-recourse basis, e-services, practice
technology, network and hardware services, as well as consulting, and continuing education services for
practitioners.
A key element to grow closer to our customers is our One Schein initiative, which is a unified go-to-market
approach that enables practitioners to work synergistically with our supply chain, equipment sales and service and
other value-added services, allowing our customers to leverage the combined value that we offer through a single
program. Specifically, One Schein provides customers with streamlined access to our comprehensive offering of
national brand products, our corporate brand products and proprietary specialty products and solutions (including
implant, orthodontic and endodontic products). In addition, customers have access to a wide range of services,
including software and other value-added services.
45
Industry Overview
In recent years, the health care industry has increasingly focused on cost containment. This trend has benefited
distributors capable of providing a broad array of products and services at low prices. It also has accelerated the
growth of HMOs, group practices, other managed care accounts and collective buying groups, which, in addition to
their emphasis on obtaining products at competitive prices, tend to favor distributors capable of providing
specialized management information support. We believe that the trend towards cost containment has the potential
to favorably affect demand for technology solutions, including software, which can enhance the efficiency and
facilitation of practice management.
Our operating results in recent years have been significantly affected by strategies and transactions that we
undertook to expand our business, domestically and internationally, in part to address significant changes in the
health care industry, including consolidation of health care distribution companies, health care reform, trends
toward managed care, cuts in Medicare and collective purchasing arrangements.
Our current and future results have been and could be impacted by the COVID-19 pandemic, the current economic
environment and continued economic and public health uncertainty. Since the onset of the COVID-19 pandemic in
early 2020, we have been carefully monitoring its impact on our global operations and have taken appropriate steps
to minimize the risk to our employees. We have seen and expect to continue to see changes in demand trends for
some of our products and services, supply chain challenges and labor challenges, as rates of infection fluctuate, new
strains or variants of COVID-19 emerge and spread, governments adapt their approaches to combatting the virus,
and local conditions change across geographies. As a result, we expect to see continued volatility.
Industry Consolidation
The health care products distribution industry, as it relates to office-based health care practitioners, is fragmented
and diverse. The industry ranges from sole practitioners working out of relatively small offices to group practices
or service organizations ranging in size from a few practitioners to a large number of practitioners who have
combined or otherwise associated their practices.
Due in part to the inability of office-based health care practitioners to store and manage large quantities of supplies
in their offices, the distribution of health care supplies and small equipment to office-based health care practitioners
has been characterized by frequent, small quantity orders, and a need for rapid, reliable and substantially complete
order fulfillment. The purchasing decisions within an office-based health care practice are typically made by the
practitioner or an administrative assistant. Supplies and small equipment are generally purchased from more than
one distributor, with one generally serving as the primary supplier.
The trend of consolidation extends to our customer base. Health care practitioners are increasingly seeking to
partner, affiliate or combine with larger entities such as hospitals, health systems, group practices or physician
hospital organizations. In many cases, purchasing decisions for consolidated groups are made at a centralized or
professional staff level; however, orders are delivered to the practitioners’ offices.
We believe that consolidation within the industry will continue to result in a number of distributors, particularly
those with limited financial, operating and marketing resources, seeking to combine with larger companies that can
provide growth opportunities. This consolidation also may continue to result in distributors seeking to acquire
companies that can enhance their current product and service offerings or provide opportunities to serve a broader
customer base.
Our approach to acquisitions and joint ventures has been to expand our role as a provider of products and services
to the health care industry. This trend has resulted in our expansion into service areas that complement our existing
operations and provide opportunities for us to develop synergies with, and thus strengthen, the acquired businesses.
As industry consolidation continues, we believe that we are positioned to capitalize on this trend, as we believe we
have the ability to support increased sales through our existing infrastructure, although there can be no assurances
that we will be able to successfully accomplish this. We also have invested in expanding our sales/marketing
46
infrastructure to include a focus on building relationships with decision makers who do not reside in the office-
based practitioner setting.
As the health care industry continues to change, we continually evaluate possible candidates for joint venture or
acquisition and intend to continue to seek opportunities to expand our role as a provider of products and services to
the health care industry. There can be no assurance that we will be able to successfully pursue any such
opportunity or consummate any such transaction, if pursued. If additional transactions are entered into or
consummated, we would incur merger and/or acquisition-related costs, and there can be no assurance that the
integration efforts associated with any such transaction would be successful.
Aging Population and Other Market Influences
The health care products distribution industry continues to experience growth due to the aging population,
increased health care awareness, the proliferation of medical technology and testing, new pharmacology treatments,
and expanded third-party insurance coverage, partially offset by the effects of unemployment on insurance
coverage. In addition, the physician market continues to benefit from the shift of procedures and diagnostic testing
from acute care settings to alternate-care sites, particularly physicians’ offices.
According to the U.S. Census Bureau’s International Database, between 2022 and 2032, the 45 and older
population is expected to grow by approximately 11%. Between 2022 and 2042, this age group is expected to grow
by approximately 21%. This compares with expected total U.S. population growth rates of approximately 6%
between 2022 and 2032 and approximately 12% between 2022 and 2042.
According to the U.S. Census Bureau’s International Database, in 2022 there are approximately seven million
Americans aged 85 years or older, the segment of the population most in need of long-term care and elder-care
services. By the year 2050, that number is projected to nearly triple to approximately 19 million. The population
aged 65 to 84 years is projected to increase by approximately 27% during the same period.
As a result of these market dynamics, annual expenditures for health care services continue to increase in the
United States. We believe that demand for our products and services will grow while continuing to be impacted by
current and future operating, economic, and industry conditions. The Centers for Medicare and Medicaid Services,
or CMS, published “National Health Expenditure Data” indicating that total national health care spending reached
approximately $4.3 trillion in 2021, or 18.3% of the nation’s gross domestic product, the benchmark measure for
annual production of goods and services in the United States. Health care spending is projected to reach
approximately $6.2 trillion in 2028, or 19.7% of the nation’s projected gross domestic product.
Government
Our businesses are generally subject to numerous laws and regulations that could impact our financial performance,
and failure to comply with such laws or regulations could have a material adverse effect on our business.
See “Item 1. Business – Governmental Regulations” for a discussion of laws, regulations and governmental activity
that may affect our results of operations and financial condition.
47
Results of Operations
Refer to Item 7: Management’s Discussion and Analysis of Financial Condition and Results of Operations in
our 2021 Annual Report on Form 10-K for management’s discussion and analysis of financial condition and results
of operations for the fiscal year 2021 compared to fiscal year 2020.
The following tables summarize the significant components of our operating results and cash flows from continuing
operations:
Operating results:
Net sales
Cost of sales
Gross profit
Operating expenses:
Selling, general and administrative
Depreciation and amortization
Restructuring and integration costs
Operating income
Other expense, net
Gain on sale of equity investments, net of tax
Net income from continuing operations
Income from discontinued operations, net of tax
Net income attributable to Henry Schein, Inc.
Years Ended
December 31, December 25,
2022
2021
December 26,
2020
$
$
$
12,647 $
8,816
3,831
2,771
182
131
747 $
(26) $
-
566
-
538
12,401 $
8,727
3,674
2,634
180
8
852 $
(21) $
7
660
-
631
10,119
7,303
2,816
2,086
163
32
535
(35)
2
419
1
404
Years Ended
December 31, December 25,
2022
2021
December 26,
2020
Cash flows:
Net cash provided by operating activities from continuing operations $
Net cash used in investing activities from continuing operations
Net cash used in financing activities from continuing operations
602 $
(276)
(315)
710 $
(677)
(333)
594
(115)
(182)
48
Plans of Restructuring and Integration Costs
On August 1, 2022, we committed to a restructuring plan focused on funding the priorities of the strategic plan and
streamlining operations and other initiatives to increase efficiency. We expect this initiative to extend through
2023. We are currently unable in good faith to make a determination of an estimate of the amount or range of
amounts expected to be incurred in connection with these activities, both with respect to each major type of cost
associated therewith and with respect to the total cost, or an estimate of the amount or range of amounts that will
result in future cash expenditures.
During the year ended December 31, 2022, we recorded restructuring charges of $128 million primarily related to
severance and employee-related costs, accelerated amortization of right-of-use lease assets, impairment of other
long-lived assets and lease exit costs.
During the three months ended December 31, 2022, in connection with our restructuring plan, we vacated one of
the buildings at our corporate headquarters in Melville NY, which resulted in an accelerated amortization of right-
of-use lease asset of $34 million. We also initiated the disposal of a non-profitable US business and recorded
related costs of $49 million which primarily consisted of impairment of intangible assets and goodwill, inventory
impairment, and severance and employee-related costs. These expenses are included in the $128 million of
restructuring charges discussed above. The disposal is expected to be completed in the first quarter of 2023.
On August 26, 2022, we acquired Midway Dental Supply. In connection with this acquisition, during the year
ended December 31, 2022, we recorded integration costs of $3 million related to one-time employee and other
costs, as well as restructuring charges of $9 million, which are included in the $128 million of restructuring charges
discussed above.
On November 20, 2019, we committed to a contemplated restructuring initiative intended to mitigate stranded costs
associated with the spin-off of our animal health business and to rationalize operations and provide expense
efficiencies. These activities were originally expected to be completed by the end of 2020 but we extended them to
the end of 2021 in light of the changes to the business environment brought on by the COVID-19 pandemic. The
restructuring activities under this prior initiative were completed in 2021.
49
2022 Compared to 2021
Net Sales
Net sales were as follows:
Health care distribution (1)
Dental
Medical
Total health care distribution
Technology and value-added services (2)
Total
2022
% of
Total
2021
% of
Total
Increase / (Decrease)
%
$
$
$
7,473
4,451
11,924
723
12,647
59.1 % $
35.2
94.3
5.7
100.0
$
7,544
4,210
11,754
647
12,401
60.8 % $
34.0
94.8
5.2
100.0
$
(71)
241
170
76
246
(0.9) %
5.7
1.4
11.8
2.0
The components of our sales growth were as follows:
Total Sales
Growth
Foreign
Exchange
Impact
Total Local
Currency
Growth
Acquisition
Growth
Extra Week
Impact
Local Internal
Growth
Local Currency Growth
Health care distribution (1)
Dental Merchandise
Dental Equipment
Total Dental
Medical
Total Health Care Distribution
Technology and value-added services (2)
Total
(2.6) %
4.7
(0.9)
5.7
1.4
11.8
2.0
(3.5) %
(4.6)
(3.7)
(0.3)
(2.5)
(1.5)
(2.4)
0.9 %
9.3
2.8
6.0
3.9
13.3
4.4
1.3 %
0.6
1.2
2.4
1.6
5.4
1.8
1.0 %
2.3
1.2
1.5
1.3
0.8
1.3
(1.4) %
6.4
0.4
2.1
1.0
7.1
1.3
Note: Percentages for Net Sales; Gross Profit; Selling, General and Administrative; Other Expense, Net; and Income Taxes are based on
actual values and may not recalculate due to rounding.
(1) Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic
products), diagnostic tests, infection-control products, PPE products and vitamins.
(2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers,
practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing
education services for practitioners, consulting and other services.
Global Sales
Global net sales for the year ended December 31, 2022 increased 2.0% based upon the components presented in the
table above. We estimate that sales for the year ended December 31, 2022 of PPE products and COVID-19 test kits
were approximately $1,245 million, an estimated decrease of 34.7% versus the prior year. Excluding PPE products
and COVID-19 test kits, the estimated increase in internally generated local currency sales was 6.7%.
Dental
Dental net sales for the year ended December 31, 2022 decreased 0.9% based upon the components presented in the
table above. Our sales growth in local currency for dental merchandise decreased primarily due to a decrease in
PPE product sales. We estimate that global dental sales for the year ended December 31, 2022 of PPE products
were approximately $447 million, an estimated decrease of 32.5% versus the prior year. Excluding PPE products,
the estimated increase in internally generated local currency dental sales was 3.8%. Dental equipment sales in local
currency increased in both our North American and international markets, primarily due to increased demand.
50
Medical
Medical net sales for the year ended December 31, 2022 increased 5.7% based upon the components presented in
the table above. Globally, we estimate our medical business recorded sales of approximately $798 million of sales
of PPE products and COVID-19 test kits for the year ended December 31, 2022, an estimated decrease of
approximately 27.4% compared to the prior year. Excluding PPE products and COVID-19 test kits, the estimated
increase in internally generated local currency medical sales was 2.1%.
Technology and value-added services
Technology and value-added services net sales for the year ended December 31, 2022 increased 11.8% based upon
the components presented in the table above. During the year ended December 31, 2022, the trend for transactional
software sales improved as we increased the number of users, generating demand for our sales cycle management
solutions, and also from cloud-based solutions that drive practice efficiency and patient engagement.
Gross Profit
Gross profit and gross margin percentages by segment and in total were as follows:
Health care distribution
Technology and value-added services
Total
$
$
3,357
474
3,831
28.2 % $
65.5
30.3
$
3,239
435
3,674
27.6 % $
67.2
29.6
$
118
39
157
2022
Gross
Margin %
2021
Gross
Margin %
Increase
$
%
3.6 %
9.0
4.3
As a result of different practices of categorizing costs associated with distribution networks throughout our
industry, our gross margins may not necessarily be comparable to other distribution companies. Additionally, we
realize substantially higher gross margin percentages in our technology and value-added services segment than in
our health care distribution segment. These higher gross margins result from being both the developer and seller of
software products and services, as well as certain financial services. The software industry typically realizes higher
gross margins to recover investments in research and development.
Within our health care distribution segment, gross profit margins may vary from one period to the next. Changes in
the mix of products sold as well as changes in our customer mix have been the most significant drivers affecting
our gross profit margin. For example, sales of our corporate brand products achieve gross profit margins that are
higher than average total gross profit margins of all products. With respect to customer mix, sales to our large-
group customers are typically completed at lower gross margins due to the higher volumes sold as opposed to the
gross margin on sales to office-based practitioners, who normally purchase lower volumes.
Health care distribution gross profit increased primarily due to the increase in net sales discussed above. The
overall increase in our health care distribution gross profit was attributable to $67 million of gross profit from
acquisitions and gross margin expansion, mainly as a result of increased sales mix of higher-margin products.
Technology and value-added services gross profit increased as a result of an increase in gross profit from internally
generated sales and gross profit from acquisitions, partially offset by a decrease in gross margin rates. Gross
margin rates decreased primarily due to lower gross margins of recently acquired companies in the business
services sector and our continued investment in product development and customer service.
51
Operating Expenses
Operating expenses (consisting of selling, general and administrative expenses; depreciation and amortization,
restructuring and integration costs) by segment and in total were as follows:
% of
Respective
Net Sales
% of
Respective
Net Sales
2021
2022
Health care distribution
Technology and value-added services
Total
$
$
2,738
346
3,084
23.0 % $
47.8
24.4
$
2,512
310
2,822
21.4 % $
48.0
22.8
$
Increase
$
226
36
262
%
9.0 %
11.4
9.3
The net increase in operating expenses is attributable to the following:
Change in
Restructuring and
Integration Costs
Increase in
Operating Costs
Acquisitions
Total
Health care distribution
Technology and value-added services
Total
$
$
121 $
2
123 $
39 $
20
59 $
66
14
80
$
$
226
36
262
The increase in restructuring and integration costs is attributable to our disposal of an unprofitable business,
acceleration of amortization of right-of-use lease assets related to the exit from one of the properties at our
corporate headquarters, severance costs, and other costs relating to the exit of some facilities. The increase in
operating costs includes a $20 million intangible assets impairment charge within our health care distribution
segment, and increases in payroll and payroll related costs and travel and convention expenses in both of our
reportable segments. While the U.S. economy has recently experienced inflationary pressures and strengthening of
the U.S dollar, their impacts have not been material to our results of operations.
Other Expense, Net
Other expense, net was as follows:
Interest income
Interest expense
Other, net
Other expense, net
2022
2021
$
$
$
17 $
(44)
1
(26) $
7 $
(28)
-
(21) $
Variance
10
(16)
1
(5)
%
158.9 %
(59.1)
n/a
(26.0)
Interest income increased primarily due to increased interest rates. Interest expense increased primarily due to
increased borrowings and increased interest rates.
Income Taxes
For the year ended December 31, 2022, our effective tax rate was 23.5% compared to 23.8% for the prior year
period. In 2022, the difference between our effective tax rate and the federal statutory tax rate primarily relates to
state and foreign income taxes and interest expense. In 2021, the difference between our effective tax rate and the
federal statutory tax rate was primarily due to state and foreign income taxes and interest expense.
Gain on Sale of Equity Investment
In the third quarter of 2021, we received contingent proceeds of $10 million from the 2019 sale of Hu-Friedy
resulting in the recognition of an additional after-tax gain of $7 million. No further proceeds are expected from this
sale.
52
Liquidity and Capital Resources
Our principal capital requirements have included funding of acquisitions, purchases of additional noncontrolling
interests, repayments of debt principal, the funding of working capital needs, purchases of fixed assets and
repurchases of common stock. Working capital requirements generally result from increased sales, special
inventory forward buy-in opportunities and payment terms for receivables and payables. Historically, sales have
tended to be stronger during the second half of the year and special inventory forward buy-in opportunities have
been most prevalent just before the end of the year, and have caused our working capital requirements to be higher
from the end of the third quarter to the end of the first quarter of the following year.
We finance our business primarily through cash generated from our operations, revolving credit facilities and debt
placements. Please see Note 12 – Debt for further information. Our ability to generate sufficient cash flows from
operations is dependent on the continued demand of our customers for our products and services, and access to
products and services from our suppliers.
Our business requires a substantial investment in working capital, which is susceptible to fluctuations during the
year as a result of inventory purchase patterns and seasonal demands. Inventory purchase activity is a function of
sales activity, special inventory forward buy-in opportunities and our desired level of inventory. We anticipate
future increases in our working capital requirements.
We finance our business to provide adequate funding for at least 12 months. Funding requirements are based on
forecasted profitability and working capital needs, which, on occasion, may change. Consequently, we may change
our funding structure to reflect any new requirements.
We believe that our cash and cash equivalents, our ability to access private debt markets and public equity markets,
and our available funds under existing credit facilities provide us with sufficient liquidity to meet our currently
foreseeable short-term and long-term capital needs.
Net cash provided by operating activities was $602 million for the year ended December 31, 2022, compared to net
cash from continuing operations provided by operating activities of $710 million for the prior year. The net change
of $108 million was primarily due to unfavorable net cash used by our working capital accounts, net of
acquisitions, driven by an impact of timing of payments which resulted in an increase in other current assets and
relative decreases in accounts payable and accrued expenses, partially offset by the relative year over year impact
of inventory increases (2021 increase was more significant than the 2022 increase).
Net cash used in investing activities was $276 million for the year ended December 31, 2022, compared to $677
million for the prior year. The net change of $401 million was primarily attributable to decreased payments for
equity investments and business acquisitions.
Net cash used in financing activities was $315 million for the year ended December 31, 2022, compared to net cash
used in financing activities of $333 million for the prior year. The net change of $18 million was primarily due to
increased net borrowings from debt, partially offset by increased repurchases of common stock.
53
The following table summarizes selected measures of liquidity and capital resources:
Cash and cash equivalents
Working capital (1)
Debt:
Bank credit lines
Current maturities of long-term debt
Long-term debt
Total debt
Leases:
Current operating lease liabilities
Non-current operating lease liabilities
December 31,
2022
December 25,
2021
$
$
$
$
$
$
$
$
117
1,764
103
6
1,040
1,149
73
275
118
1,537
51
11
811
873
76
268
(1) Includes $327 million and $138 million of certain accounts receivable which serve as security for U.S. trade accounts receivable
securitization at December 31, 2022 and December 25, 2021, respectively.
Our cash and cash equivalents consist of bank balances and investments in money market funds representing
overnight investments with a high degree of liquidity.
Accounts receivable days sales outstanding and inventory turns
Our accounts receivable days sales outstanding from operations increased to 41.9 days as of December 31, 2022
from 41.8 days as of December 25, 2021. During the years ended December 31, 2022 and December 25, 2021, we
wrote off approximately $10 million and $8 million, respectively, of fully reserved accounts receivable against our
trade receivable reserve. Our inventory turns from operations was 4.7 as of December 31, 2022 and 5.2 as of
December 25, 2021. Our working capital accounts may be impacted by current and future economic conditions.
Contractual obligations
The following table summarizes our contractual obligations related to fixed and variable rate long-term debt and
finance lease obligations, including interest (assuming a weighted average interest rate of 4.3%), as well as
inventory purchase commitments and operating lease obligations as of December 31, 2022:
< 1 year
2 - 3 years
4 - 5 years
> 5 years
Total
Payments due by period
Contractual obligations:
Long-term debt, including interest
$
41 $
508 $
134 $
538 $
1,221
Inventory purchase commitments
Operating lease obligations
Transition tax obligations
Finance lease obligations, including interest
5
82
19
5
8
122
23
4
8
79
-
1
-
98
-
1
21
381
42
11
Total
$
152 $
665 $
222 $
637 $
1,676
For information relating to our debt please see Note 12 – Debt.
54
Leases
We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles
and certain equipment. Our leases have remaining terms of less than one year to approximately 19 years, some of
which may include options to extend the leases for up to 15 years. As of December 31, 2022, our right-of-use
assets related to operating leases were $284 million and our current and non-current operating lease liabilities were
$73 million and $275 million, respectively. Please see Note 6 – Leases for further information.
Stock Repurchases
On March 8, 2021, we announced the reinstatement of our share repurchase program, which had been temporarily
suspended in April of 2020.
From March 3, 2003 through December 31, 2022, we repurchased $4.5 billion, or 87,180,669 shares, under our
common stock repurchase programs, with $115 million available as of December 31, 2022 for future common stock
share repurchases.
On February 8, 2023, our Board of Directors authorized the repurchase of up to an additional $400 million in shares
of our common stock.
Redeemable Noncontrolling Interests
Some minority stockholders in certain of our consolidated subsidiaries have the right, at certain times, to require us
to acquire their ownership interest in those entities. Accounting Standards Codification (“ASC”) Topic 480-10 is
applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the
outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put
option contained in contractual agreements. As of December 31, 2022 and December 25, 2021, our balance for
redeemable noncontrolling interests was $576 million and $613 million, respectively. Please see Note 18 –
Redeemable Noncontrolling Interests for further information.
Unrecognized tax benefits
As more fully disclosed in Note 13 – Income Taxes of “Notes to Consolidated Financial Statements,” we cannot
reasonably estimate the timing of future cash flows related to the unrecognized tax benefits, including accrued
interest, of $94 million as of December 31, 2022.
Critical Accounting Policies and Estimates
Our accounting policies are more fully described in Note 1 – Basis of Presentation and Significant Accounting
Policies of the consolidated financial statements. The preparation of consolidated financial statements requires us
to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and
related disclosures of contingent assets and liabilities. We base our estimates on historical data, when available,
experience, industry and market trends, and on various other assumptions that are believed to be reasonable under
the circumstances, the combined results of which form the basis for making judgments about the carrying values of
assets and liabilities that are not readily apparent from other sources. We believe that the estimates, judgments and
assumptions upon which we rely are reasonable based upon information available to us at the time that these
estimates, judgments and assumptions are made. However, by their nature, estimates are subject to various
assumptions and uncertainties. Therefore, reported results may differ from estimates and any such differences may
be material to our consolidated financial statements.
We believe that the following critical accounting estimates, which have been discussed with the Audit Committee
of our Board of Directors, affect the significant estimates and judgments used in the preparation of our financial
statements:
55
Inventories and Reserves
Inventories consist primarily of finished goods and are valued at the lower of cost or net realizable value. Cost is
determined by the first-in, first-out method for merchandise or actual cost for large equipment and high tech
equipment. In estimating carrying value of inventory, we consider many factors including the condition and
salability of the inventory by reviewing on-hand quantities, historical sales, forecasted sales and market and
economic trends. Certain of our products, specifically PPE and COVID-19 test kits, have experienced changes in
net realizable value, due to volatility of pricing and changes in demand for these products.
Business Combinations
The estimated fair value of acquired identifiable intangible assets (trademarks and trade names, customer
relationships and lists, non-compete agreements and product development) is based on critical estimates, judgments
and assumptions derived from: analysis of market conditions; discount rates; projected cash flows; customer
retention rates; and estimated useful lives. Please see Note 4 – Business Acquisitions and Divestitures for further
discussion of our acquisitions.
Goodwill
Goodwill is subject to impairment analysis at least once annually as of the first day of our fourth quarter, or if an
event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit
below its carrying value. Such impairment analyses for goodwill require a comparison of the fair value to the
carrying value of reporting units. We regard our reporting units to be our operating segments: global dental, global
medical, and technology and value-added services. Goodwill is allocated to such reporting units, for the purposes
of preparing our impairment analyses, based on a specific identification basis.
Application of the goodwill impairment test requires judgment, including the identification of reporting units,
assignment of assets and liabilities that are considered shared services to the reporting units, and ultimately the
determination of the fair value of each reporting unit. The fair value of each reporting unit is calculated by
applying the discounted cash flow methodology and confirming with a market approach. There are inherent
uncertainties, however, related to fair value models, the inputs and our judgments in applying them to this analysis.
The most significant inputs include estimation of detailed future cash flows based on budget expectations, and
determination of comparable companies to develop a weighted average cost of capital for each reporting unit.
On an annual basis, we prepare annual and medium-term financial projections. These projections are based on
input from our leadership and are presented annually to our Board of Directors. Influences on this year's forecasted
financial information and the fair value model include: the impact of planned strategic initiatives, the continued
integration of recent acquisitions and overall market conditions. The estimates used to calculate the fair value of a
reporting unit change from year to year based on operating results, market conditions, and other factors.
Our third-party valuation specialists provide inputs into our determination of the discount rate. The rate is
dependent on a number of underlying assumptions, including the risk-free rate, tax rate, equity risk premium, debt
to equity ratio and pre-tax cost of debt.
Long-term growth rates are applied to our estimation of future cash flows. The long-term growth rates are tied to
growth rates we expect to achieve beyond the years for which we have forecasted operating results. We also
consider external benchmarks, and other data points which we believe are applicable to our industry and the
composition of our global operations.
Based on our quantitative assessment for the year ended December 31, 2022, we recorded a $20 million impairment
of goodwill relating to the disposal of an unprofitable business whose estimated fair value was lower than its
carrying value. As part of our analysis for the rest of the goodwill balance, we performed a sensitivity analysis on
the discount rate and long-term growth rate assumptions. The sensitivities did not result in any additional
impairment charges.
56
Definite-Lived Intangible Assets
Annually, definite-lived intangible assets such as non-compete agreements, trademarks, trade names, customer
relationships and lists, and product development are reviewed for impairment indicators. If any impairment
indicators exist, quantitative testing is performed on the asset.
The quantitative impairment model is a two-step test under which we first calculate the recoverability of the
carrying value by comparing the undiscounted, probability-weighted value of the projected cash flows associated
with the asset or asset group, including its estimated residual value, to the carrying amount. If the cash flows
associated with the asset or asset group are less than the carrying value, we would perform a fair value assessment
of the asset, or asset group. If the carrying amount is found to be greater than the fair value, we record an
impairment loss for the excess of book value over the fair value. In addition, in all cases of an impairment review,
we re-evaluate the remaining useful lives of the assets and modify them, as appropriate. Although we believe our
judgments, estimates and/or assumptions used in estimating cash flows and determining fair value are reasonable,
making material changes to such judgments, estimates and/or assumptions could materially affect such impairment
analyses and our financial results.
During the years ended December 31, 2022, December 25, 2021 and December 26, 2020, we recorded total
impairment charges on intangible assets of approximately $49 million ($34 million related to impairment of
customer lists and relationships attributable to customer attrition rates being higher than expected in certain
businesses and $15 million due to the disposal of an unprofitable business), $1 million and $20 million,
respectively. For the year ended December 31, 2022 impairment charges were recorded within our health care
distribution segment. For the years ended December 25, 2021 and December 26, 2020, impairment charges were
recorded within our health care distribution and technology and value-added services segments.
Income Tax
When determining if the realization of the deferred tax asset is likely by assessing the need for a valuation
allowance, estimates and judgement are required. We consider all available evidence, both positive and negative,
including estimated future taxable earnings, ongoing planning strategies, future reversals of existing temporary
differences and historical operating results. Additionally, changes to tax laws and statutory tax rates can have an
impact on our determination. Our intention is to evaluate the realizability of our deferred tax assets quarterly.
ASC Topic 740 prescribes the accounting for uncertainty in income taxes recognized in the financial statements in
accordance with other provisions contained within this guidance. This topic prescribes a recognition threshold and
a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected
to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be
sustained upon examination by the taxing authorities. The amount recognized is measured as the largest amount of
benefit that has a greater than 50% likely of being realized upon ultimate audit settlement. In the normal course of
business, our tax returns are subject to examination by various taxing authorities. Such examinations may result in
future tax and interest assessments by these taxing authorities for uncertain tax positions taken in respect of certain
tax matters. Please see Note 13 – Income Taxes for further discussion.
The FASB Staff Q&A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income (“GILTI”), states
that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences
expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is
incurred. We elected to recognize the tax on GILTI as a period expense in the period the tax is incurred.
Accounting Standards Update
For a discussion of accounting standards updates that have been adopted or will be adopted in the future, please see
Note 1 – Basis of Presentation and Significant Accounting Policies included under Item 8.
57
ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to market risks as well as changes in foreign currency exchange rates as measured against the U.S.
dollar and each other, and changes to the credit markets. We attempt to minimize these risks by primarily using
foreign currency forward contracts and by maintaining counter-party credit limits. These hedging activities provide
only limited protection against currency exchange and credit risks. Factors that could influence the effectiveness of
our hedging programs include currency markets and availability of hedging instruments and liquidity of the credit
markets. All foreign currency forward contracts that we enter into are components of hedging programs and are
entered into for the sole purpose of hedging an existing or anticipated currency exposure. We do not enter into such
contracts for speculative purposes and we manage our credit risks by diversifying our investments, maintaining a
strong balance sheet and having multiple sources of capital.
Foreign Currency Agreements
The value of certain foreign currencies as compared to the U.S. dollar and the value of certain underlying functional
currencies of the Company, including its foreign subsidiaries, may affect our financial results. Fluctuations in
exchange rates may positively or negatively affect our revenues, gross margins, operating expenses and retained
earnings, all of which are expressed in U.S. dollars. Where we deem it prudent, we engage in hedging programs
using primarily foreign currency forward contracts aimed at limiting the impact of foreign currency exchange rate
fluctuations on earnings. We purchase short-term (i.e., generally 18 months or less) foreign currency forward
contracts to protect against currency exchange risks associated with intercompany loans due from our international
subsidiaries and the payment of merchandise purchases to foreign suppliers. We do not hedge the translation of
foreign currency profits into U.S. dollars, as we regard this as an accounting exposure, not an economic
exposure. A hypothetical 5% change in the average value of the U.S. dollar in 2022 compared to foreign currencies
would have changed our 2022 reported Net income attributable to Henry Schein, Inc. by approximately $7 million.
As of December 31, 2022, we had forward foreign currency exchange agreements, which expire through November
16, 2023, with a fair value of $23 million as determined by quoted market prices. Included in the forward foreign
currency exchange agreements, Henry Schein, Inc. had net investment designated EUR/USD forward contracts
with notional values of approximately €200 million, with a reported fair value of these contracts of $20 million. A
5% increase in the value of the Euro to the USD from December 31, 2022, with all other variables held constant,
would have had an unfavorable effect on the fair value of these forward contracts by decreasing the value of these
instruments by $10 million.
Total Return Swaps
On March 20, 2020, we entered into a total return swap for the purpose of economically hedging our unfunded non-
qualified supplemental retirement plan (“SERP”) and our deferred compensation plan (“DCP”). This swap will
offset changes in our SERP and DCP liabilities. At the inception, the notional value of the investments in these
plans was $43 million. At December 31, 2022, the notional value of the investments in these plans was $78
million. At December 31, 2022, the financing blended rate for this swap was based on LIBOR of 4.03% plus
0.55%, for a combined rate of 4.58%. For the years ended December 31, 2022 ended and December 25, 2021, we
have recorded a gain/(loss), within the selling, general and administrative line item in our consolidated statement of
income, of approximately $(17) million and $12 million, respectively, net of transaction costs, related to this
undesignated swap. This swap is expected to be renewed on an annual basis after its current expiration date of
March 31, 2023, and is expected to result in a neutral impact to our results of operations.
Short-Term Investments
We limit our credit risk with respect to our cash equivalents, short-term investments and derivative instruments, by
monitoring the credit worthiness of the financial institutions who are the counterparties to such financial
instruments. As a risk management policy, we limit the amount of credit exposure by diversifying and utilizing
numerous investment grade counterparties.
58
Variable Interest Rate Debt
As of December 31, 2022, we had variable interest rate exposure for certain of our revolving credit facilities and
our U.S. trade accounts receivable securitization.
Our revolving credit facility which we entered into on August 20, 2021 and expires on August 20, 2026, has an
interest rate that is based on the U.S. Dollar LIBOR plus a spread based on our leverage ratio at the end of each
financial reporting quarter. As of December 31, 2022, there was $0 million outstanding under this revolving credit
facility. During the year ended December 31, 2022, we had no borrowings under this revolving credit facility.
Our U.S trade accounts receivable securitization, which we entered into on April 17, 2013 and expires on
December 15, 2025, has an interest rate that is based upon the asset-backed commercial paper rate. As of
December 31, 2022, the commercial paper rate was 4.58% plus 0.75%, for a combined rate of 5.33%. At
December 31, 2022 the outstanding balance was $330 million under this securitization facility. During the year
ended December 31, 2022, the average outstanding balance under this securitization facility was approximately
$166 million. Based upon our average outstanding balance for this securitization facility, for each hypothetical
increase of 25 basis points, our interest expense thereunder would have increased by $0.4 million.
59
ITEM 8. Financial Statements and Supplementary Data
INDEX TO FINANCIAL STATEMENTS
HENRY SCHEIN, INC.
Report of Independent Registered Public Accounting Firm (BDO USA, LLP; New York, NY; PCAOB
ID#243)
Consolidated Financial Statements:
Balance Sheets as of December 31, 2022 and December 25, 2021
Statements of Income for the years ended December 31, 2022,
December 25, 2021 and December 26, 2020
Statements of Comprehensive Income for the years ended December 31, 2022,
December 25, 2021 and December 26, 2020
Statements of Changes in Stockholders’ Equity for the years ended
December 31, 2022, December 25, 2021 and December 26, 2020
Statements of Cash Flows for the years ended December 31, 2022,
December 25, 2021 and December 26, 2020
Notes to Consolidated Financial Statements
Note 1 – Basis of Presentation and Significant Accounting Policies
Note 2 – Net Sales from Contracts with Customers
Note 3 – Segment and Geographic Data
Note 4 – Business Acquisitions and Divestiture
Note 5 – Property and Equipment, Net
Note 6 – Leases
Note 7 – Goodwill and Other Intangibles, Net
Note 8 – Investments and Other
Note 9 – Fair Value Measurements
Note 10 – Concentrations of Risk
Note 11 – Derivatives and Hedging Activities
Note 12 – Debt
Note 13 – Income Taxes
Note 14 – Plans of Restructuring and Integration Costs
Note 15 – Commitments and Contingencies
Note 16 – Stock-Based Compensation
Note 17 – Employee Benefit Plans
Note 18 – Redeemable Noncontrolling Interests
Note 19 – Comprehensive Income
Note 20 – Discontinued Operations
Note 21 – Earnings Per Share
Note 22 – Supplemental Cash Flow Information
Note 23 – Related Party Transactions
Page
Number
61
63
64
65
66
67
68
68
78
79
81
85
86
88
89
90
92
92
94
97
101
103
105
108
111
111
113
114
115
115
All other schedules are omitted because the required information is either inapplicable or is included in the consolidated
financial statements or the notes thereto.
60
Report Of Independent Registered Public Accounting Firm
Shareholders and Board of Directors
Henry Schein, Inc.
Melville, NY
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Henry Schein, Inc. (the “Company”) as of
December 31, 2022 and December 25, 2021, the related consolidated statements of income, comprehensive income,
stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2022, and the
related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company at December 31,
2022 and December 25, 2021, and the results of its operations and its cash flows for each of the three years in the
period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States
of America.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United
States) (“PCAOB”), the Company's internal control over financial reporting as of December 31, 2022, based on
criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (“COSO”) and our report dated February 21, 2023, expressed an
unqualified opinion thereon.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is
to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public
accounting firm registered with the PCAOB and are required to be independent with respect to the Company in
accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and
Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of
material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks
of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the
amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of the
consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated
financial statements that was communicated or required to be communicated to the audit committee and that: (1)
relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our
especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not
alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by
communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the
accounts or disclosures to which it relates.
61
Revenue growth rates utilized in the determination of the fair value of acquired customer relationships for a
certain acquisition
As described in Note 4 of the consolidated financial statements, the Company acquired several companies in the
current year. As a result of the acquisitions, management was required to determine estimated fair values of the
assets acquired and liabilities assumed, including certain identifiable intangible assets. In some instances,
management utilized third-party valuation specialists to assist in the preparation of the valuation of certain
identifiable intangible assets. Management exercised judgment to develop and select revenue growth rates in the
measurement of the fair value of the customer relationships.
We identified the revenue growth rates utilized in the determination of the fair value of acquired customer
relationships for a certain acquisition, as a critical audit matter. The principal considerations for our determination
included the subjectivity and judgment required to determine the revenue growth rates used in the fair value
measurement of acquired customer relationships for a certain acquisition. Auditing these revenue growth rates
involved especially subjective auditor judgment due to the nature and extent of audit effort required.
The primary procedures we performed to address this critical audit matter included:
• Evaluating the reasonableness of the revenue growth rates by i) reviewing the historical performance
of the acquired company using its audited financial statements and (ii) assessing revenue projections
against industry metrics and peer-group companies.
/s/ BDO USA, LLP
We have served as the Company's auditor since 1984.
New York, NY
February 21, 2023
62
HENRY SCHEIN, INC.
CONSOLIDATED BALANCE SHEETS
(in millions, except share data)
December 31,
December 25,
2022
2021
ASSETS
Current assets:
Cash and cash equivalents
Accounts receivable, net of reserves of $65 and $67
Inventories, net
Prepaid expenses and other
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Goodwill
Other intangibles, net
Investments and other
Total assets
LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND
STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
Bank credit lines
Current maturities of long-term debt
Operating lease liabilities
Accrued expenses:
$
$
$
Payroll and related
Taxes
Other
Total current liabilities
Long-term debt
Deferred income taxes
Operating lease liabilities
Other liabilities
Total liabilities
Redeemable noncontrolling interests
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value, 1,000,000 shares authorized,
none outstanding
Common stock, $0.01 par value, 480,000,000 shares authorized,
131,792,817 outstanding on December 31, 2022 and
137,145,558 outstanding on December 25, 2021
Additional paid-in capital
Retained earnings
Accumulated other comprehensive loss
Total Henry Schein, Inc. stockholders' equity
Noncontrolling interests
Total stockholders' equity
Total liabilities, redeemable noncontrolling interests and stockholders' equity
$
$
117
1,442
1,963
466
3,988
383
284
2,893
587
472
8,607 $
$
1,004
103
6
73
314
132
592
2,224
1,040
36
275
361
3,936
576
(nil)
-
1
-
3,678
(233)
3,446
649
4,095
8,607 $
118
1,452
1,861
413
3,844
366
325
2,854
668
424
8,481
1,054
51
11
76
385
137
593
2,307
811
42
268
377
3,805
613
(nil)
-
1
-
3,595
(171)
3,425
638
4,063
8,481
See accompanying notes.
63
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF INCOME
(in millions, except share and per share data)
Years Ended
December 31, December 25, December 26,
2021
2022
2020
$
12,647 $
8,816
3,831
12,401 $
8,727
3,674
Net sales
Cost of sales
Gross profit
Operating expenses:
Selling, general and administrative
Depreciation and amortization
Restructuring and integration costs
Operating income
Other income (expense):
Interest income
Interest expense
Other, net
Income from continuing operations before taxes, equity in
earnings of affiliates and noncontrolling interests
Income taxes
Equity in earnings of affiliates
Gain on sale of equity investment
Net income from continuing operations
Income from discontinued operations, net of tax
Net Income
Less: Net income attributable to noncontrolling interests
Net income attributable to Henry Schein, Inc.
Amounts attributable to Henry Schein, Inc.:
Continuing operations
Discontinued operations
Net income attributable to Henry Schein, Inc.
Earnings per share from continuing operations attributable to
Henry Schein, Inc.:
Basic
Diluted
Earnings per share from discontinued operations attributable to Henry
Schein, Inc.:
Basic
Diluted
Earnings per share attributable to Henry Schein, Inc.:
Basic
Diluted
Weighted-average common shares outstanding:
Basic
Diluted
See accompanying notes.
64
$
$
$
$
$
$
$
$
$
10,119
7,303
2,816
2,086
163
32
535
10
(41)
(4)
500
(95)
12
2
419
1
420
(16)
404
403
1
404
2,771
182
131
747
17
(44)
1
721
(170)
15
-
566
-
566
(28)
538 $
538 $
-
538 $
2,634
180
8
852
7
(28)
-
831
(198)
20
7
660
-
660
(29)
631 $
631 $
-
631 $
3.95 $
3.91 $
4.51 $
4.45 $
2.83
2.81
- $
- $
- $
- $
3.95 $
3.91 $
4.51 $
4.45 $
0.01
0.01
2.83
2.82
136,064,221
137,755,670
140,090,889
141,772,781
142,504,193
143,403,682
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in millions)
Years Ended
December 31, December 25, December 26,
2022
2021
2020
Net income
$
566 $
660 $
Other comprehensive income, net of tax:
Foreign currency translation gain (loss)
Unrealized gain (loss) from foreign currency hedging activities
Pension adjustment gain
Other comprehensive income (loss), net of tax
Comprehensive income
Comprehensive income attributable to noncontrolling interests:
Net income
Foreign currency translation loss
Comprehensive income attributable to noncontrolling interests
(88)
7
12
(69)
497
(28)
7
(21)
(84)
9
6
(69)
591
(29)
6
(23)
Comprehensive income attributable to Henry Schein, Inc.
$
476 $
568 $
420
63
(7)
-
56
476
(16)
3
(13)
463
See accompanying notes.
65
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(In millions, except share and per share data)
Common Stock
$.01 Par Value
Amount
Additional
Paid-in
Capital
Accumulated
Other
Total
Retained
Earnings
Comprehensive Noncontrolling Stockholders'
Income (Loss)
Interests
Equity
1 $
48 $
3,116 $
(167) $
632 $
3,630
Balance, December 28, 2019
Net income (excluding $14 attributable to Redeemable
noncontrolling interests from continuing operations)
Foreign currency translation gain (excluding loss of $4
attributable to Redeemable noncontrolling interests)
Unrealized loss from foreign currency hedging activities,
net of tax benefit of $3
Dividends paid
Purchase of noncontrolling interests
Change in fair value of redeemable securities
Noncontrolling interests and adjustments related to
business acquisitions
Repurchase and retirement of common stock
Stock-based compensation expense
Shares withheld for payroll taxes
Separation of Animal Health business
Transfer of charges in excess of capital
Balance, December 26, 2020
Net income (excluding $23 attributable to Redeemable
noncontrolling interests from continuing operations)
Foreign currency translation loss (excluding loss of $6
attributable to Redeemable noncontrolling interests)
Unrealized gain from foreign currency hedging activities,
net of tax of $3
Pension adjustment gain, including tax of $2
Dividends paid
Change in fair value of redeemable securities
Noncontrolling interests and adjustments related to
business acquisitions
Repurchase and retirement of common stock
Stock-based compensation expense
Shares withheld for payroll taxes
Transfer of charges in excess of capital
Balance, December 25, 2021
Net income (excluding $21 attributable to Redeemable
noncontrolling interests from continuing operations)
Foreign currency translation loss (excluding loss of $6
attributable to Redeemable noncontrolling interests)
Unrealized gain from foreign currency hedging activities,
net of tax of $3
Pension adjustment gain, including tax of $4
Dividends paid
Purchase of noncontrolling interests
Change in fair value of redeemable securities
Noncontrolling interests and adjustments related to
business acquisitions
Repurchase and retirement of common stock
Stock issued upon exercise of stock options
Stock-based compensation expense
Shares withheld for payroll taxes
Settlement of stock-based compensation awards
Transfer of charges in excess of capital
Balance, December 31, 2022
-
66
(7)
-
-
-
-
-
-
-
-
-
(108)
-
(78)
9
6
-
-
-
-
-
-
-
(171)
-
(81)
7
12
-
-
-
-
-
-
-
-
-
-
(233) $
2
1
-
(1)
(1)
-
3
-
-
-
-
-
636
6
-
-
-
(11)
-
7
-
-
-
-
638
7
(1)
-
-
(1)
(7)
-
13
-
-
-
-
-
-
649 $
406
67
(7)
(1)
(3)
(33)
3
(74)
9
(15)
2
-
3,984
637
(78)
9
6
(11)
(160)
7
(401)
78
(8)
-
4,063
545
(82)
7
12
(1)
(7)
4
13
(485)
2
54
(32)
2
-
4,095
Shares
143,353,459 $
-
-
-
-
-
-
-
(1,200,000)
545,864
(236,752)
-
-
142,462,571
-
-
-
-
-
-
-
(5,505,704)
303,643
(114,952)
-
137,145,558
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
(2)
(33)
-
(11)
9
(15)
2
2
-
-
-
-
-
-
(160)
-
(53)
78
(8)
143
-
-
-
-
-
-
-
4
404
-
-
-
-
-
-
(63)
-
-
-
(2)
3,455
631
-
-
-
-
-
-
(348)
-
-
(143)
3,595
538
-
-
-
-
-
-
-
(6,111,676)
35,792
1,102,108
(376,034)
(2,931)
-
131,792,817 $
-
-
-
-
-
-
-
1 $
-
(65)
2
54
(32)
2
35
- $
-
(420)
-
-
-
-
(35)
3,678 $
See accompanying notes.
66
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)
December 31,
Years Ended
December 25,
December 26,
2022
2021
2020
$
566 $
-
566
660 $
-
660
Cash flows from operating activities:
Net income
Income from discontinued operations
Income from continuing operations
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
Impairment charge on intangible assets
Non-cash restructuring charges
Gain on sale of equity investment
Stock-based compensation expense
Provision for (benefits from) losses on trade and other accounts receivable
Benefit from deferred income taxes
Equity in earnings of affiliates
Distributions from equity affiliates
Changes in unrecognized tax benefits
Other
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable
Inventories
Other current assets
Accounts payable and accrued expenses
Net cash provided by operating activities from continuing operations
Net cash provided by operating activities from discontinued operations
Net cash provided by operating activities
Cash flows from investing activities:
Purchases of fixed assets
Payments related to equity investments and business
acquisitions, net of cash acquired
Proceeds from sale of equity investment
Proceeds from (repayments to) loan to affiliate
Other
Net cash used in investing activities
Cash flows from financing activities:
Net change in bank borrowings
Proceeds from issuance of long-term debt
Principal payments for long-term debt
Debt issuance costs
Proceeds from issuance of stock upon exercise of stock options
Payments for repurchases of common stock
Payments for taxes related to shares withheld for employee taxes
Distributions to noncontrolling shareholders
Acquisitions of noncontrolling interests in subsidiaries
Proceeds from Henry Schein Animal Health Business
Net cash used in financing activities from continuing operations
Net cash used in financing activities from discontinued operations
Net cash used in financing activities
Effect of exchange rate changes on cash and cash equivalents from continuing operations
Net change in cash and cash equivalents from continuing operations
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
$
See accompanying notes.
67
212
34
93
-
54
5
(73)
(15)
15
12
(20)
(7)
(126)
(52)
(96)
602
-
602
(96)
(158)
-
11
(33)
(276)
48
270
(59)
-
2
(485)
(32)
(21)
(38)
-
(315)
-
(315)
(12)
(1)
118
117 $
210
1
-
(10)
78
(8)
(11)
(20)
18
(2)
(10)
4
(295)
9
86
710
-
710
(79)
(571)
10
(4)
(33)
(677)
(18)
305
(122)
(3)
-
(401)
(8)
(26)
(60)
-
(333)
-
(333)
(3)
(303)
421
118 $
420
1
419
186
20
-
(2)
9
35
(53)
(12)
16
(25)
32
(189)
(32)
(6)
196
594
5
599
(49)
(60)
14
(1)
(19)
(115)
45
501
(611)
(4)
-
(74)
(14)
(8)
(19)
2
(182)
(5)
(187)
18
315
106
421
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Note 1 –Basis of Presentation and Significant Accounting Policies
Nature of Operations
We distribute health care products and services primarily to office-based dental and medical practitioners, across
dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government,
institutional health care clinics and alternate care clinics. We also provide software, technology and other value-
added services to health care practitioners. Our dental businesses serve office-based dental practitioners, dental
laboratories, schools, government and other institutions. Our medical businesses serve physician offices, urgent
care centers, ambulatory care sites, emergency medical technicians, dialysis centers, home health, federal and state
governments and large enterprises, such as group practices and integrated delivery networks, among other providers
across a wide range of specialties.
We have operations or affiliates in the United States, Australia, Austria, Belgium, Brazil, Canada, Chile, China, the
Czech Republic, France, Germany, Hong Kong SAR, Ireland, Israel, Italy, Japan, Liechtenstein, Luxembourg,
Malaysia, Mexico, the Netherlands, New Zealand, Poland, Portugal, Singapore, South Africa, Spain, Sweden,
Switzerland, Thailand, United Arab Emirates and the United Kingdom.
Basis of Presentation
Our consolidated financial statements include the accounts of Henry Schein, Inc. and all of our controlled
subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Investments in
unconsolidated affiliates in which we have the ability to influence the operating or financial decisions are accounted
for under the equity method. Certain prior period amounts have been reclassified to conform to the current period
presentation. These reclassifications, individually and in the aggregate, did not have a material impact on our
consolidated financial condition, results of operations or cash flows.
We consolidate the results of operations and financial position of a trade accounts receivable securitization which
we consider a Variable Interest Entity (“VIE”) because we are the primary beneficiary, and we have the power to
direct activities that most significantly affect the economic performance and have the obligation to absorb the
majority of the losses or benefits. For this VIE, the trade accounts receivable transferred to the VIE are pledged as
collateral to the related debt. The creditors have recourse to us for losses on these trade accounts receivable. At
December 31, 2022 and December 25, 2021, certain trade accounts receivable that can only be used to settle
obligations of this VIE were $327 million and $138 million, respectively, and the liabilities of this VIE where the
creditors have recourse to us were $255 million and $105 million, respectively.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United
States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. Actual results could differ from those estimates.
In March 2020, the World Health Organization declared the Novel Coronavirus Disease 2019 (“COVID-19”) a
pandemic. The COVID-19 pandemic negatively impacted the global economy, disrupted global supply chains and
created significant volatility and disruption of global financial markets. In response, many countries implemented
business closures and restrictions, stay-at-home and social distancing ordinances and similar measures to combat
the pandemic, which significantly impacted global business and dramatically reduced demand for dental products
and certain medical products in the second quarter of 2020. Demand for these non-PPE products increased in the
second half of 2020 and continued throughout the years ended December 25, 2021 and December 31, 2022,
resulting in growth over the prior years. Demand for PPE products declined during the year ended December 31,
2022.
68
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Our consolidated financial statements reflect estimates and assumptions made by us that affect, among other things,
our goodwill, long-lived asset and definite-lived intangible asset valuation; inventory valuation; equity investment
valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax
contingencies; the allowance for doubtful accounts; hedging activity; supplier rebates; measurement of
compensation cost for certain share-based performance awards and cash bonus plans; and pension plan
assumptions. Due to the significant uncertainty surrounding the future impact of COVID-19, our judgments
regarding estimates and impairments could change in the future. There is an ongoing risk that the COVID-19
pandemic may again have a material adverse effect on our business, results of operations and cash flows and may
result in a material adverse effect on our financial condition and liquidity. However, the extent of the potential
impact cannot be reasonably estimated at this time.
Fiscal Year
We report our results of operations and cash flows on a 52-53 week basis ending on the last Saturday of December.
The year ended December 31, 2022 consisted of 53 weeks, and the years ended, December 25, 2021 and December
26, 2020 consisted of 52 weeks.
Revenue Recognition
Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the
consideration that we expect to receive for those goods or services. To recognize revenue, we do the following:
• identify the contract(s) with a customer;
• identify the performance obligations in the contract;
• determine the transaction price;
• allocate the transaction price to the performance obligations in the contract; and
• recognize revenue when, or as, the entity satisfies a performance obligation.
We generate revenue from the sale of dental and medical consumable products, equipment (Health care distribution
revenues), software products and services and other sources (Technology and value-added services revenues).
Provisions for discounts, rebates to customers, customer returns and other contra revenue adjustments are included
in the transaction price at contract inception by estimating the most likely amount based upon historical data and
estimates and are provided for in the period in which the related sales are recognized.
Revenue derived from the sale of consumable products is recognized at a point in time when control transfers to the
customer. Such sales typically entail high-volume, low-dollar orders shipped using third-party common carriers.
We believe that the shipment date is the most appropriate point in time indicating control has transferred to the
customer because we have no post-shipment obligations and this is when legal title and risks and rewards of
ownership transfer to the customer and the point at which we have an enforceable right to payment.
Revenue derived from the sale of equipment is recognized when control transfers to the customer. This occurs
when the equipment is delivered. Such sales typically entail scheduled deliveries of large equipment primarily by
equipment service technicians. Most equipment requires minimal installation, which is typically completed at the
time of delivery. Our product generally carries standard warranty terms provided by the manufacturer, however, in
instances where we provide warranty labor services, the warranty costs are accrued in accordance with Accounting
Standards Codification (“ASC”) 460 “Guarantees”. At December 31, 2022 and December 25, 2021, we had
accrued approximately $8 million and $8 million, respectively, for warranty costs.
69
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Revenue derived from the sale of software products is recognized when products are delivered to customers or
made available electronically. Such software is generally installed by customers and does not require extensive
training due to the nature of its design. Revenue derived from post-contract customer support for software,
including annual support and/or training, is generally recognized over time using time elapsed as the input method
that best depicts the transfer of control to the customer. Revenue derived from software sold on Software-as-a -
Service basis is recognized ratably over the subscription period as control is transferred to the customer.
Revenue derived from other sources, including freight charges, equipment repairs and financial services, is
recognized when the related product revenue is recognized or when the services are provided. We apply the
practical expedient to treat shipping and handling activities performed after the customer obtains control as
fulfillment activities, rather than a separate performance obligation in the contract.
Sales, value-add and other taxes we collect concurrent with revenue-producing activities are excluded from
revenue.
Certain of our revenue is derived from bundled arrangements that include multiple distinct performance obligations,
which are accounted for separately. When we sell software products together with related services (i.e., training
and technical support), we allocate revenue to software using the residual method, using an estimate of the
standalone selling price to estimate the fair value of the undelivered elements. Bundled arrangements that include
elements that are not considered software consist primarily of equipment and the related installation service. We
allocate revenue for such arrangements based on the relative selling prices of the goods or services. If an
observable selling price is not available (i.e., we do not sell the goods or services separately), we use one of the
following techniques to estimate the standalone selling price: adjusted market approach; cost-plus approach; or the
residual method. There is no specific hierarchy for the use of these methods, but the estimated selling price reflects
our best estimate of what the selling prices of each deliverable would be if it were sold regularly on a standalone
basis taking into consideration the cost structure of our business, technical skill required, customer location and
other market conditions.
See Note 2 – Revenue from Contracts with Customers for additional disclosures of disaggregated net sales and
Note 3 – Segment and Geographic Data for disclosures of net sales by segment and geographic data.
Sales Returns
Sales returns are recognized as a reduction of revenue by the amount of expected returns and are recorded as refund
liability within current liabilities. We estimate the amount of revenue expected to be reversed to calculate the sales
return liability based on historical data for specific products, adjusted as necessary for new products. The
allowance for returns is presented gross as a refund liability and we record an inventory asset (and a corresponding
adjustment to cost of sales) for any products that we expect to be returned.
Cost of Sales
The primary components of cost of sales include the cost of the product (net of purchase discounts, supplier
chargebacks and rebates) and inbound and outbound freight charges.
Costs related to purchasing, receiving, inspections, warehousing, internal inventory transfers and other costs of our
distribution network are included in selling, general and administrative expenses along with other operating costs.
Total distribution network costs were $103 million, $89 million and $72 million for the years ended December 31,
2022, December 25, 2021 and December 26, 2020.
70
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Supplier Rebates
Supplier rebates are included as a reduction of cost of sales and are recognized over the period they are earned. The
factors we consider in estimating supplier rebate accruals include forecasted inventory purchases and sales, in
conjunction with supplier rebate contract terms, which generally provide for increasing rebates based on either
increased purchase or sales volume.
Direct Shipping and Handling Costs
Freight and other direct shipping costs are included in cost of sales. Direct handling costs, which represent
primarily direct compensation costs of employees who pick, pack and otherwise prepare, if necessary, merchandise
for shipment to our customers are reflected in selling, general and administrative expenses. Direct handling costs
were $96 million, $97 million and $79 million for the years ended December 31, 2022, December 25, 2021 and
December 26, 2020.
Advertising and Promotional Costs
We generally expense advertising and promotional costs as incurred. Total advertising and promotional expenses
were $47 million, $48 million and $32 million for the years ended December 31, 2022, December 25, 2021 and
December 26, 2020.
Stock Compensation Costs
We measure stock-based compensation at the grant date, based on the estimated fair value of the award, and
recognize the cost (net of estimated forfeitures) as compensation expense on a straight-line basis over the requisite
service period for time-based restricted stock units and on a graded vesting basis for the option awards. For
performance-based awards, at each reporting date, we reassess whether achievement of the performance condition
is probable and accrue compensation expense when achievement of the performance condition is probable. Our
stock-based compensation expense is reflected in selling, general and administrative expenses.
Employment Benefit Plans and other Postretirement Benefit Plans
Certain of our employees in our international markets participate in various noncontributory defined benefit plans.
We recognize the funded status, measured as the difference between the fair value of plan assets and the benefit
obligation, of each applicable plan, within accumulated other comprehensive income in the consolidated balance
sheets, whereby each unfunded plan is recognized as a liability and each funded plan is recognized as either an
asset or liability based on its funded status. We measure our plan assets and liabilities at the end of our fiscal year.
Net periodic pension costs and valuations are dependent on assumptions used by third-party actuaries in calculating
those amounts. These assumptions include discount rates, expected return on plan assets, rate of future
compensation levels, retirement rates, mortality rates, and other factors. We record the service cost component of
net pension cost in selling, general and administrative expenses within our consolidated statements of income.
Cash and Cash Equivalents
We consider all highly liquid short-term investments with an original maturity of three months or less to be cash
equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of
fair value. Outstanding checks in excess of funds on deposit of $54 million and $2 million, primarily related to
payments for inventory, were classified as accounts payable as of December 31, 2022 and December 25, 2021.
71
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Contract Balances
Contract balances represent amounts presented in our consolidated balance sheets when either we have transferred
goods or services to the customer or the customer has paid consideration to us under the contract. These contract
balances include accounts receivable, contract assets and contract liabilities.
Accounts Receivable and Allowance for Credit Losses
Accounts receivable are generally recognized when health care distribution and technology and value-added
services revenues are recognized. In accordance with the “expected credit loss” model, the carrying amount of
accounts receivable is reduced by a valuation allowance that reflects our best estimate of the amounts that we do
not expect to collect. In addition to reviewing delinquent accounts receivable, we consider many factors in
estimating our reserve, including types of customers and their credit worthiness, experience and historical data
adjusted for current conditions and reasonable supportable forecasts.
We record allowances for credit losses based upon a specific review of all significant outstanding invoices. For
those invoices not specifically reviewed, provisions are provided at differing rates, based upon the age of the
receivable, the collection history associated with the geographic region that the receivable was recorded in, current
economic trends and reasonable supportable forecasts. We write-off a receivable and charge it against its recorded
allowance when we deem them uncollectible.
Our allowance for doubtful accounts was $65 million, $67 million and $88 million as of December 31, 2022,
December 25, 2021 and December 26, 2020, respectively. Additions to the allowance for the years ended
December 31, 2022, December 25, 2021 and December 26, 2020 were $8 million, $0 million and $36 million.
Deductions to the allowance for the years ended December 31, 2022, December 25, 2021 and December 26, 2020
were $10 million, $21 million and $8 million.
Contract Assets
Contract assets include amounts related to any conditional right to consideration for work completed but not billed
as of the reporting date, and generally represent amounts owed to us by customers, but not yet billed. Contract
assets are transferred to accounts receivable when the right becomes unconditional. The contract assets primarily
relate to our bundled arrangements for the sale of equipment and consumables and sales of term software licenses.
Current contract assets are included in Prepaid expenses and other and the non-current contract assets are included
in investments and other within our consolidated balance sheets. Current and non-current contract asset balances as
of December 31, 2022 and December 25, 2021 were not material.
Contract Liabilities
Contract liabilities are comprised of advance payments and upfront payments for service arrangements provided
over time that are accounted for as deferred revenue amounts. Contract liabilities are transferred to revenue once
the performance obligation has been satisfied. Current contract liabilities are included in accrued expenses: Other
and the non-current contract liabilities are included in other liabilities within our consolidated balance sheets. At
December 25, 2021, the current portion of contract liabilities of $89 million was reported in accrued expenses:
Other, and $10 million related to non-current contract liabilities was reported in other liabilities. During the year
ended December 31, 2022, we recognized substantially all of the current contract liability amounts that were
previously deferred at December 25, 2021. At December 31, 2022, the current and non-current portion of contract
liabilities were $86 million and $8 million, respectively.
72
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Inventories and Reserves
Inventories consist primarily of finished goods and are valued at the lower of cost or net realizable value. Cost is
determined by the first-in, first-out method for merchandise or actual cost for large equipment and high tech
equipment. In accordance with our policy for inventory valuation, we consider many factors including the
condition and salability of the inventory, historical sales, forecasted sales and market and economic trends. From
time to time, we adjust our assumptions for anticipated changes in any of these or other factors expected to affect
the value of inventory.
Property and Equipment
Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is
computed primarily under the straight-line method (see Note 5 – Property and Equipment, Net for estimated useful
lives). Amortization of leasehold improvements is computed using the straight-line method over the lesser of the
useful life of the assets or the lease term.
Capitalized Software Development Costs
Capitalized internal-use software costs consist of costs to purchase and develop software. For software to be used
solely to meet internal needs and cloud-based applications used to deliver our services, we capitalize costs incurred
during the application development stage and include such costs within property and equipment, net within our
consolidated balance sheets. For software to be sold, leased, or marketed to external users, we capitalize software
development costs when technological feasibility is reached and include such costs in Investments and other within
our consolidated balance sheets.
Leases
We determine if an arrangement contains a lease at inception. An arrangement contains a lease if it implicitly or
explicitly identifies an asset to be used and conveys the right to control the use of the identified asset in exchange
for consideration. As a lessee, we include operating leases in operating lease right-of-use (“ROU”) assets,
operating lease liabilities, and non-current operating lease liabilities in our consolidated balance sheets. Finance
leases are included in property and equipment, current maturities of long-term debt, and long-term debt in our
consolidated balance sheets.
ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our
obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized
upon commencement of the lease based on the present value of the lease payments over the lease term. As most of
our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate based on the
estimated rate of interest for fully collateralized and fully amortizing borrowings over a similar term of the lease
payments at commencement date to determine the present value of lease payments. When readily determinable, we
use the implicit rate. Our lease terms may include options to extend or terminate the lease when it is reasonably
certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis
over the lease term. Expenses associated with operating leases and finance leases are included in “selling, general
and administrative” and “interest expense”, respectively within our consolidated statement of income. Short-term
leases with a term of 12 months or less are not capitalized. During the years ended December 31, 2022, December
25, 2021 and December 26, 2020, such short-term lease expense was $7 million, $4 million, and $2 million,
respectively.
We have lease agreements with lease and non-lease components, which are generally accounted for as a single
lease component, except non-lease components for leases of vehicles, which are accounted for separately. When a
vehicle lease contains both lease and non-lease components, we allocate the transaction price based on the relative
standalone selling price.
73
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Goodwill
Goodwill represents the excess of the purchase price over the estimated fair value of the net assets acquired,
including the amount assigned to identifiable intangible assets. Goodwill is subject to impairment analysis annually
or more frequently if needed. Such impairment analyses for goodwill requires a comparison of the fair value to the
carrying value of reporting units. We regard our reporting units to be our operating segments: global dental; global
medical; and technology and value-added services. Goodwill was allocated to such reporting units, for the
purposes of preparing our impairment analyses, based on a specific identification basis.
For the years ended December 31, 2022 and December 25, 2021, we tested goodwill for impairment, on the first
day of the fourth quarter, using a quantitative analysis comparing the carrying value of our reporting units,
including goodwill, to the estimated fair value of our reporting units using a discounted cash flow methodology. If
the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not
impaired. Conversely, impairment loss would be equivalent to the excess of a reporting unit’s carrying value over
its fair value limited to the total amount of goodwill allocated to that reporting unit.
Application of the goodwill impairment test requires judgment, including the identification of reporting units,
assignment of assets and liabilities that are considered shared services to the reporting units, and ultimately the
determination of the fair value of each reporting unit. The fair value of each reporting unit is calculated by
applying the discounted cash flow methodology and confirming with a market approach. There are inherent
uncertainties related to fair value models, the inputs and our judgments in applying them to this analysis. The most
significant inputs include estimation of future cash flows based on budget expectations, and determination of
comparable companies to develop a weighted average cost of capital for each reporting unit.
For the year ended December 31, 2022, we recorded a $20 million impairment of goodwill relating to the disposal
of an unprofitable business whose estimated fair value was lower than its carrying value. The disposal of this
business is part of our restructuring initiative as more fully discussed in Note 14 – Plans of Restructuring and
Integration Costs. For the year ended December 25, 2021, the results of our goodwill impairment analysis did not
result in any impairments.
Intangible Assets
Intangible assets, other than goodwill, are evaluated for impairment whenever events or changes in circumstances
indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future
cash flows to be derived from such assets.
Definite-lived intangible assets primarily consist of non-compete agreements, trademarks, trade names, customer
lists, customer relationships and product development. For long-lived assets used in operations, impairment losses
are only recorded if the asset’s carrying amount is not recoverable through its undiscounted, probability-weighted
future cash flows. We measure the impairment loss based on the difference between the carrying amount and the
estimated fair value. When an impairment exists, the related assets are written down to fair value.
During the years ended December 31, 2022, December 25, 2021 and December 26, 2020, we recorded total
impairment charges on intangible assets of $34 million, $1 million and $20 million, respectively, as more fully
discussed in Note 7 – Goodwill and Other Intangibles, Net.
Income Taxes
We account for income taxes under an asset and liability approach that requires the recognition of deferred income
tax assets and liabilities for the expected future tax consequences of events that have been recognized in our
financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future
74
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
events other than enactments of changes in tax laws or rates. The effect on deferred income tax assets and
liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date.
We file a consolidated U.S. federal income tax return with our 80% or greater owned U.S. subsidiaries.
Redeemable Noncontrolling Interests
Some minority stockholders in certain of our consolidated subsidiaries have the right, at certain times, to require us
to acquire their ownership interest in those entities at fair value. Their interests in these subsidiaries are classified
outside permanent equity on our consolidated balance sheets and are carried at the estimated redemption amounts.
The redemption amounts have been estimated based on expected future earnings and cash flow and, if such
earnings and cash flow are not achieved, the value of the redeemable noncontrolling interests might be impacted.
Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are reflected at
each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the
carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling
interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests
cannot go below the floor level. Adjustments to the carrying amount of noncontrolling interests to
reflect a fair value redemption feature do not impact the calculation of earnings per share. Our net income is
reduced by the portion of the subsidiaries’ net income that is attributable to redeemable noncontrolling interests.
Noncontrolling Interests
Non-controlling interest represents the ownership interests of certain minority owners of our consolidated
subsidiaries. Our net income is reduced by the portion of the subsidiaries net income that is attributable to
noncontrolling interests.
Comprehensive Income
Comprehensive income includes certain gains and losses that, under accounting principles generally accepted in the
United States, are excluded from net income as such amounts are recorded directly as an adjustment to
stockholders’ equity. Our comprehensive income is primarily comprised of net income, foreign currency
translation gain (loss), unrealized gain (loss) from foreign currency hedging activities and pension adjustment gain.
Risk Management and Derivative Financial Instruments
We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our
objective is to manage the impact that foreign currency exchange rate fluctuations could have on recognized asset
and liability fair values, earnings and cash flows, as well as our net investments in foreign subsidiaries. Our risk
management policy requires that derivative contracts used as hedges be effective at reducing the risks associated
with the exposure being hedged and be designated as a hedge at the inception of the contract. We do not enter into
derivative instruments for speculative purposes. Our derivative instruments primarily include foreign currency
forward agreements related to certain intercompany loans, certain forecasted inventory purchase commitments with
foreign suppliers and foreign currency forward contracts to hedge a portion of our euro-denominated foreign
operations which are designated as net investment hedges.
Foreign currency forward agreements related to forecasted inventory purchase commitments with foreign suppliers
and foreign currency swaps related to foreign currency denominated debt are designated as cash flow hedges. For
derivatives that are designated and qualify as cash flow hedges, the changes in the fair value of the derivative is
recorded as a component of Accumulated other comprehensive income in stockholders’ equity and subsequently
reclassified into earnings in the period(s) during which the hedged transaction affects earnings. We classify the
cash flows related to our hedging activities in the same category on our consolidated statements of cash flows as the
cash flows related to the hedged item.
75
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Foreign currency forward contracts related to our euro-denominated foreign operations are designated as net
investment hedges. For derivatives that are designated and qualify as net investment hedges, the changes in the fair
value of the derivative is recorded in the foreign currency translation gain (loss) component of Accumulated other
comprehensive income in stockholders’ equity until the net investment is sold or substantially liquidated.
Our foreign currency forward agreements related to foreign currency balance sheet exposure provide economic
hedges but are not designated as hedges for accounting purposes.
For agreements not designated as hedges, changes in the value of the derivative, along with the transaction gain or
loss on the hedged item, are recorded in other, net, within our consolidated statements of income.
Total return swaps are entered into for the purpose of economically hedging our unfunded non-qualified
supplemental retirement plan (“SERP”) and our deferred compensation plan (“DCP”). This swap will offset
changes in our SERP and DCP liabilities. This swap is expected to be renewed on an annual basis and is recorded
in selling, general, and administrative expenses within our consolidated statements of income.
Foreign Currency Translation and Transactions
The financial position and results of operations of our foreign subsidiaries are determined using local currency as
the functional currency. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at
each year-end. Income statement accounts are translated at the average rate of exchange prevailing during the year.
Translation adjustments arising from the use of differing exchange rates from period to period are included in
Accumulated other comprehensive income in stockholders’ equity. Gains and losses resulting from foreign
currency transactions are included in earnings.
Accounting Pronouncements Adopted
On December 26, 2021 we adopted Accounting Standards Update (“ASU”) No. 2021 – 08, “Accounting for
Contract Assets and Contract Liabilities from Contracts with Customers” (Subtopic 805). ASU 2021 – 08 requires
an acquirer to recognize and measure contract assets and contract liabilities acquired in a business combination in
accordance with ASU No. 2014 - 09, “Revenue from Contracts with Customers” (Topic 606). At the acquisition
date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had
originated the contracts. To achieve this, an acquirer may assess how the acquiree applied Topic 606 to determine
what to record for the acquired revenue contracts. Generally, this should result in an acquirer recognizing and
measuring the acquired contract assets and contract liabilities consistent with how they were recognized and
measured in the acquiree’s financial statements. Our adoption of ASU 2021 - 08 did not have a material impact on
our consolidated financial statements.
On December 27, 2020 we adopted ASU No. 2019-12, “Income Taxes” (Topic 740): Simplifying the Accounting
for Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain
exceptions to the general principles in Topic 740. The amendments also improve consistent application of and
simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. Our adoption of
ASU 2019-12 did not have a material impact on our consolidated financial statements.
Recently Issued Accounting Standards
In September 2022, the FASB issued ASU No. 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-
50): Disclosure of Supplier Finance Program Obligations” which will increase transparency of supplier finance
programs by requiring entities that use such programs in connection with the purchase of goods and services to
disclose certain qualitative and quantitative information about such programs. ASU 2022-04 is effective for fiscal
years beginning after December 15, 2022, including interim periods within those fiscal years, except for amended
76
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
rollforward information, which is effective for fiscal years beginning after December 15, 2023. We do not expect
that the requirements of this guidance will have a material impact on our consolidated financial statements.
In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the
Effects of Reference Rate Reform on Financial Reporting” which provides optional expedients and exceptions for
applying GAAP to contracts, hedging relationships and other transactions affected by the discontinuation of the
London Interbank Offered Rate (“LIBOR”) or by another reference rate expected to be discontinued because of
reference rate reform. The guidance was effective beginning March 12, 2020 and can be applied prospectively
through December 31, 2022. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic
848): Scope (“ASU 2021-01”). ASU 2021-01 provides temporary optional expedients and exceptions to certain
guidance in U.S. GAAP to ease the financial reporting burdens related to the expected market transition from
LIBOR and other interbank offered rates to alternative reference rates, such as the Secured Overnight Financing
Rate. The guidance became effective upon issuance, on January 7, 2021, and can be applied through December 31,
2022. In December 2022, the FASB issued ASU No. 2022-06, “Reference Rate Reform (Topic 848): Deferral of
the Sunset Date of Topic 848,” which extends the period of application of temporary optional expedients from
December 21, 2022 to December 31, 2024. We do not expect that the requirements of this guidance will have a
material impact on our consolidated financial statements.
77
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Note 2 – Net Sales from Contracts with Customers
Net sales is recognized in accordance with policies disclosed in Note 1 – Basis of Presentation and Significant
Accounting Policies.
Disaggregation of Net sales
The following table disaggregates our Net sales by reportable segment and geographic area:
Net Sales:
Health care distribution
Dental
Medical
Total health care distribution
Technology and value-added services
Net sales
Net Sales:
Health care distribution
Dental
Medical
Total health care distribution
Technology and value-added services
Net sales
Net Sales:
Health care distribution
Dental
Medical
Total health care distribution
Technology and value-added services
Total excluding Corporate TSA net sales (1)
Corporate TSA net sales (1)
Net sales
North America
Year Ended
December 31, 2022
International
Global
4,628 $
4,375
9,003
633
9,636 $
2,845 $
76
2,921
90
3,011 $
7,473
4,451
11,924
723
12,647
North America
Year Ended
December 25, 2021
International
Global
4,506 $
4,107
8,613
560
9,173 $
3,038 $
103
3,141
87
3,228 $
7,544
4,210
11,754
647
12,401
North America
Year Ended
December 26, 2020
International
Global
3,472 $
3,515
6,987
447
7,434
-
7,434 $
2,441 $
102
2,543
67
2,610
75
2,685 $
5,913
3,617
9,530
514
10,044
75
10,119
$
$
$
$
$
$
(1) Corporate TSA net sales represents sales of certain animal health products to Covetrus under the transition services agreement
entered into in connection with the Animal Health Spin-off, which ended in December 2020.
78
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Note 3 – Segment and Geographic Data
We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and
value-added services. These segments offer different products and services to the same customer base. Our global
dental businesses serve office-based dental practitioners, dental laboratories, schools, government and other
institutions. Our medical businesses serve physician offices, urgent care centers, ambulatory care sites, emergency
medical technicians, dialysis centers, home health, federal and state governments and large enterprises, such as
group practices and integrated delivery networks, among other providers across a wide range of specialties. Our
global dental and medical groups serve practitioners in 32 countries worldwide.
The health care distribution reportable segment aggregates our global dental and medical operating segments. This
segment distributes consumable products, dental specialty products, small equipment, laboratory products, large
equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic
tests, infection-control products, PPE and vitamins.
Our global technology and value-added services reportable segment provides software, technology and other value-
added services to health care practitioners. Our technology offerings include practice management software
systems for dental and medical practitioners. Our value-added practice solutions include practice consultancy,
education, revenue cycle management and financial services on a non-recourse basis, e-services, practice
technology, network and hardware services, as well as continuing education services for practitioners.
The following tables present information about our reportable and operating segments:
Net Sales:
Health care distribution (1)
Dental
Medical
Total health care distribution
Technology and value-added services (2)
Total excluding Corporate TSA net sales
Corporate TSA net sales(3)
Total
Years Ended
December 31,
2022
December 25, December 26,
2021
2020
$
$
7,473 $
4,451
11,924
723
12,647
-
12,647 $
7,544 $
4,210
11,754
647
12,401
-
12,401 $
5,913
3,617
9,530
514
10,044
75
10,119
(1) Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic
products), diagnostic tests, infection-control products, PPE and vitamins.
(2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers,
practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing
education services for practitioners, consulting and other services.
(3) Corporate TSA net sales represents sales of certain products to Covetrus under the transition services agreement entered into in
connection with the Animal Health Spin-off, which ended in December 2020. See Note-23 Related Party Transactions for further
information.
79
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
December 31,
Years ended
December 25,
December 26,
2022
2021
2020
Operating Income:
Health care distribution
Technology and value-added services
Total
Income from continuing operations before taxes
and equity in earnings of affiliates:
Health care distribution
Technology and value-added services
Total
Depreciation and Amortization:
Health care distribution
Technology and value-added services
Total
Interest Income:
Health care distribution
Technology and value-added services
Total
Interest Expense:
Health care distribution
Total
Income Tax Expense:
Health care distribution
Technology and value-added services
Total
Purchases of Fixed Assets:
Health care distribution
Technology and value-added services
Total
Total Assets:
Health care distribution
Technology and value-added services
Total
$
$
$
$
$
$
$
$
$
$
$
$
$
$
619 $
128
747 $
592 $
129
721 $
160 $
52
212 $
16 $
1
17 $
44 $
44 $
141 $
29
170 $
86 $
10
96 $
727 $
125
852 $
706 $
125
831 $
157 $
53
210 $
7 $
-
7 $
28 $
28 $
168 $
30
198 $
74 $
5
79 $
436
99
535
400
100
500
143
43
186
10
-
10
41
41
71
24
95
44
5
49
As of
December 31,
December 25,
December 26,
2022
2021
2020
$
$
7,287 $
1,320
8,607 $
7,157 $
1,324
8,481 $
6,503
1,270
7,773
80
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
The following table presents information about our operations by geographic area as of and for the three years
ended December 31, 2022. Net sales by geographic area are based on the respective locations of our subsidiaries.
No country, except for the United States, generated net sales greater than 10% of consolidated net sales. There
were no material amounts of sales or transfers among geographic areas and there were no material amounts of
export sales.
2022
2021
2020
Net Sales
Long-Lived
Assets
Net Sales
Long-Lived
Assets
Net Sales
Long-Lived
Assets
United States
$
Other
Consolidated total
9,190 $
3,457
$
12,647 $
2,891 $
1,256
4,147 $
8,722 $
3,679
12,401 $
2,981 $
1,232
4,213 $
7,090 $
3,029
10,119 $
2,363
1,252
3,615
Note 4 – Business Acquisitions and Divestiture
Acquisitions
We account for business acquisitions and combinations under the acquisition method of accounting, where the net
assets of acquired businesses are recorded at their fair value at the acquisition date and our consolidated financial
statements include their results of operations from that date. Any excess of acquisition consideration over the fair
value of identifiable net assets acquired is recorded as goodwill. Goodwill is an asset representing the future
economic benefits arising from other assets acquired in a business combination that are not individually identified
and separately recognized, such as future customers and technology, as well as the assembled workforce.
Excluding goodwill, the major classes of assets and liabilities to which we generally allocate acquisition
consideration include identifiable intangible assets (i.e., customer relationships and lists, trademarks and trade
names, product development, and non-compete agreements), inventory and accounts receivable. The estimated fair
value of identifiable intangible assets is based on critical judgments and assumptions derived from analysis of
market conditions, including discount rates, projected revenue growth rates (which are based on historical trends
and assessment of financial projections), estimated customer attrition and projected cash flows. These assumptions
are forward-looking and could be affected by future economic and market conditions.
Some prior owners of acquired subsidiaries are eligible to receive additional purchase price cash consideration, or
we may be entitled to recoup a portion of purchase price cash consideration if certain financial targets are met. We
have accrued liabilities for the estimated fair value of additional purchase price consideration at the time of the
acquisition, using the income approach, including a probability-weighted discounted cash flow method or an option
pricing method, where applicable. Any adjustments to these accrual amounts are recorded in selling, general and
administrative expenses within our consolidated statements of income.
While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the
acquisition date as well as contingent consideration, where applicable, our estimates are inherently uncertain and
subject to refinement. As a result, within 12 months following the date of acquisition, or the measurement period,
we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill
within our consolidated balance sheets. At the end of the measurement period or final determination of the values
of such assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recognized in
our consolidated statements of operations.
81
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
2022 Acquisitions
We completed several acquisitions during the year ended December 31, 2022, which were immaterial to our
consolidated financial statements. Our acquired ownership interest ranged between 55% to 100%. Acquisitions
within our health care distribution segment included companies that specialize in the distribution of dental products.
Within our technology and value-added services segment, we acquired a company that educates and connects
dental office managers, practice administrators and dental business leaders across North America.
The following table aggregates the estimated fair value, as of the date of acquisition, of consideration paid and net
assets acquired for acquisitions during the year ended December 31, 2022. Approximately half of the acquired
goodwill is deductible for tax purposes.
Acquisition consideration:
Cash
Deferred consideration
Fair value of previously held equity method investment
Redeemable noncontrolling interests
Total consideration
Identifiable assets acquired and liabilities assumed:
Current assets
Intangible assets
Other noncurrent assets
Current liabilities
Deferred income taxes
Other noncurrent liabilities
Total identifiable net assets
Goodwill
Total net assets acquired
$
$
$
$
2022
158
2
16
17
193
41
96
13
(29)
(6)
(8)
107
86
193
The following table summarizes the identifiable intangible assets acquired during the year ended December 31,
2022 and their estimated useful lives as of the date of the acquisition:
Customer relationships and lists
Trademark / Tradename
Non-compete agreements
Other
Estimated
Useful Lives
2022
(in years)
81
8-12
5
2-5
10
9
3
3
96
$
$
The accounting for certain of our acquisitions during the year ended December 31, 2022 had not been completed in
several areas, including but not limited to pending assessments of accounts receivable, inventory, intangible assets,
right-of-use lease assets, accrued liabilities and income and non-income based taxes.
The pro forma financial information has not been presented because the impact of the acquisitions during the year
ended December 31, 2022 to our consolidated financial statements was immaterial.
82
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
2021 Acquisitions
We completed several acquisitions during the year ended December 25, 2021, which were immaterial to our
financial statements. Our acquired ownership interests ranged from between approximately 51% to 100%.
Acquisitions within our health care distribution segment included companies that specialize in the distribution and
manufacturing of dental and medical products, a provider of home medical supplies, and a provider of product
kitting and sterile packaging. Within our technology and value-added services segment, we acquired companies
that focus on dental marketing and website solutions, practice transition services, revenue cycle management, and
business analytics and intelligence software. Approximately half of the acquired goodwill is deductible for tax
purposes.
The following table aggregates the estimated fair value, as of the date of acquisition, of consideration paid and net
assets acquired for acquisitions during the year ended December 25, 2021.
Acquisition consideration:
Cash
Deferred consideration
Estimated fair value of contingent consideration receivable
Fair value of previously held equity method investment
Redeemable noncontrolling interests
Total consideration
Identifiable assets acquired and liabilities assumed:
Current assets
Intangible assets
Other noncurrent assets
Current liabilities
Deferred income taxes
Other noncurrent liabilities
Total identifiable net assets
Goodwill
Total net assets acquired
2021
579
11
(5)
8
181
774
195
317
51
(93)
(26)
(46)
398
376
774
$
$
$
$
The following table summarizes the identifiable intangible assets acquired during the year ended December 25,
2021 and their estimated useful lives as of the date of the acquisition:
Customer relationships and lists
Trademark / Tradename
Product development
Non-compete agreements
Other
Estimated
Useful Lives
2021
(in years)
5-12
5-12
5-10
3-5
18
220
58
19
5
15
317
$
$
83
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
2020 Acquisitions
We completed several acquisitions during the year ended December 26, 2020, which were immaterial to our
financial statements. Our acquired ownership interests ranged from between approximately 51% to 100%.
Acquisitions within our health care distribution segment included companies that manufacture endodontic files and
companies that distribute dental supplies. Within our technology and value-added services segment, we acquired
companies that focus on practice management software and provide software as a solution for dental practices.
Approximately half of the acquired goodwill is deductible for tax purposes.
The following table aggregates the estimated fair value, as of the date of acquisition, of consideration paid and net
assets acquired for acquisitions during the year ended December 26, 2020:
Acquisition consideration:
Cash
Deferred consideration
Fair value of previously held equity method investment
Redeemable noncontrolling interests
Total consideration
Identifiable assets acquired and liabilities assumed:
Current assets
Intangible assets
Other noncurrent assets
Current liabilities
Deferred income taxes
Other noncurrent liabilities
Total identifiable net assets
Goodwill
Total net assets acquired
$
$
$
$
2020
52
6
9
26
93
36
38
22
(21)
(4)
(1)
70
23
93
The following table summarizes the identifiable intangible assets acquired during the year ended December 26,
2020 and their estimated useful lives as of the date of the acquisition:
Customer relationships and lists
Product development
Trademark / Tradename
Non-compete agreements
Estimated
Useful Lives
2020
(in years)
10-12
7-10
5
5
23
9
4
2
38
$
$
For the years ended December 31, 2022, December 25, 2021 and December 26, 2020, there were no material
adjustments recorded in our consolidated balance sheets relating to accounting for acquisitions incomplete in prior
periods. At December 25, 2021 we recorded an estimated contingent consideration receivable of $5 million, which
was subsequently increased by additional $5 million during 2022 based on delays in timing of government approval
of a certain product.
84
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
During the years ended December 31, 2022, December 25, 2021 and December 26, 2020 we incurred $9 million, $7
million and $6 million in acquisition costs reported within income from continuing operations.
Divestiture
In the third quarter of 2021 we received contingent proceeds of $10 million from the 2019 sale of Hu-Friedy,
resulting in the recognition of an additional after-tax gain of $7 million. During the fourth quarter of 2020 we
received contingent proceeds of $2 million from the 2019 sale of Hu-Friedy, resulting in the recognition of an
additional after-tax gain of $2 million. We do expect to receive any additional proceeds from the sale of Hu-Friedy.
Note 5 – Property and Equipment, Net
Property and equipment, including related estimated useful lives, consisted of the following:
December 31,
December 25,
2022
2021
Land
Buildings and permanent improvements
Leasehold improvements
Machinery and warehouse equipment
Furniture, fixtures and other
Computer equipment and software
Less accumulated depreciation
Property and equipment, net
Buildings and permanent improvements
Machinery and warehouse equipment
Furniture, fixtures and other
Computer equipment and software
21
140
98
153
119
385
916
(550)
366
$
20 $
135
94
169
127
411
956
(573)
383 $
$
Estimated Useful
Lives (in years)
40
5-10
3-10
3-10
Amortization of leasehold improvements is computed using the straight-line method over the lesser of the useful
life of the assets or the lease term.
Property and equipment related depreciation expense for the years ended December 31, 2022, December 25, 2021
and December 26, 2020 was $68 million, $71 million and $64 million, respectively. Please see Note 6 – Leases for
finance lease amounts included in property and equipment, net within our consolidated balance sheets.
85
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Note 6 – Leases
We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles
and certain equipment. Our leases have remaining terms of less than one year to approximately 19 years, some of
which may include options to extend the leases for up to 15 years. The components of lease expense were as
follows:
Operating lease cost: (1) (2)
Finance lease cost:
Amortization of right-of-use assets
Total finance lease cost
December 31,
2022
Years Ended
December 25,
December 26,
2021
2020
$
$
150
$
103
$
3
3
$
3
3
$
87
2
2
(1) Includes variable lease expenses.
(2) Operating lease cost for the years ended December 31, 2022, December 25, 2021, and December 26, 2020, include accelerated
amortization of right-of-use assets of $42 million, $0 million and $0 million, respectively, related to facility leases recorded in
“Restructuring and integration costs” within our consolidated statements of income.
Further, for the years ended December 31, 2022, December 25, 2021 and December 26, 2020, we recognized
impairment of right-of-use assets of $3 million, $0 million, and $4 million respectively, related to facility leases
recorded in “Restructuring and integration costs” within our consolidated statement of income.
Supplemental balance sheet information related to leases is as follows:
Operating Leases:
Operating lease right-of-use assets
Current operating lease liabilities
Non-current operating lease liabilities
Total operating lease liabilities
Finance Leases:
Property and equipment, at cost
Accumulated depreciation
Property and equipment, net of accumulated depreciation
Current maturities of long-term debt
Long-term debt
Total finance lease liabilities
Weighted Average Remaining Lease Term in Years:
Operating leases
Finance leases
Weighted Average Discount Rate:
Operating leases
Finance leases
86
Years Ended
December 31,
December 25,
2022
2021
$
284 $
$
$
$
$
$
73
275
348 $
16 $
(6)
10 $
4 $
6
10 $
6.7
3.1
2.8 %
3.3 %
325
76
268
344
13
(5)
8
3
4
7
7.3
3.6
2.4 %
1.7 %
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Supplemental cash flow information related to leases is as follows:
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases
Financing cash flows for finance leases
Right-of-use assets obtained in exchange for lease obligations:
Operating leases
Finance leases
Maturities of lease liabilities are as follows:
2023
2024
2025
2026
2027
Thereafter
Total future lease payments
Less imputed interest
Total
Years Ended
December 31, December 25,
2022
2021
$
$
$
$
87
3
88
6
85
3
121
4
December 31, 2022
Operating
Leases
Finance
Leases
82
66
56
46
33
98
381
(33)
348
$
$
5
3
1
1
-
1
11
(1)
10
As of December 31, 2022, we have additional operating leases with total lease payments of $8 million for buildings
and vehicles that have not yet commenced. These operating leases will commence subsequent to December 31,
2022, with lease terms of two years to five years.
Certain of our facilities related to our acquisitions are leased from employees and minority shareholders. These
leases are classified as operating leases and have a remaining lease term ranging from 4 months to 9 years. As of
December 31, 2022, current and non-current liabilities associated with related party operating leases were $4
million and $14 million, respectively. Related party leases represented 5.0% and 5.3% of the total current and non-
current operating lease liabilities, respectively. The present value of lease payments under these related party leases
is not material to our consolidated financial statements.
87
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Note 7 – Goodwill and Other Intangibles, Net
The changes in the carrying amount of goodwill for the years ended December 31, 2022 and December 25, 2021
were as follows:
Balance as of December 26, 2020
Adjustments to goodwill:
Acquisitions
Foreign currency translation
Balance as of December 25, 2021
Adjustments to goodwill:
Acquisitions
Impairment
Foreign currency translation
Balance as of December 31, 2022
Health Care
Distribution
Technology and
Value-Added
Services
$
1,501 $
1,003 $
Total
359
(29)
1,831
86
(20)
(22)
1,875 $
24
(4)
1,023
(1)
-
(4)
1,018 $
$
2,504
383
(33)
2,854
85
(20)
(26)
2,893
For the year ended December 31, 2022, we recorded a $20 million impairment of goodwill relating to the disposal of
an unprofitable business whose estimated fair value was lower than its carrying value. The disposal of this business
is part of our restructuring initiative as more fully discussed in Note 14 – Plans of Restructuring and Integration Costs.
Other intangible assets consisted of the following:
Customer lists and relationships
Trademarks / trade names - definite lived
Product Development
Non-compete agreements
Other
Total
$
$
December 31, 2022
Accumulated
Amortization
Cost
826 $
125
90
25
31
1,097 $
(387) $
(51)
(56)
(6)
(10)
(510) $
Net
Cost
December 25, 2021
Accumulated
Amortization
Net
439 $
74
34
19
21
587 $
853 $
129
114
25
28
1,149 $
(353) $
(44)
(70)
(6)
(8)
(481) $
500
85
44
19
20
668
Trademarks, trade names, customer lists and customer relationships were established through business acquisitions.
Definite-lived trademarks and trade names are amortized on a straight-line basis over a weighted-average period of
approximately 8.4 years as of December 31, 2022. Customer lists and customer relationships are definite-lived
intangible assets that are amortized on a straight-line basis over a weighted-average period of approximately 10.0
years as of December 31, 2022. Product development is a definite-lived intangible asset that is amortized on a
straight-line basis over a weighted-average period of approximately 8.6 years as of December 31, 2022.
Non-compete agreements represent amounts paid primarily to prior owners of acquired businesses, as well as
certain sales persons, in exchange for placing restrictions on their ability to pose a competitive risk to us. Such
amounts are amortized, on a straight-line basis over the respective non-compete period, which generally
commences upon termination of employment or separation from us. The weighted-average non-compete period for
agreements currently being amortized was approximately 5.3 years as of December 31, 2022.
Amortization expense, excluding impairment charges, related to definite-lived intangible assets for the years ended
December 31, 2022, December 25, 2021 and December 26, 2020 was $126 million, $124 million and $106 million.
During the year ended December 31, 2022, we recorded $49 million of impairment charges related to businesses
within our health care distribution segment, represented by an intangible asset impairment of $15 million related to
the disposal of an unprofitable business and a $34 million impairment of customer lists and relationships
88
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
attributable to customer attrition rates being higher than expected in certain other businesses. Our impairment loss
was calculated as the difference between the carrying value and the estimated fair value of the intangible assets,
using a discounted estimate of future cash flows. Please see Note 14 – Plans of Restructuring and Integration Costs
for additional details.
During the year ended December 25, 2021, we recorded a $1 million impairment charge related ratably to a
business within our health care distribution segment and a business within our technology and value-added services
segment.
During the year ended December 26, 2020, we recorded a $20 million impairment charge related to businesses
within our technology and value-added services segment due to customer attrition rates being higher than expected.
The above intangible asset impairment charges were recorded within selling, general and administrative expenses;
and restructuring and integration charges in our consolidated statement of income.
The annual amortization expense expected to be recorded for existing intangibles assets for the years 2023 through
2027 is $120 million, $96 million, $84 million, $68 million and $55 million.
Note 8 – Investments and Other
Investments and other consisted of the following:
Investment in unconsolidated affiliates
Non-current deferred foreign, state and local income taxes
Notes receivable (1)
Capitalized costs for software to be sold, leased or marketed to external users
Security deposits
Acquisition-related indemnification
Non-current pension assets
Other long-term assets
Total
December 31, December 25,
2022
2021
$
161 $
168
88
28
79
3
59
8
46
35
36
65
2
66
-
52
$
472 $
424
(1) Long-term notes receivable carry interest rates ranging from 3.0% to 7.5% and are due in varying installments through
May 11, 2028.
Amortization expense, primarily related to capitalized costs for software to be sold, leased or marketed to external
users, for the years ended December 31, 2022, December 25, 2021 and December 26, 2020 was $18 million, $15
million and $16 million, respectively.
89
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Note 9 – Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. The fair value hierarchy distinguishes between
(1) market participant assumptions developed based on market data obtained from independent sources (observable
inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best
information available in the circumstances (unobservable inputs).
The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices
in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).
The three levels of the fair value hierarchy are described as follows:
• Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the
measurement date.
• Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability,
either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets;
quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted
prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by
observable market data by correlation or other means.
• Level 3— Inputs that are unobservable for the asset or liability.
The following section describes the fair values of our financial instruments and the methodologies that we used to
measure their fair values.
Investments and notes receivable
There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable.
Certain of our notes receivable contain variable interest rates. We believe the carrying amounts are a reasonable
estimate of fair value based on the interest rates in the applicable markets.
Debt
The fair value of our debt (including bank credit lines, current maturities of long-term debt and long-term debt) is
classified as Level 3 within the fair value hierarchy, and as of December 31, 2022 and December 25, 2021 was
estimated at $1,149 million and $873 million, respectively. Factors that we considered when estimating the fair
value of our debt include market conditions, such as interest rates and credit spreads.
Derivative contracts
Derivative contracts are valued using quoted market prices and significant other observable inputs. We use
derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our derivative
instruments primarily include foreign currency forward agreements related to certain intercompany loans, certain
forecasted inventory purchase commitments with foreign suppliers, foreign currency forward contracts to hedge a
portion of our euro-denominated foreign operations which are designated as net investment hedges and a total
return swap for the purpose of economically hedging our unfunded non-qualified SERP and our DCP.
The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract
rate to a published forward price of the underlying market rates, which is based on market rates for comparable
transactions and are classified within Level 2 of the fair value hierarchy. See Note 11-Derivatives and Hedging
Activities for further information.
90
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Total Return Swaps
The fair value for the Total Return Swap is measured by valuing the underlying ETFs of the swap using market-on-
close pricing by industry providers as of the valuation date and are classified within Level 2 of the fair value
hierarchy.
Redeemable noncontrolling interests
The values for Redeemable noncontrolling interests are classified within Level 3 of the fair value hierarchy and are
based on recent transactions and/or implied multiples of earnings. See Note 18 – Redeemable Noncontrolling
Interests for additional information.
Assets measured on a non-recurring basis at fair value include Goodwill and Other intangibles, net, and are
classified as Level 3 within the fair value hierarchy. See Note 1 – Basis of Presentation and Significant Accounting
Policies and Note 7 – Goodwill and Other Intangibles, Net for additional information. The following table presents
our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the
appropriate level of the fair value hierarchy as of December 31, 2022 and December 25, 2021:
Assets:
Derivative contracts designated as hedges
Derivative contracts undesignated
Total assets
Liabilities:
Derivative contracts designated as hedges
Derivative contracts undesignated
Total return swaps
Total liabilities
Redeemable noncontrolling interests
Assets:
Derivative contracts designated as hedges
Derivative contracts undesignated
Total return swap
Total assets
Liabilities:
Derivative contracts designated as hedges
Derivative contracts undesignated
Total liabilities
Redeemable noncontrolling interests
Level 1
Level 2
Level 3
Total
December 31, 2022
- $
-
- $
- $
-
-
- $
- $
23 $
4
27 $
1 $
3
3
7 $
- $
- $
-
- $
- $
-
-
- $
23
4
27
1
3
3
7
576 $
576
Level 1
Level 2
Level 3
Total
December 25, 2021
- $
-
-
- $
- $
-
- $
- $
8 $
1
1
10 $
1 $
2
3 $
- $
- $
-
-
- $
- $
-
- $
8
1
1
10
1
2
3
613 $
613
$
$
$
$
$
$
$
$
$
$
91
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Note 10 – Concentrations of Risk
Certain financial instruments potentially subject us to concentrations of credit risk. These financial instruments
consist primarily of cash equivalents, trade receivables, long-term investments, notes receivable and derivative
instruments. In all cases, our maximum exposure to loss from credit risk equals the gross fair value of the financial
instruments. We routinely maintain cash balances at financial institutions in excess of insured amounts. We have
not experienced any loss in such accounts and we manage this risk through maintaining cash deposits and other
highly liquid investments in high quality financial institutions. We continuously assess the need for reserves for
such losses, which have been within our expectations. We do not require collateral or other security to support
financial instruments subject to credit risk, except for long-term notes receivable.
We limit our credit risk with respect to our cash equivalents, short-term and long-term investments and derivative
instruments, by monitoring the credit worthiness of the financial institutions who are the counter-parties to such
financial instruments. As a risk management policy, we limit the amount of credit exposure by diversifying and
utilizing numerous investment grade counter-parties.
With respect to our trade receivables, our credit risk is somewhat limited due to a relatively large customer base and
its dispersion across different types of health care professionals and geographic areas. No single customer
accounted for more than 2% of our net sales in 2022 or 2021. With respect to our sources of supply, our top 10
health care distribution suppliers and our single largest supplier accounted for approximately 28% and 4%,
respectively, of our aggregate purchases in each of the years ended December 31, 2022 and December 25, 2021.
Our long-term notes receivable primarily represent strategic financing arrangements with certain affiliates.
Generally, these notes are secured by certain assets of the counterparty; however, in most cases our security is
subordinate to other commercial financial institutions. While we have exposure to credit loss in the event of non-
performance by these counter-parties, we conduct ongoing assessments of their financial and operational
performance.
Note 11 – Derivatives and Hedging Activities
We are exposed to market risks as well as changes in foreign currency exchange rates as measured against the U.S.
dollar and each other, and changes to the credit risk of the derivative counterparties. We attempt to minimize these
risks by primarily using foreign currency forward contracts and by maintaining counter-party credit limits. These
hedging activities provide only limited protection against currency exchange and credit risks. Factors that could
influence the effectiveness of our hedging programs include currency markets and availability of hedging
instruments and liquidity of the credit markets. All foreign currency forward contracts that we enter into are
components of hedging programs and are entered into for the sole purpose of hedging an existing or anticipated
currency exposure. We do not enter into such contracts for speculative purposes and we manage our credit risks by
diversifying our counterparties, maintaining a strong balance sheet and having multiple sources of capital.
During 2019 we entered into foreign currency forward contracts to hedge a portion of our euro-denominated
foreign operations which are designated as net investment hedges. These net investment hedges offset the change
in the U.S. dollar value of our investment in certain euro-functional currency subsidiaries due to fluctuating foreign
exchange rates. Gains and losses related to these net investment hedges are recorded in accumulated other
comprehensive loss within our consolidated balance sheets. Amounts excluded from the assessment of hedge
effectiveness are included in interest expense within our consolidated statements of income. The aggregate
notional value of this net investment hedge, which matures on November 16, 2023, is approximately €200 million.
During the years ended December 31, 2022 and December 25, 2021, we recorded losses of $9 million and $11
million, respectively, within other comprehensive income related to these foreign currency forward contracts. See
Note 9 – Fair Value Measurements for additional information.
92
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
On March 20, 2020, we entered into a total return swap for the purpose of economically hedging our unfunded non-
qualified SERP and our DCP. This swap will offset changes in our SERP and DCP liabilities. At the inception, the
notional value of the investments in these plans was $43 million. At December 31, 2022, the notional value of the
investments in these plans was $78 million. At December 31, 2022, the financing blended rate for this swap was
based on the Secured Overnight Financing Rate (“SOFR”) of 4.03% plus 0.55%, for a combined rate of 4.58%. For
the years ended December 31, 2022 and December 25, 2021, we have recorded a gain/(loss), within selling, general
and administrative in our consolidated statement of income, of approximately ($17) million and $12 million,
respectively, net of transaction costs, related to this undesignated swap. During the years ended December 31, 2022
and December 25, 2021, the swap resulted in a neutral impact to our results of operations. This swap is expected to
be renewed on an annual basis after its current expiration date of March 31, 2023, and is expected to result in a
neutral impact to our results of operations. See Note 17 – Employee Benefit Plans for additional information.
Fluctuations in the value of certain foreign currencies as compared to the U.S. dollar may positively or negatively
affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed in U.S.
dollars. Where we deem it prudent, we engage in hedging programs using primarily foreign currency forward
contracts aimed at limiting the impact of foreign currency exchange rate fluctuations on earnings. We purchase
short-term (i.e., generally 18 months or less) foreign currency forward contracts to protect against currency
exchange risks associated with intercompany loans due from our international subsidiaries and the payment of
merchandise purchases to our foreign suppliers. We do not hedge the translation of foreign currency profits into
U.S. dollars, as we regard this as an accounting exposure, not an economic exposure. Amounts related to our
hedging activities are recorded in prepaid expenses and other and/or accrued expenses: other within our
consolidated balance sheets. Our hedging activities have historically not had a material impact on our consolidated
financial statements. Accordingly, additional disclosures related to derivatives and hedging activities required by
ASC 815 have been omitted.
93
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Note 12 – Debt
Bank Credit Lines
Bank credit lines consisted of the following:
Revolving credit agreement
Other short-term bank credit lines
Total
Revolving Credit Agreement
December 31,
December 25,
2022
2021
$
$
-
$
103
103
$
-
51
51
On August 20, 2021, we entered into a $1.0 billion revolving credit agreement (the “Credit Agreement”). This
facility which matures on August 20, 2026 replaced our $750 million revolving credit facility which was scheduled
to mature in April 2022. The interest rate is based on the USD LIBOR plus a spread based on our leverage ratio at
the end of each financial reporting quarter. Most LIBOR rates have been discontinued after December 31, 2021,
while the remaining LIBOR rates will be discontinued immediately after June 30, 2023. We do not expect the
discontinuation of LIBOR as a reference rate in our debt agreements to have a material adverse effect on our
financial position or to materially affect our interest expense. The Credit Agreement requires, among other things,
that we maintain certain maximum leverage ratios. Additionally, the Credit Agreement contains customary
representations, warranties and affirmative covenants as well as customary negative covenants, subject to
negotiated exceptions, on liens, indebtedness, significant corporate changes (including mergers), dispositions and
certain restrictive agreements. As of December 31, 2022 and December 25, 2021, we had no borrowings under this
revolving credit facility. As of December 31, 2022 and December 25, 2021, there were $9 million and $9 million
of letters of credit, respectively, provided to third parties under the credit facility.
Other Short-Term Bank Credit Lines
As of December 31, 2022 and December 25, 2021, we had various other short-term bank credit lines available, with
a maximum borrowing capacity of $402 million as of December 31, 2022, of which $103 million and $51 million,
respectively, were outstanding. At December 31, 2022 and December 25, 2021, borrowings under all of these
credit lines had a weighted average interest rate of 10.11% and 10.44%, respectively.
Long-term debt
Long-term debt consisted of the following:
Private placement facilities
U.S. trade accounts receivable securitization
Various collateralized and uncollateralized loans payable with interest,
in varying installments through 2023 at interest rates
ranging from 0.00% to 3.50% at December 31, 2022 and
ranging from 2.62% to 4.27% at December 25, 2021
Finance lease obligations
Total
Less current maturities
Total long-term debt
94
December 31, December 25,
2022
2021
$
699 $
330
7
10
1,046
(6)
1,040 $
$
706
105
4
7
822
(11)
811
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Private Placement Facilities
Our private placement facilities were amended on October 20, 2021 to include four (previously three) insurance
companies, have a total facility amount of $1.5 billion (previously $1.0 billion), and are available on an
uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time
through October 20, 2026 (previously June 23, 2023). The facilities allow us to issue senior promissory notes to
the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of
issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an
average life no longer than 12 years). The proceeds of any issuances under the facilities will be used for general
corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness, and/or
to fund potential acquisitions. The agreements provide, among other things, that we maintain certain maximum
leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of
assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay
off the facilities prior to the applicable due dates.
On March 5, 2021, we amended the private placement facilities to, among other things, (a) modify the financial
covenant from being based on a net leverage ratio to a total leverage ratio and (b) restore the maximum
maintenance total leverage ratio to 3.25x and remove the 1.00% interest rate increase triggered if the net leverage
ratio were to exceed 3.0x.
The components of our private placement facility borrowings, which have a weighted average interest rate of
2.99%, as of December 31, 2022 are presented in the following table:
Amount of
Borrowing
Outstanding
$
Date of
Borrowing
January 20, 2012
December 24, 2012
June 16, 2017
September 15, 2017
January 2, 2018
September 2, 2020
June 2, 2021
June 2, 2021
Less: Deferred debt issuance costs
Total
$
U.S. Trade Accounts Receivable Securitization
Borrowing
Rate
3.45 %
3.00
3.42
3.52
3.32
2.35
2.48
2.58
50
50
100
100
100
100
100
100
(1)
699
Due Date
January 20, 2024
December 24, 2024
June 16, 2027
September 15, 2029
January 2, 2028
September 2, 2030
June 2, 2031
June 2, 2033
We have a facility agreement based on the securitization of our U.S. trade accounts receivable that is structured as
an asset-backed securitization program with pricing committed for up to three years. On December 15, 2022, we
extended the expiration date of this facility agreement to December 15, 2025 (the previous maturity date was
October 18, 2024) and maintained the purchase limit under the facility as $450 million with two banks as agents.
As of December 31, 2022 and December 25, 2021, the borrowings outstanding under this securitization facility
were $330 million and $105 million, respectively. At December 31, 2022, the interest rate on borrowings under
this facility was based on the asset-backed commercial paper rate of 4.58% plus 0.75%, for a combined rate of
5.33%. At December 25, 2021, the interest rate on borrowings under this facility was based on the asset-backed
commercial paper rate of 0.19% plus 0.75%, for a combined rate of 0.94%.
95
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
If our accounts receivable collection pattern changes due to customers either paying late or not making payments,
our ability to borrow under this facility may be reduced.
We are required to pay a commitment fee of 30 to 35 basis points depending upon program utilization.
As of December 31, 2022, the aggregate amounts of long-term debt, including finance lease obligations and net of
deferred debt issuance costs of $1 million, maturing in each of the next five years and thereafter are as follows:
2023
2024
2025
2026
2027
Thereafter
Total
$
$
6
109
331
-
100
500
1,046
96
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Note 13 – Income Taxes
Income before taxes and equity in earnings of affiliates was as follows:
Domestic
Foreign
Total
The provisions for income taxes were as follows:
Current income tax expense:
U.S. Federal
State and local
Foreign
Total current
Deferred income tax expense (benefit):
U.S. Federal
State and local
Foreign
Total deferred
Total provision
Years ended
December 31,
December 25,
December 26,
2022
2021
2020
$
$
506 $
215
721 $
593 $
238
831 $
431
69
500
December 31,
Years ended
December 25,
December 26,
2022
2021
2020
$
150 $
49
44
243
(48)
(13)
(12)
(73)
$
170 $
129 $
37
43
209
(12)
(3)
4
(11)
198 $
83
24
41
148
(18)
(5)
(30)
(53)
95
97
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
The tax effects of temporary differences that give rise to our deferred income tax asset (liability) were as follows:
Years Ended
December 31,
December 25,
2022
2021
Deferred income tax asset:
Net operating losses and other carryforwards
Inventory, premium coupon redemptions and accounts receivable
$
64 $
valuation allowances
Stock-based compensation
Uniform capitalization adjustment to inventories
Operating lease liability
Other asset
Total deferred income tax asset
Valuation allowance for deferred tax assets (1)
Net deferred income tax asset
Deferred income tax liability
Intangibles amortization
Operating lease right-of-use asset
Property and equipment
Total deferred tax liability
Net deferred income tax asset (liability)
57
11
11
77
48
268
(36)
232
(112)
(61)
(7)
(180)
52 $
$
55
46
13
10
79
41
244
(36)
208
(134)
(74)
(7)
(215)
(7)
(1) Primarily relates to operating losses, the benefits of which are uncertain. Any future reductions of such valuation allowances will be
reflected as a reduction of income tax expense.
The assessment of the amount of value assigned to our deferred tax assets under the applicable accounting rules is
judgmental. We are required to consider all available positive and negative evidence in evaluating the likelihood
that we will be able to realize the benefit of our deferred tax assets in the future. Such evidence includes reversals
of deferred tax liabilities and projected future taxable income. Since this evaluation requires consideration of
events that may occur some years into the future, there is an element of judgment involved. Realization of our
deferred tax assets is dependent on generating sufficient taxable income in future periods. We believe that it is
more likely than not that future taxable income will be sufficient to allow us to recover substantially all of the value
assigned to our deferred tax assets. However, if future events cause us to conclude that it is not more likely than
not that we will be able to recover the value assigned to our deferred tax assets, we will be required to adjust our
valuation allowance accordingly.
As of December 31, 2022, we had federal, state and foreign net operating loss carryforwards of approximately
$30 million, $31 million and $220 million, respectively. The federal, state and foreign net operating loss
carryforwards will begin to expire in various years from 2023 through 2041. The amounts of federal, state and
foreign net operating losses that can be carried forward indefinitely are $21 million, $4 million and $218 million,
respectively.
98
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
The tax provisions differ from the amount computed using the federal statutory income tax rate as follows:
December 31,
Years ended
December 25,
December 26,
2022
2021
2020
$
Income tax provision at federal statutory rate
State income tax provision, net of federal income tax effect
Foreign income tax provision
Pass-through noncontrolling interest
Valuation allowance
Unrecognized tax benefits and audit settlements
Interest expense related to loans
Tax benefit related to legal entity reorganization outside the U.S.
Other
Total income tax provision
$
151 $
20
4
(4)
(2)
11
(12)
-
2
170 $
175 $
21
6
(4)
(6)
7
(11)
-
10
198 $
105
13
-
(3)
1
(18)
(11)
(6)
14
95
For the year ended December 31, 2022, our effective tax rate was 23.5%, compared to 23.8% for the prior year
period. In 2022, the difference between our effective tax rate and the federal statutory tax rate primarily relates to
state and foreign income taxes and interest expense. In 2021, the difference between our effective tax rate and the
federal statutory tax rate was primarily due to state and foreign income taxes and interest expense. In 2020, our
effective tax rate was 19.1%. The difference between our effective tax rate and the federal statutory tax rate was
primarily due to an Advance Pricing Agreement with the U.S Internal Revenue Service (the “IRS”) in the U.S.,
other audit resolutions, state and foreign income taxes and interest expense.
On August 16, 2022, the Inflation Reduction Act (H.R. 5376) (“IRA”) was signed into law in the United States.
Among other things, the IRA imposes a 15% corporate alternative minimum tax for tax years beginning after
December 31, 2022 and levies a 1% excise tax on net stock repurchases after December 31, 2022. We are still in
the process of analyzing the provisions of the IRA.
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in
response to the COVID-19 pandemic. The CARES Act includes, but is not limited to, certain income tax
provisions that modify the Section 163(j) limitation of business interest and net operating loss carryover and
carryback rules. The modifications to Section 163(j) increase the allowable business interest deduction from 30%
of adjusted taxable income to 50% of adjusted taxable income for years beginning in 2019 and 2020. The CARES
Act eliminated the NOL income limitation for years beginning before 2021 and it extended the carryback period to
five years for losses incurred in 2018, 2019 and 2020. We have analyzed the income tax provisions of the CARES
Act and have accounted for the impact in the year ended December 26, 2020, which did not have a material impact
on our consolidated financial statements. There are certain other non-income tax benefits available to us under the
CARES Act that require further clarification or interpretation that may affect our consolidated financial statements
in the future. On December 27, 2020, the Consolidated Appropriations Act was enacted into law and extended
certain non-income tax benefits under the CARES Act.
On July 20, 2020, the IRS issued final regulations related to the Tax Cuts and Jobs Act enacted in 2017 (the “Tax
Act”). The final regulations concern the global intangible low-taxed income (“GILTI”) and subpart F income
provisions of the Tax Act. To provide flexibility to taxpayers, the IRS is permitting the application of these final
regulations to prior tax years, if the taxpayer elects to do so. We have analyzed the final regulations, which do not
have a material impact to our consolidated financial statements.
99
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
On December 22, 2017, the U.S. government passed the Tax Act, which requires U.S. companies to pay a
mandatory one-time transition tax on historical offshore earnings that have not been repatriated to the U.S. The
transition tax is payable over eight years. Within our consolidated balance sheets, transition tax of $19 million and
$14 million were included in “accrued taxes” for 2022 and 2021, respectively, and $23 million and $42 million
were included in “other liabilities” for 2022 and 2021, respectively.
Due to the one-time transition tax and the imposition of the GILTI provisions, all previously unremitted earnings
will no longer be subject to U.S. federal income tax; however, there could be U.S., state and/or foreign withholding
taxes upon distribution of such unremitted earnings. Determination of the amount of unrecognized deferred tax
liability with respect to such earnings is not practicable.
ASC 740 prescribes the accounting for uncertainty in income taxes recognized in the financial statements in
accordance with other provisions contained within this guidance. This topic prescribes a recognition threshold and
a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected
to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be
sustained upon examination by the taxing authorities. The amount recognized is measured as the largest amount of
benefit that has a greater than 50% likely of being realized upon ultimate audit settlement. In the normal course of
business, our tax returns are subject to examination by various taxing authorities. Such examinations may result in
future tax and interest assessments by these taxing authorities for uncertain tax positions taken in respect of certain
tax matters.
The total amount of unrecognized tax benefits, which are included in “other liabilities” within our consolidated
balance sheets, as of December 31, 2022 and December 25, 2021 was approximately $94 million and $84 million,
respectively, of which $80 million and $69 million, respectively would affect the effective tax rate if recognized. It
is possible that the amount of unrecognized tax benefits will change in the next 12 months, which may result in a
material impact on our consolidated statements of income.
All tax returns audited by the IRS are officially closed through 2018. The tax years subject to examination by the
IRS include years 2019 and forward. In addition, limited positions reported in the 2017 tax year are subject to IRS
examination. During the quarter ended December 25, 2021, we were notified by the IRS that tax year 2019 was
selected for examination. During the quarter ended June 26, 2021 we reached a resolution with the Appellate
Division for all remaining outstanding issues for 2012 and 2013.
During the quarter ended September 26, 2020 we reached an agreement with the Advanced Pricing Division on an
appropriate transfer pricing methodology for the years 2014-2025. The objective of this resolution was to mitigate
future transfer pricing audit adjustments.
In the fourth quarter of 2020, we reached a resolution with the IRS for the 2014-2016 audit cycle.
The total amounts of interest and penalties are classified as a component of the provision for income taxes. The
amount of tax interest expense (credit) was approximately $0 million, $0 million and $(3) million in 2022, 2021
and 2020, respectively. The total amount of accrued interest is included in “other liabilities”, and was
approximately $12 million as of December 31, 2022 and $12 million as of December 25, 2021. The amount of
penalties accrued for during the periods presented were not material to our consolidated financial statements.
100
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
The following table provides a reconciliation of unrecognized tax benefits:
December 31,
December 25,
December 26,
2022
2021
2020
Balance, beginning of period
$
71 $
Additions based on current year tax positions
Additions based on prior year tax positions
Reductions based on prior year tax positions
Reductions resulting from settlements with taxing authorities
Reductions resulting from lapse in statutes of limitations
14
8
-
(1)
(10)
Balance, end of period
$
82 $
70 $
3
11
(1)
(9)
(3)
71 $
91
5
8
(1)
(19)
(14)
70
Note 14 – Plans of Restructuring and Integration Costs
On August 1, 2022, we committed to a restructuring plan focused on funding the priorities of the strategic plan and
streamlining operations and other initiatives to increase efficiency. We expect this initiative to extend through
2023. We are currently unable in good faith to make a determination of an estimate of the amount or range of
amounts expected to be incurred in connection with these activities, both with respect to each major type of cost
associated therewith and with respect to the total cost, or an estimate of the amount or range of amounts that will
result in future cash expenditures.
During the year ended December 31, 2022, we recorded restructuring charges of $128 million primarily related to
severance and employee-related costs, accelerated amortization of right-of-use lease assets, impairment of other
long-lived assets and lease exit costs.
During the three months ended December 31, 2022, in connection with our restructuring plan, we vacated one of
the buildings at our corporate headquarters in Melville NY, which resulted in an accelerated amortization of right-
of-use lease asset of $34 million. We also initiated the disposal of a non-profitable US business and recorded
related costs of $49 million which primarily consisted of impairment of intangible assets and goodwill, inventory
impairment, and severance and employee-related costs. These expenses are included in the $128 million of
restructuring charges discussed above. The disposal is expected to be completed in the first quarter of 2023.
On August 26, 2022, we acquired Midway Dental Supply. In connection with this acquisition, during the year
ended December 31, 2022, we recorded integration costs of $3 million related to one-time employee and other
costs, as well as restructuring charges of $9 million, which are included in the $128 million of restructuring charges
discussed above.
On November 20, 2019, we committed to a contemplated restructuring initiative intended to mitigate stranded costs
associated with the spin-off of our animal health business and to rationalize operations and provide expense
efficiencies. These activities were originally expected to be completed by the end of 2020 but we extended them to
the end of 2021 in light of the changes to the business environment brought on by the COVID-19 pandemic. The
restructuring activities under this prior initiative were completed in 2021.
101
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Restructuring and integration costs recorded during our 2022, 2021 and 2020 fiscal years consisted of the
following:
Year Ended December 31, 2022
Health-Care Distribution
Technology and Value-Added
Services
Restructuring
Costs
Integration
Costs
Restructuring
Costs
Integration
Costs
Severance and employee-related costs
$
25 $
- $
Impairment and accelerated depreciation and
amortization of right-of-use lease assets and
other long-lived assets
Exit and other related costs
Loss on disposal of a business
Integration employee-related and other costs
Total restructuring and integration costs
Severance and employee-related costs
Total restructuring and integration costs
$
$
$
47
3
49
-
124 $
-
-
-
3
3 $
4 $
-
-
-
-
4 $
-
-
-
-
-
-
Total
29
$
47
3
49
3
131
$
Year Ended December 25, 2021
Health-Care Distribution
Technology and Value-Added
Services
Restructuring
Costs
Integration
Costs
Restructuring
Costs
Integration
Costs
6 $
6 $
- $
- $
2 $
2 $
-
-
Total
8
8
$
$
Year Ended December 26, 2020
Health-Care Distribution
Technology and Value-Added
Services
Restructuring
Costs
Integration
Costs
Restructuring
Costs
Integration
Costs
Severance and employee-related costs
$
25 $
- $
Impairment and accelerated depreciation and
amortization of right-of-use lease assets and
other long-lived assets
Exit and other related costs
Total restructuring and integration costs
$
4
2
31 $
-
-
- $
1 $
-
-
1 $
-
-
-
-
Total
26
$
4
2
32
$
102
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
The following table summarizes, by reportable segment, the activity related to the liabilities associated with our
restructuring initiatives for the year ended December 31, 2022. The remaining accrued balance of restructuring
costs as of December 31, 2022 is included in accrued expenses: other within our condensed consolidated balance
sheet.
Health Care
Distribution
Technology and
Value-Added
Services
Total
Balance, December 25, 2021
Restructuring charges
$
Non-cash asset impairment and accelerated depreciation and
amortization of right-of-use lease assets and other long-lived
assets
Non-cash impairment on disposal of a business
Cash payments and other adjustments
Balance, December 31, 2022
$
3 $
124
(47)
(46)
(13)
21 $
1 $
4
-
-
(2)
3 $
4
128
(47)
(46)
(15)
24
Note 15 – Commitments and Contingencies
Purchase Commitments
In our health care distribution business, we sometimes enter into long-term purchase commitments to ensure the
availability of products for distribution. Future minimum annual payments for inventory purchase commitments as
of December 31, 2022 were:
2023
2024
2025
2026
2027
Thereafter
Total minimum inventory purchase commitment payments
Employment, Consulting and Non-Compete Agreements
$
$
5
4
4
4
4
-
21
We have employment, consulting and non-compete agreements that have varying base aggregate annual payments
for the years 2023 through 2027 and thereafter of approximately $23 million, $7 million, $5 million, $0 million, $0
million, and $0 million, respectively. We also have lifetime consulting agreements that provide for current
compensation of four-hundred thousand dollars per year, increasing twenty-five thousand dollars every fifth year
with the next increase in 2026. In addition, some agreements have provisions for additional incentives and
compensation.
Litigation
Henry Schein, Inc. has been named as a defendant in multiple opioid related lawsuits (currently less than one-
hundred and fifty (150); in approximately half of those cases one or more of Henry Schein, Inc.’s subsidiaries is
also named as a defendant). Generally, the lawsuits allege that the manufacturers of prescription opioid drugs
engaged in a false advertising campaign to expand the market for such drugs and their own market share and that
the entities in the supply chain (including Henry Schein, Inc. and its affiliated companies) reaped financial rewards
by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs.
These actions consist of some that have been consolidated within the MultiDistrict Litigation (“MDL”) proceeding
103
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) and are currently stayed, and
others which remain pending in state courts and are proceeding independently and outside of the MDL. At this
time, the following cases are set for trial: the action filed by DCH Health Care Authority, et al. in Alabama state
court, which has been designated a bellwether with eight of thirty-eight plaintiffs set for a jury trial on July 24,
2023; and the action filed by Florida Health Sciences Center, Inc. (and 38 other hospitals located throughout the
State of Florida) in Florida state court, which is currently scheduled for a jury trial in October 2024. In December
2022, we settled seven cases filed in Utah (plus one case in which we were not yet named a defendant) by nineteen
plaintiffs for a total amount of sixty thousand dollars. The seven cases have been dismissed. Of Henry Schein’s
2022 net sales of approximately $12.6 billion from continuing operations, sales of opioids represented less than
two-tenths of 1 percent. Opioids represent a negligible part of our business. We intend to defend ourselves
vigorously against these actions.
In August 2022, Henry Schein received a Grand Jury Subpoena from the United States Attorney’s Office for the
Western District of Virginia, seeking documents in connection with an investigation of possible violations of the
Federal Food, Drug & Cosmetic Act by Butler Animal Health Supply, LLC (“Butler”), a former subsidiary of
Henry Schein. The investigation relates to the sale of veterinary prescription drugs to certain customers. In
October 2022, Henry Schein received a second Grand Jury Subpoena from the United States Attorney’s Office for
the Western District of Virginia. The October Subpoena seeks documents relating to payments Henry Schein
received from Butler or Covetrus, Inc. (“Covetrus”). Butler was spun off into a separate company and became a
subsidiary of Covetrus in 2019 and is no longer owned by Henry Schein. We are cooperating with the
investigation.
From time to time, we may become a party to other legal proceedings, including, without limitation, product
liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may
in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out
of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty,
in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our
consolidated financial position, liquidity or results of operations.
As of December 31, 2022, we had accrued our best estimate of potential losses relating to claims that were probable
to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as
related expenses, was not material to our financial position, results of operations or cash flows. Our method for
determining estimated losses considers currently available facts, presently enacted laws and regulations and other
factors, including probable recoveries from third parties.
104
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Note 16 – Stock-Based Compensation
Stock-based awards are provided to certain employees under the terms of our 2020 Stock Incentive Plan and to
non-employee directors under the terms of our 2015 Non-Employee Director Stock Incentive Plan (together, the
“Plans”). The Plans are administered by the Compensation Committee of the Board of Directors (the
“Compensation Committee”). Historically, equity-based awards to our employees have been granted solely in the
form of time-based and performance-based restricted stock units (“RSUs”). However, for our 2021 fiscal year, in
light of the COVID-19 pandemic, the Compensation Committee determined it would be difficult for management
to set a meaningful three-year cumulative earnings per share target as the goal applicable to performance-based
RSU awards as it had done in prior years. Instead, the Compensation Committee set our equity-based awards to
employees for fiscal 2021 in the form of time-based RSUs and non-qualified stock options which focus on stock
value appreciation and retention instead of pre-established performance goals. Our non-employee directors
continued to receive equity-based awards for fiscal 2021 solely in the form of time-based RSUs. In March 2022,
the Compensation Committee reinstated performance-based RSUs for equity-based awards to employees for fiscal
2022 and awarded grants in the form of performance-based RSUs, time-based RSUs and non-qualified stock
options.
As of December 31, 2022, there were 70,942,657 shares authorized and 8,034,696 shares available to be granted
under the 2020 Stock Incentive Plan and 1,892,657 shares authorized and 192,400 shares available to be granted
under the 2015 Non-Employee Director Stock Incentive Plan.
RSUs are stock-based awards granted to recipients with specified vesting provisions. In the case of RSUs, common
stock is delivered on or following satisfaction of vesting conditions. We issue RSUs to employees that primarily
vest (i) solely based on the recipient’s continued service over time, primarily with four-year cliff vesting and/or (ii)
based on achieving specified performance measurements and the recipient’s continued service over time, primarily
with three-year cliff vesting. RSUs granted under the 2015 Non-Employee Director Stock Incentive Plan primarily
are granted with 12-month cliff vesting. For these RSUs, we recognize the cost as compensation expense on a
straight-line basis.
With respect to time-based RSUs, we estimate the fair value on the date of grant based on our closing stock price at
the time of grant. With respect to performance-based RSUs, the number of shares that ultimately vest and are
received by the recipient is based upon our performance as measured against specified targets over a specified
period, as determined by the Compensation Committee. Although there is no guarantee that performance targets
will be achieved, we estimate the fair value of performance-based RSUs based on our closing stock price at time of
grant.
Each of the Plans provide for certain adjustments to the performance measurement in connection with awards under
the Plans. With respect to the performance-based RSUs granted under our 2020 Stock Incentive Plan, such
performance measurement adjustments relate to significant events, including, without limitation, acquisitions,
divestitures, new business ventures, certain capital transactions (including share repurchases), differences in
budgeted average outstanding shares (other than those resulting from capital transactions referred to above),
restructuring costs, if any, certain litigation settlements or payments, if any, changes in accounting principles or in
applicable laws or regulations, changes in income tax rates in certain markets, foreign exchange fluctuations, the
financial impact of certain products and unforeseen events or circumstances affecting us.
Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the
related compensation expense is adjusted upward or downward based upon our estimation of achieving such
performance targets. The ultimate number of shares delivered to recipients and the related compensation cost
recognized as an expense will be based on our actual performance metrics as defined under the Plans.
105
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Stock options are awards that allow the recipient to purchase shares of our common stock at a fixed price following
vesting of the stock options. Stock options are granted at an exercise price equal to our closing stock price on the
date of grant. Stock options issued beginning in 2021 vest one-third per year based on the recipient’s continued
service, subject to the terms and conditions of the 2020 Stock Incentive Plan, are fully vested three years from the
grant date and have a contractual term of ten years from the grant date, subject to earlier termination of the term
upon certain events. Compensation expense for these stock options is recognized using a graded vesting method.
We estimate the fair value of stock options using the Black-Scholes valuation model.
In addition to equity-based awards granted in fiscal 2021 under the long-term incentive program, the Compensation
Committee granted a Special Pandemic Recognition Award under the 2020 Stock Incentive Plan to recipients of
performance-based RSUs under the 2018 long-term incentive program. The payout under the performance-based
restricted stock units granted under the fiscal 2018 long-term incentive program (the “2018 LTIP”) was negatively
impacted by the global COVID-19 pandemic. Given the significance of the impact of the pandemic on our three-
year EPS goal under such equity awards and the contributions made by our employees (including those who
received such awards), on March 3, 2021, the Compensation Committee granted a Special Pandemic Recognition
Award to recipients of performance-based restricted stock units under the 2018 LTIP who were employed by us on
the grant date of the Special Pandemic Recognition Award. These time-based RSU awards vest 50% on the first
anniversary of the grant date and 50% on the second anniversary of the grant date, based on the recipient’s
continued service and subject to the terms and conditions of the 2020 Stock Incentive Plan, and are recorded as
compensation expense using a graded vesting method. The combination of the 20% payout based on actual
performance of the 2018 LTIP and the one-time Special Pandemic Recognition Award granted in 2021 will
generate a cumulative payout of 75% of each recipient’s original number of performance-based restricted stock
units awarded in 2018 if the recipient satisfies the two-year vesting schedule commencing on the grant date.
Our accompanying consolidated statements of income reflect pre-tax share-based compensation expense of $54
million ($41 million after-tax), $78 million ($60 million after-tax) and $9 million ($7 million after-tax) for the years
ended December 31, 2022, December 25, 2021 and December 26, 2020.
Total unrecognized compensation cost related to non-vested awards as of December 31, 2022 was $75 million,
which is expected to be recognized over a weighted-average period of approximately 2.1 years.
The weighted-average grant date fair value of stock-based awards granted before forfeitures was $85.51, $62.72
and $60.23 per share during the years ended December 31, 2022, December 25, 2021 and December 26, 2020.
Certain stock-based compensation granted may require us to settle in the form of a cash payment. During the year
ended December 31, 2022, we recorded a liability of $0.4 million relating to the grant date fair value of stock-based
compensation to be settled in cash.
We record deferred income tax assets for awards that will result in future deductions on our income tax returns
based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will
receive a deduction.
Our accompanying consolidated statements of cash flows present our stock-based compensation expense as an
adjustment to reconcile net income to net cash provided by operating activities for all periods presented. In the
accompanying consolidated statements of cash flows, there were no benefits associated with tax deductions in
excess of recognized compensation as a cash inflow from financing activities for the years ended December 31,
2022, December 25, 2021 and December 26, 2020.
106
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
The following weighted-average assumptions were used in determining the most recent fair values of stock options
using the Black-Scholes valuation model:
Expected dividend yield
Expected stock price volatility
Risk-free interest rate
Expected life of options (years)
2022
0.00 %
27.80 %
3.62 %
6.00
We have not declared cash dividends on our stock in the past and we do not anticipate declaring cash dividends in
the foreseeable future. The expected stock price volatility is based on implied volatilities from traded options on
our stock, historical volatility of our stock, and other factors. The risk-free interest rate is based on the U.S.
Treasury yield curve in effect at the time of grant in conjunction with considering the expected life of options. The
six-year expected life of the options was determined using the simplified method for estimating the expected term
as permitted under SAB Topic 14. Estimates of fair value are not intended to predict actual future events or the
value ultimately realized by recipients of stock options, and subsequent events are not indicative of the
reasonableness of the original estimates of fair value made by us.
The following table summarizes the stock option activity for the year ended December 31, 2022:
Outstanding at beginning of year
Granted
Exercised
Forfeited
Outstanding at end of year
Options exercisable at end of year
Shares
767,717 $
420,075
(36,150)
(34,068)
1,117,574 $
220,688 $
Stock Options
Weighted
Average
Exercise
Price
Remaining
Weighted Average
Remaining Contractual
Life in Years
Aggregate
Intrinsic
Value
63.24
85.81
62.92
74.84
71.38
63.35
8.5 $
12
Number of
Options
Weighted
Average
Exercise
Price
Weighted Average
Remaining
Contractual
Life (in years)
Aggregate
Intrinsic
Value
Vested or expected to vest
885,428 $
73.50
8.7 $
8
The following tables summarize the activity of our unvested RSUs for the year ended December 31, 2022:
Time-Based Restricted Stock Units
Performance-Based Restricted Stock Units
Weighted Average
Grant Date Fair Intrinsic Value
Weighted Average
Grant Date Fair
Shares/Units Value Per Share
Intrinsic Value
Per Share
Shares/Units Value Per Share
Per Share
Outstanding at beginning of period
Granted
Vested
Forfeited
Outstanding at end of period
1,945,862 $
471,840
(566,887)
(94,771)
1,756,044 $
58.79
85.49
55.46
67.87
66.59 $
674,753 $
267,865
(396,220)
(25,482)
520,916 $
79.87
59.63
82.35
59.21
67.65
60.23
$
79.87
The total intrinsic value per share of RSUs that vested was $78.74, $73.99 and $61.49 during the years ended
December 31, 2022, December 25, 2021 and December 26, 2020.
107
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Note 17 – Employee Benefit Plans
Defined benefit plans
Certain of our employees in our international markets participate in various noncontributory defined benefit plans.
These plans are managed to provide pension benefits to covered employees in accordance with local regulations
and practices. Our net unfunded liability for these plans are recorded in accrued expenses: other; and other
liabilities within our consolidated balance sheets. The following table presents the changes in projected benefit
obligations, plan assets, and the funded status of our defined benefit pension plans:
Years Ended
December 31,
2022
December 25,
2021
Obligation and funded status:
Change in benefit obligation
Projected benefit obligation, beginning of period
$
Service costs
Interest cost
Past service cost
Actuarial loss
Benefits paid (1)
Participant contributions
Settlements
Effect of foreign currency translation
Projected benefit obligation, end of period
Change in plan assets
Fair value of plan assets at beginning of period
Actual return on plan assets
Employer contributions
Plan participant contributions
Expected return on plan assets
Benefit received (1)
Settlements
Effect of foreign currency translation
Fair value of plan assets at end of period
Unfunded status at end of period
$
$
$
$
$
128
3
1
-
(19)
(1)
1
(1)
(4)
108 $
75 $
(3)
2
1
1
-
(1)
(2)
73 $
35 $
130
4
-
5
(5)
-
1
(2)
(5)
128
65
5
2
1
4
2
(3)
(1)
75
53
(1)
Includes regular benefit payments and amounts transferred in by new participants.
The majority of our defined benefit plans are unfunded, with the exception of one plan in one country where the
amount of assets exceeds the projected benefit obligation by approximately $6 million and $6 million as of
December 31, 2022 and December 25, 2021, respectively.
108
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
The following table provides the amounts recognized in our consolidated balance sheets for our defined benefit
pension plans:
Years Ended
December 31,
2022
December 25,
2021
Non-current assets
Current liabilities
Non-current liabilities
Accumulated other comprehensive loss, pre-tax
$
25 $
(1)
(59)
4
22
(1)
(74)
21
The following table provides the net periodic pension cost for our defined benefit plans:
Service cost
Interest cost
Expected return on plan assets
Employee contributions
Amortization of prior service credit
Recognized net actuarial loss
Settlements
Net periodic pension cost
$
$
December 31,
2022
Years Ended
December 25,
2021
December 26,
2020
3 $
1
(1)
-
1
-
-
4 $
4 $
-
(1)
-
1
-
-
4 $
-
-
-
-
-
3
1
4
The following tables present the weighted-average actuarial assumptions used to determine our pension benefit
obligation and our net periodic pension cost for the periods presented:
Pension Benefit Obligation
Weighted average discount rate
Net Periodic Pension Cost
Discount rate-pension benefit
Expected return on plan assets
Rate of compensation increase
Pension increase rate
Years Ended
December 31,
2022
December 25,
2021
1.67 %
0.87 %
December 31,
2022
Years Ended
December 25,
2021
December 26,
2020
1.25 %
0.81 %
1.68 %
0.61 %
0.56 %
0.71 %
1.95 %
0.72 %
0.51 %
0.87 %
1.97 %
0.67 %
109
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
The following table presents the estimated pension benefit payments that are payable to the plan’s participants as of
December 31, 2022:
$
Year
2023
2024
2025
2026
2027
2028 to 2032
Total
$
401(k) Plans
6
6
5
5
7
38
67
We offer qualified 401(k) plans to substantially all our domestic full-time employees. As determined by our Board
of Directors, matching contributions to these plans generally do not exceed 100% of the participants’ contributions
up to 7% of their base compensation, subject to applicable legal limits. Matching contributions consist of cash and
were allocated entirely to the participants’ investment elections on file, subject to a 20% allocation limit to the
Henry Schein Stock Fund. Due to the impact of COVID-19, as part of our initiative to generate cash savings, we
suspended the matching contribution for the second half of 2020. The matching contribution was reinstated in
2021. Forfeitures attributable to participants whose employment terminates prior to becoming fully vested are used
to reduce our matching contributions and offset administrative expenses of the 401(k) plans.
Assets of the 401(k) and other defined contribution plans are held in self-directed accounts enabling participants to
choose from various investment fund options. Matching contributions related to these plans charged to operations
during the years ended December 31, 2022, December 25, 2021 and December 26, 2020 amounted to $45 million,
$38 million and $21 million, respectively. Within our consolidated statements of income, $37 million is included
in selling, general and administrative expenses; and $8 million is included in cost of goods sold.
Supplemental Executive Retirement Plan (“SERP”)
We offer an unfunded, non-qualified SERP to eligible employees. This plan generally covers officers and certain
highly compensated employees after they have reached the maximum IRS allowed pre-tax 401(k) contribution
limit. Our contributions to this plan are equal to the 401(k) employee-elected contribution percentage applied to
base compensation for the portion of the year in which such employees are not eligible to make pre-tax
contributions to the 401(k) plan. Due to the impact of COVID-19, as part of our initiative to generate cash savings,
we suspended contributions under the SERP for the second half of 2020. Contributions to the SERP were restored
in 2021. The amounts charged to operations during the years ended December 31, 2022, December 25, 2021 and
December 26, 2020 amounted to $(1) million, $2 million and $3 million, respectively. The charges are included in
selling, general and administrative expenses line item within our consolidated statements of income. Please see
Note 11 – Derivatives and Hedging Activities for additional information.
Deferred Compensation Plan (“DCP”)
During 2011, we began to offer DCP to a select group of management or highly compensated employees of the
Company and certain subsidiaries. This plan allows for the elective deferral of base salary, bonus and/or
commission compensation by eligible employees. The amounts charged to operations during the years ended
December 31, 2022, December 25, 2021 and December 26, 2020 were approximately $(11) million, $8 million and
$8 million, respectively. The charges are included in selling, general and administrative expenses line item within
our consolidated statements of income. Please see Note 11 – Derivatives and Hedging Activities for additional
information.
110
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Note 18 – Redeemable Noncontrolling Interests
Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire
their ownership interest in those entities at fair value. ASC 480-10 is applicable for noncontrolling interests where
we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from
the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The
components of the change in the redeemable noncontrolling interests for the years ended December 31, 2022,
December 25, 2021 and December 26, 2020 are presented in the following table:
December 31, December 25, December 26,
2021
2022
2020
Balance, beginning of period
Decrease in redeemable noncontrolling interests due to acquisitions of
noncontrolling interests in subsidiaries
Increase in redeemable noncontrolling interests due to business
acquisitions
Net income attributable to redeemable noncontrolling interests
Dividends declared
Effect of foreign currency translation loss attributable to redeemable
noncontrolling interests
Change in fair value of redeemable securities
Balance, end of period
$
613 $
328 $
(31)
4
21
(21)
(6)
(4)
576 $
(60)
189
23
(21)
(6)
160
613 $
$
287
(17)
28
14
(13)
(4)
33
328
Note 19 – Comprehensive Income
Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income as
such amounts are recorded directly as an adjustment to stockholders’ equity.
The following table summarizes our Accumulated other comprehensive loss, net of applicable taxes as of:
December 31, December 25, December 26,
2021
2022
2020
Attributable to Redeemable noncontrolling interests:
Foreign currency translation adjustment
Attributable to noncontrolling interests:
Foreign currency translation adjustment
Attributable to Henry Schein, Inc.:
Foreign currency translation adjustment
Unrealized gain (loss) from foreign currency hedging activities
Pension adjustment loss
Accumulated other comprehensive loss
Total Accumulated other comprehensive loss
$
$
$
$
$
(37) $
(31) $
(25)
(1) $
- $
-
(236) $
5
(2)
(233) $
(155) $
(2)
(14)
(171) $
(77)
(11)
(20)
(108)
(271) $
(202) $
(133)
111
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
The following table summarizes the components of comprehensive income, net of applicable taxes as follows:
December 31, December 25, December 26,
2021
2022
2020
Net income
$
566
$
660 $
420
Foreign currency translation gain (loss)
Tax effect
Foreign currency translation gain (loss)
Unrealized gain (loss) from foreign currency hedging activities
Tax effect
Unrealized gain (loss) from foreign currency hedging activities
Pension adjustment gain
Tax effect
Pension adjustment gain
Comprehensive income
(88)
-
(88)
10
(3)
7
16
(4)
12
(84)
-
(84)
12
(3)
9
8
(2)
6
63
-
63
(10)
3
(7)
-
-
-
$
497 $
591 $
476
Our financial statements are denominated in the U.S. Dollar currency. Fluctuations in the value of foreign
currencies as compared to the U.S. Dollar may have a significant impact on our comprehensive income. The
foreign currency translation gain (loss) during the years ended December 31, 2022, December 25, 2021 and
December 26, 2020 was primarily due to changes in foreign currency exchange rates of the Euro, British Pound,
Australian Dollar, Brazilian Real, New Zealand Dollar and Canadian Dollar. The foreign currency translation gain
(loss) during the years ended December 31, 2022, December 25, 2021 and December 26, 2020 was primarily
attributable to a net investment hedge that was entered into during 2019. See Note 11-Derivatives and Hedging
Activities for further information.
The following table summarizes our total comprehensive income, net of applicable taxes as follows:
December 31, December 25, December 26,
2021
2020
2022
Comprehensive income attributable to
Henry Schein, Inc.
Comprehensive income attributable to
noncontrolling interests
Comprehensive income attributable to
Redeemable noncontrolling interests
Comprehensive income
$
476 $
568 $
6
15
497 $
6
17
591 $
$
463
3
10
476
112
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Note 20 – Discontinued Operations
Animal Health Spin-off
On February 7, 2019 (the “Distribution Date”), we completed the separation (the “Separation”) and subsequent
merger (“Merger”) of our animal health business (the “Henry Schein Animal Health Business”) with Direct Vet
Marketing, Inc. (d/b/a Vets First Choice, “Vets First Choice”). This was accomplished by a series of transactions
among us, Vets First Choice, Covetrus, Inc. (f/k/a HS Spinco, Inc. “Covetrus”), a wholly owned subsidiary of ours
prior to the Distribution Date, and HS Merger Sub, Inc., a wholly owned subsidiary of Covetrus (“Merger
Sub”). In connection with the Separation, we contributed, assigned and transferred to Covetrus certain applicable
assets, liabilities and capital stock or other ownership interests relating to the Henry Schein Animal Health
Business. On the Distribution Date, we received a tax-free distribution of $1,120 million from Covetrus pursuant to
certain debt financing incurred by Covetrus. On the Distribution Date and prior to the Animal Health Spin-off,
Covetrus issued shares of Covetrus common stock to certain institutional accredited investors (the “Share Sale
Investors”) for $361 million (the “Share Sale”). The proceeds of the Share Sale were paid to Covetrus and
distributed to us. Subsequent to the Share Sale, we distributed, on a pro rata basis, all of the shares of the common
stock of Covetrus held by us to our stockholders of record as of the close of business on January 17, 2019 (the
“Animal Health Spin-off”). After the Share Sale and Animal Health Spin-off, Merger Sub consummated the
Merger whereby it merged with and into Vets First Choice, with Vets First Choice surviving the Merger as a
wholly owned subsidiary of Covetrus. Immediately following the consummation of the Merger, on a fully diluted
basis, (i) approximately 63% of the shares of Covetrus common stock were (a) owned by our stockholders and the
Share Sale Investors, and (b) held by certain employees of the Henry Schein Animal Health Business (in the form
of certain equity awards), and (ii) approximately 37% of the shares of Covetrus common stock were (a) owned by
stockholders of Vets First Choice immediately prior to the Merger, and (b) held by certain employees of Vets First
Choice (in the form of certain equity awards). After the Separation and the Merger, we no longer beneficially
owned any shares of Covetrus common stock and, following the Distribution Date, will not consolidate the
financial results of Covetrus for the purpose of our financial reporting. Following the Separation and the Merger,
Covetrus was an independent, publicly traded company on the Nasdaq Global Select Market.
In connection with the completion of the Animal Health Spin-off, we entered into a transition services agreement,
which ended in December 2020, with Covetrus under which we agreed to provide certain transition services for up
to twenty-four months in areas such as information technology, finance and accounting, human resources, supply
chain, and real estate and facility services.
As a result of the Separation, the financial position and results of operations of the Henry Schein Animal Health
Business are presented as discontinued operations and have been excluded from continuing operations and segment
results for all periods presented. The accompanying notes to the consolidated financial statements have been
revised to reflect the effect of the Separation and all prior year balances have been revised accordingly to reflect
continuing operations only. The historical statements of Comprehensive Income (Loss) and Shareholders' Equity
have not been revised to reflect the Separation and instead reflect the Separation as an adjustment to the balances at
December 26, 2020.
In February 2019, we completed the Animal Health Spin-off. During the year ended December 26, 2020, we
incurred $0 million in transaction costs associated with this transaction. All transaction costs related to the Animal
Health Spin-off have been included in results from discontinued operations.
113
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Summarized financial information for our discontinued operations is as follows:
Selling, general and administrative
Operating loss
Income tax benefit
Income from discontinued operations
Net income from discontinued operations attributable to Henry Schein, Inc.
Year Ended
December 26,
2020
$
2
(2)
(3)
1
1
The operating loss from discontinued operations for the year ended December 26, 2020 was primarily attributable
to costs directly related to the Animal Health Spin-off. See Note 23 – Related Party Transactions for additional
information.
The net income from discontinued operations for the year ended December 26, 2020 was primarily attributable to a
reduction in a liability for tax indemnification and a tax refund received during 2020 by a holding company
previously part of our Animal Health legal structure and other favorable tax resolutions.
Note 21 – Earnings Per Share
Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted-
average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly
to basic earnings per share, except that it reflects the effect of common shares issuable for presently unvested RSUs
and upon exercise of stock options using the treasury stock method in periods in which they have a dilutive effect.
A reconciliation of shares used in calculating earnings per basic and diluted share follows:
Years Ended
December 31, December 25, December 26,
2021
2022
2020
Basic
Effect of dilutive securities:
Stock options and restricted stock units
Diluted
136,064,221
140,090,889
142,504,193
1,691,449
137,755,670
1,681,892
141,772,781
899,489
143,403,682
The number of antidilutive securities that were excluded from the calculation of diluted weighted average common
shares outstanding are as follows:
Years Ended
December 31, December 25, December 26,
2021
2022
2020
Stock options
Restricted stock units
Total anti-dilutive securities excluded from EPS computation
342,716
19,466
362,182
611,869
1,048
612,917
-
2,398
2,398
114
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
Note 22 – Supplemental Cash Flow Information
Cash paid for interest and income taxes was:
Interest
Income taxes
December 31,
2022
Years ended
December 25,
2021
December 26,
2020
$
47 $
265
29 $
242
43
207
For the years ended December 31, 2022, December 25, 2021 and December 26, 2020, we had $10 million, $12
million and $(10) million of non-cash net unrealized gains (losses) related to foreign currency hedging activities,
respectively.
Note 23 – Related Party Transactions
In connection with the completion of the Animal Health Spin-off during our 2019 fiscal year, we entered into a
transition services agreement with Covetrus under which we agreed to provide certain transition services for up to
twenty-four months in areas such as information technology, finance and accounting, human resources, supply
chain, and real estate and facility services. (see Note 20 – Discontinued Operations for additional details).
For the year ended December 26, 2020, we recorded approximately $13 million of fees for these services. Pursuant
to the transition services agreement, Covetrus purchased certain products from us. During the year December 26,
2020, net sales to Covetrus under the transition services agreement were approximately $75 million. Sales to
Covetrus under the transition services agreement ended in December 2020.
In connection with the formation of Henry Schein One, LLC, our joint venture with Internet Brands, which was
formed on July 1, 2018, we entered into a ten-year royalty agreement with Internet Brands whereby we will pay
Internet Brands approximately $31 million annually for the use of their intellectual property. During the years
ended December 31, 2022, December 25, 2021 and December 26, 2020, we recorded $31 million, $31 million and
$31 million, respectively in connection with costs related to this royalty agreement. As of December 31, 2022 and
December 25, 2021, Henry Schein One, LLC had a net receivable (payable) balance from (to) Internet Brands of
($8) million and $9 million, respectively, comprised of amounts related to results of operations and the royalty
agreement. The components of this receivable and payable are recorded within prepaid expenses and other; and
accrued expenses: other, respectively, within our consolidated balance sheets.
During our normal course of business, we have interests in entities that we account for under the equity accounting
method. During the years ended December 31, 2022, December 25, 2021 and December 26, 2020, we recorded net
sales of $46 million, $48 million, and $38 respectively, to such entities. During our fiscal years ended 2022, 2021
and 2020, we purchased $9 million, $15 million and $12 million respectively, from such entities. At December 31,
2022 and December 25, 2021, we had in aggregate $36 million and $44 million, due from our equity affiliates, and
$6 million and $7 million due to our equity affiliates, respectively.
Certain of our facilities related to our acquisitions are leased from employees and minority shareholders. Please see
Note 6 – Leases for further information.
115
ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
ITEM 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of management, including our principal executive officer and
principal financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and
procedures as of the end of the period covered by this annual report as such term is defined in Rules 13a-15(e) and
15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on
this evaluation, our management, including our principal executive officer and principal financial officer,
concluded that our disclosure controls and procedures were effective as of December 31, 2022, to ensure that all
material information required to be disclosed by us in reports that we file or submit under the Exchange Act is
accumulated and communicated to them as appropriate to allow timely decisions regarding required disclosure and
that all such information is recorded, processed, summarized and reported within the time periods specified in the
SEC’s rules and forms.
Changes in Internal Control over Financial Reporting
The combination of acquisitions, continued acquisition integrations and systems implementation activity
undertaken during the quarter ended December 31, 2022 and carried over from prior quarters when considered in
the aggregate, does not represent a material change in our internal control over financial reporting.
Management’s Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting,
as such term is defined in Exchange Act Rule 13a-15(f). Our internal control system is designed to provide
reasonable assurance to our management and Board of Directors regarding the preparation and fair presentation of
published financial statements. Under the supervision and with the participation of our management, including our
principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our
internal control over financial reporting based on the framework in Internal Control-Integrated Framework (2013),
updated and reissued by the Committee of Sponsoring Organizations, or the COSO Framework. Based on our
evaluation under the COSO Framework, our management concluded that our internal control over financial
reporting was effective at a reasonable assurance level as of December 31, 2022.
The effectiveness of our internal control over financial reporting as of December 31, 2022, has been independently
audited by BDO USA, LLP, an independent registered public accounting firm, and their attestation is included
herein.
Limitations of the Effectiveness of Internal Control
A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the internal control system are met. Because of the inherent limitations of any internal control
system, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company
have been detected.
116
Report Of Independent Registered Public Accounting Firm
Shareholders and Board of Directors
Henry Schein, Inc.
Melville, NY
Opinion on Internal Control over Financial Reporting
We have audited Henry Schein, Inc.’s (the “Company’s”) internal control over financial reporting as of December
31, 2022, based on criteria established in Internal Control – Integrated Framework (2013) (the “COSO criteria”). In
our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as
of December 31, 2022, based on the COSO criteria.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United
States) (“PCAOB”), the consolidated balance sheets of the Company as of December 31, 2022 and December 25,
2021, the related consolidated statements of income, comprehensive income, stockholders’ equity, and cash flows
for each of the three years in the period ended December 31, 2022, and the related notes and our report dated February
21, 2023 expressed as an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for
its assessment of the effectiveness of internal control over financial reporting, included in the accompanying “Item
9A, Management’s Report on Internal Control over Financial Reporting”. Our responsibility is to express an opinion
on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm
registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S.
federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the
PCAOB.
We conducted our audit of internal control over financial reporting in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective
internal control over financial reporting was maintained in all material respects. Our audit included obtaining an
understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and
testing and evaluating the design and operating effectiveness of internal control based on assessed risk. Our audit also
included performing such other procedures as we considered necessary in the circumstances. We believe that our
audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles. A company’s internal control over financial reporting includes those
policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that
transactions are recorded as necessary to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance
with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have
a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may
deteriorate.
/s/ BDO USA, LLP
New York, NY
February 21, 2023
117
ITEM 9B. Other Information
Not applicable.
ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
ITEM 10. Directors, Executive Officers and Corporate Governance
PART III
Information required by this item regarding our directors and executive officers and our corporate governance is
hereby incorporated by reference to the Section entitled “Election of Directors,” with respect to directors, and the
first paragraph of the Section entitled “Corporate Governance - Board of Directors Meetings and Committees -
Audit Committee,” with respect to corporate governance, in each case in our definitive 2023 Proxy Statement to be
filed pursuant to Regulation 14A and to the Section entitled “Information about our Executive Officers” in Part I of
this report, with respect to executive officers.
There have been no changes to the procedures by which stockholders may recommend nominees to our Board of
Directors since our last disclosure of such procedures, which appeared in our definitive 2022 Proxy Statement filed
pursuant to Regulation 14A on April 6, 2022.
Information required by this item concerning compliance with Section 16(a) of the Securities Exchange Act of
1934 is hereby incorporated by reference to the Section entitled “Delinquent Section 16(a) Reports” in our
definitive 2023 Proxy Statement to be filed pursuant to Regulation 14A, to the extent responsive disclosure is
required.
We have adopted a Code of Ethics that applies to our Chief Executive Officer, Chief Financial Officer, Chief
Accounting Officer and Controller. We make available free of charge through our Internet website,
www.henryschein.com, under the “About Henry Schein--Corporate Governance Highlights” caption, our Code of
Ethics. We intend to disclose on our Web site any amendment to, or waiver of, a provision of the Code of Ethics.
ITEM 11. Executive Compensation
The information required by this item is hereby incorporated by reference to the Sections entitled “Compensation
Discussion and Analysis,” “Compensation Committee Report” (which information shall be deemed furnished in
this Annual Report on Form 10-K), “Executive and Director Compensation” and “Compensation Committee
Interlocks and Insider Participation” in our definitive 2023 Proxy Statement to be filed pursuant to Regulation 14A.
118
ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
Matters
We maintain several stock incentive plans for the benefit of certain officers, directors and employees. All active
plans have been approved by our stockholders. Descriptions of these plans appear in the notes to our consolidated
financial statements. The following table summarizes information relating to these plans as of December 31, 2022:
Number of Common
Plan Category
Plans Approved by Stockholders
Plans Not Approved by Stockholders
Total
Shares to be Issued Upon Weighted- Average Number of Common
Shares Available for
Exercise of Outstanding
Future Issuances
Options and Rights
Exercise Price of
Outstanding Options
-
-
- $
-
- $
-
8,227,096
-
8,227,096
The other information required by this item is hereby incorporated by reference to the Section entitled “Security
Ownership of Certain Beneficial Owners and Management” in our definitive 2023 Proxy Statement to be filed
pursuant to Regulation 14A.
ITEM 13. Certain Relationships and Related Transactions, and Director Independence
The information required by this item is hereby incorporated by reference to the Section entitled “Certain
Relationships and Related Transactions” and “Corporate Governance – Board of Directors Meetings and
Committees – Independent Directors” in our definitive 2023 Proxy Statement to be filed pursuant to Regulation
14A.
ITEM 14. Principal Accounting Fees and Services
The information required by this item is hereby incorporated by reference to the Section entitled “Independent
Registered Public Accounting Firm Fees and Pre-Approval Policies and Procedures” in our definitive 2023 Proxy
Statement to be filed pursuant to Regulation 14A.
ITEM 15. Exhibits, Financial Statement Schedules
(a)
List of Documents Filed as a Part of This Report:
PART IV
1. Financial Statements:
Our Consolidated Financial Statements filed as a part of this report are listed on the index on
Page 60.
2.
Index to Exhibits:
See exhibits listed under Item 15(b) below.
119
(b) Exhibits
2.1
Contribution and Distribution Agreement, dated as of April 20, 2018, by and
among us, HS Spinco, Inc., Direct Vet Marketing, Inc. and Shareholder
Representative Services LLC. (Incorporated by reference to Exhibit 2.1 to our
Current Report on Form 8-K filed on April 23, 2018 (film no. 18767875).)*
2.2
2.3
2.4
2.5
2.6
3.1
3.2
4.1
Agreement and Plan of Merger, dated as of April 20, 2018, by and among us, HS
Spinco, Inc, HS Merger Sub, Inc., Direct Vet Marketing, Inc. and Shareholder
Representative Services LLC. (Incorporated by reference to Exhibit 2.2 to our
Current Report on Form 8-K filed on April 23, 2018 (film no. 18767875).)*
Letter Agreement, Amendment No. 1 to Contribution and Distribution Agreement
and Amendment No. 1 to Agreement and Plan of Merger, dated as of September
14, 2018, by and among us, HS Spinco, Inc., HS Merger Sub, Inc., Direct Vet
Marketing, Inc. and Shareholder Representative Services LLC.( Incorporated by
reference to Exhibit 2.3 to our Annual Report on Form 10-K for the fiscal year
ended December 29, 2018 filed on February 20, 2019.)
Letter Agreement and Amendment No. 2 to Contribution and Distribution
Agreement, dated as of November 30, 2018, by and among us, HS Spinco, Inc.,
Direct Vet Marketing, Inc. and Shareholder Representative Services LLC.
(Incorporated by reference to Exhibit 2.4 to our Annual Report on Form 10-K for
the fiscal year ended December 29, 2018 filed on February 20, 2019.)
Letter Agreement and Amendment No. 3 to Contribution and Distribution
Agreement and Amendment No. 2 to Agreement and Plan of Merger, dated as of
December 25, 2018, by and among us, HS Spinco, Inc., HS Merger Sub, Inc.,
Direct Vet Marketing, Inc. and Shareholder Representative Services
LLC.(Incorporated by reference to Exhibit 2.5 to our Annual Report on Form 10-K
for the fiscal year ended December 29, 2018 filed on February 20, 2019.)
Letter Agreement and Amendment No. 4 to Contribution and Distribution
Agreement, dated as of January 15, 2019, by and among us, HS Spinco, Inc., Direct
Vet Marketing, Inc. and Shareholder Representative Services LLC.(Incorporated
by reference to Exhibit 2.6 to our Annual Report on Form 10-K for the fiscal year
ended December 29, 2018 filed on February 20, 2019.)
Second Amended and Restated Certificate of Incorporation of Henry Schein, Inc.
(Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed
on June 1, 2018.)
Third Amended and Restated By-Laws of the Company, effective May 13, 2021.
(Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed
on May 17, 2021.)
Third Amended and Restated Multicurrency Master Note Purchase Agreement,
dated as of October 20, 2021, by and among us, Metropolitan Life Insurance
Company, MetLife Investment Management, LLC and each MetLife affiliate
which becomes party thereto. (Incorporated by reference to Exhibit 4.4 to our
Current Report on Form 8-K filed on October 21, 2021.)
120
4.2
4.3
4.4
4.5
10.1
10.2
10.3
10.4
10.5
Third Amended and Restated Master Note Facility, dated as of October 20, 2021,
by and among us, NYL Investors LLC and each New York Life affiliate which
becomes party thereto. (Incorporated by reference to Exhibit 4.3 to our Current
Report on Form 8-K filed on October 21, 2021.)
Third Amended and Restated Multicurrency Private Shelf Agreement, dated as of
October 20, 2021, by and among us, PGIM, Inc. and each Prudential affiliate which
becomes party thereto. (Incorporated by reference to Exhibit 4.2 to our Current
Report on Form 8-K filed on October 21, 2021.)
Multicurrency Private Shelf Agreement, dated as of October 20, 2021, by and
among us, AIG Asset Management (U.S.), LLC and each AIG affiliate which
becomes party thereto. (Incorporated by reference to Exhibit 4.1 to our Current
Report on Form 8-K filed on October 21, 2021.)
Description of Securities. (Incorporated by reference to Exhibit 4.5 to our Annual
Report on Form 10-K for the fiscal year ended December 25, 2021 filed on
February 15, 2022.)
Henry Schein, Inc. 2013 Stock Incentive Plan, as amended and restated effective as
of May 14, 2013. (Incorporated by reference to Exhibit 10.2 to our Current Report
on Form 8-K filed on May 16, 2013.)**
Form of 2019 Restricted Stock Unit Agreement for performance-based restricted
stock unit awards pursuant to the Henry Schein, Inc. 2013 Stock Incentive Plan (as
amended and restated effective as of May 14, 2013). (Incorporated by reference to
Exhibit 10.2 to our Quarterly Report on Form 10-Q for the fiscal quarter ended
March 30, 2019 filed on May 7, 2019.)**
Form of 2019 Restricted Stock Unit Agreement for time-based restricted stock unit
awards pursuant to the Henry Schein, Inc. 2013 Stock Incentive Plan (as amended
and restated effective as of May 14, 2013). (Incorporated by reference to Exhibit
10.1 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 30,
2019 filed on May 7, 2019.)**
Henry Schein, Inc. 2020 Stock Incentive Plan, as amended and restated effective as
of May 21, 2020. (Incorporated by reference to Exhibit 10.1 to our Current Report
on Form 8-K filed on May 26, 2020.)**
Form of 2021 Stock Option Agreement pursuant to the Henry Schein, Inc. 2020
Stock Incentive Plan (as amended and restated effective as of May 21, 2020).
(Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed
on March 8, 2021.)**
121
10.6
10.7
10.8
10.9
10.10
10.11
10.12
10.13
10.14
Form of 2021 Special Pandemic Recognition Award Restricted Stock Unit
Agreement for time-based restricted stock unit awards pursuant to the Henry
Schein, Inc. 2020 Stock Incentive Plan (as amended and restated effective as of
May 21, 2020). (Incorporated by reference to Exhibit 10.2 to our Quarterly Report
on Form 10-Q for the fiscal quarter ended March 27, 2021 filed on May 4,
2021.)**
Form of 2022 Restricted Stock Unit Agreement for time-based restricted stock unit
awards pursuant to the Henry Schein, Inc. 2020 Stock Incentive Plan (as amended
and restated effective as of May 21, 2020). (Incorporated by reference to Exhibit
10.1 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 26,
2022 filed on May 3, 2022.)**
Form of 2022 Restricted Stock Unit Agreement for performance-based restricted
stock unit awards pursuant to the Henry Schein, Inc. 2020 Stock Incentive Plan (as
amended and restated effective as of May 21, 2020). (Incorporated by reference to
Exhibit 10.2 to our Quarterly Report on Form 10-Q for the fiscal quarter ended
March 26, 2022 filed on May 3, 2022.)**
Henry Schein, Inc. 2015 Non-Employee Director Stock Incentive Plan.
(Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q
for the fiscal quarter ended June 27, 2015 filed on July 29, 2015.)**
Form of 2018 Restricted Stock Unit Agreement for time-based restricted stock unit
awards pursuant to the Henry Schein, Inc. 2015 Non-Employee Director Stock
Incentive Plan (as amended and restated effective as of June 22, 2015).
(Incorporated by reference to Exhibit 10.6 to our Quarterly Report on Form 10-Q
for the fiscal quarter ended March 31, 2018 filed on May 8, 2018.)**
Henry Schein, Inc. Supplemental Executive Retirement Plan, amended and restated
effective as of January 1, 2014. (Incorporated by reference to Exhibit 10.1 to our
Quarterly Report on Form 10-Q for the fiscal quarter ended September 28, 2013
filed on November 5, 2013.)**
Amendment Number One to the Henry Schein, Inc. Supplemental Executive
Retirement Plan, amended and restated effective as of January 1, 2014.
(Incorporated by reference to Exhibit 10.18 to our Annual Report on Form 10-K for
the fiscal year ended December 28, 2020 filed on February 20, 2020.)**
Amendment Number Two to the Henry Schein, Inc. Supplemental Executive
Retirement Plan, amended and restated effective as of January 1, 2014.
(Incorporated by reference to Exhibit 10.3 to our Quarterly Report on Form 10-Q
for the fiscal quarter ended March 28, 2020 filed on May 5, 2020.)**
Amendment Number Three to the Henry Schein, Inc. Supplemental Executive
Retirement Plan, amended and restated effective as of January 1, 2014.
(Incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q
for the fiscal quarter ended September 26, 2020 filed on November 2, 2020.)**
122
10.15
10.16
10.17
10.18
10.19
10.20
10.21
10.22
10.23
10.24
10.25
Henry Schein, Inc. 2004 Employee Stock Purchase Plan, effective as of May 25,
2004. (Incorporated by reference to Exhibit D to our definitive 2004 Proxy
Statement on Schedule 14A, filed on April 27, 2004.)**
Henry Schein, Inc. Non-Employee Director Deferred Compensation Plan, amended
and restated effective as of January 1, 2005. (Incorporated by reference to Exhibit
10.11 to our Annual Report on Form 10-K for the fiscal year ended December 27,
2008 filed on February 24, 2009.)**
Henry Schein, Inc. Deferred Compensation Plan. (Incorporated by reference to
Exhibit 10.23 to our Annual Report on Form 10-K for the fiscal year ended
December 25, 2010 filed on February 22, 2011.)**
Amendment to the Henry Schein, Inc. Deferred Compensation Plan. (Incorporated
by reference to Exhibit 10.26 to our Annual Report on Form 10-K for the fiscal
year ended December 31, 2011 filed on February 15, 2012.)**
Amendment Number Two to the Henry Schein, Inc. Deferred Compensation
Plan. (Incorporated by reference to Exhibit 10.20 to our Annual Report on Form
10-K for the fiscal year ended December 28, 2013 filed on February 11, 2014.)**
Amendment Number Three to the Henry Schein, Inc. Deferred Compensation Plan.
(Incorporated by reference to Exhibit 10.21 to our Annual Report on Form 10-K for
the fiscal year ended December 28, 2013 filed on February 11, 2014.)**
Amendment Number Four to the Henry Schein, Inc. Deferred Compensation Plan.
(Incorporated by reference to Exhibit 10.46 to our Annual Report on Form 10-K for
the fiscal year ended December 31, 2016 filed on February 21, 2017.)**
Amendment Number Five to the Henry Schein, Inc. Deferred Compensation Plan.
(Incorporated by reference to Exhibit 10.32 to our Annual Report on Form 10-K for
the fiscal year ended December 28, 2020 filed on February 20, 2020.)**
Amendment Number Six to the Henry Schein, Inc. Deferred Compensation Plan.
(Incorporated by reference to Exhibit 10.4 to our Quarterly Report on Form 10-Q
for the fiscal quarter ended March 28, 2020 filed on May 5, 2020.)**
Henry Schein Management Team Performance Incentive Plan and Plan Summary,
effective as of January 1, 2014. (Incorporated by reference to Exhibit 10.7 to our
Quarterly Report on Form 10-Q for the fiscal quarter ended March 29, 2014 filed
on May 6, 2014.)**
Form of Performance-Based RSU Award Agreement for Stanley M. Bergman
Pursuant to the Henry Schein, Inc. 2013 Stock Incentive Plan (as Amended and
Restated as of May 14, 2013). (Incorporated by reference to Exhibit 10.2 to our
Current Report on Form 8-K filed on August 9, 2019.)**
123
10.26
10.27
10.28
10.29
10.30
10.31
10.32
10.33
10.34
Amended and Restated Employment Agreement dated as of November 28, 2022,
by and between Henry Schein, Inc. and Stanley M. Bergman. (Incorporated by
reference to Exhibit 10.1 to our Current Report on Form 8-K filed on November
29, 2022.)**
Letter Agreement dated November 11, 2021 between Henry Schein, Inc. and Brad
Connett.**+
Agreement dated November 11, 2021 between Henry Schein, Inc. and Brad
Connett.**+
Special Incentive Plan dated May 24, 2021 between Henry Schein, Inc. and Brad
Connett.**#+
Form of Amended and Restated Change in Control Agreement dated December 12,
2008 between us and certain executive officers who are a party thereto (James
Breslawski, Michael S. Ettinger, Mark Mlotek and Steven Paladino, respectively).
(Incorporated by reference to Exhibit 10.15 to our Annual Report on Form 10-K for
the fiscal year ended December 27, 2008 filed on February 24, 2009.)**
Form of Amendment to Amended and Restated Change in Control Agreement
effective January 1, 2012 between us and certain executive officers who are a party
thereto (James Breslawski, Michael S. Ettinger, Mark Mlotek and Steven Paladino,
respectively). (Incorporated by reference to Exhibit 10.1 to our Current Report on
Form 8-K filed on January 20, 2012.)**
Form of Change in Control Agreement between us and certain executive officers
who are a party thereto (Walter Siegel). (Incorporated by reference to Exhibit 10.3
to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 30, 2019
filed on May 7, 2019.)**
Henry Schein, Inc. Executive Change in Control Plan, effective as of May 2, 2022
between us and certain executive officers who are a party thereto (Ronald N. South,
Brad Connett, David Brous, and Lorelei McGlynn). (Incorporated by reference to
Exhibit 10.3 to our Quarterly Report on Form 10-Q for the fiscal quarter ended
March 26, 2022 filed on May 3, 2022.)**
Form of Indemnification Agreement between us and certain directors and executive
officers who are a party thereto (Mohamed Ali, Deborah Derby, Joseph L. Herring,
Kurt P. Kuehn, Philip A. Laskawy, Anne H. Margulies, Steven Paladino, Carol
Raphael, Scott P. Serota, Bradley T. Sheares, Ph.D., Reed V. Tuckson, M.D.,
FACP, Stanley M. Bergman, James P. Breslawski, David Brous, Brad Connett,
Michael S. Ettinger, Lorelei McGlynn, Mark E. Mlotek, Walter Siegel and Ronald
N. South, respectively). (Incorporated by reference to Exhibit 10.1 to our Quarterly
Report on Form 10-Q for the fiscal quarter ended September 26, 2015 filed on
November 4, 2015.)**
124
10.35
10.36
10.37
10.38
10.39
10.40
10.41
Amended and Restated Revolving Credit Agreement, dated as of August 20, 2021,
among us, the several lenders parties thereto, and JPMorgan Chase Bank, N.A., as
administrative agent. (Incorporated by reference to Exhibit 10.1 to our Current
Report on Form 8-K filed on August 23, 2021.)
Receivables Purchase Agreement, dated as of April 17, 2013, by and among us, as
servicer, HSFR, Inc., as seller, The Bank of Tokyo-Mitsubishi UFJ, Ltd., as agent
and the various purchaser groups from time to time party thereto. (Incorporated by
reference to Exhibit 10.1 to our Current Report on Form 8-K filed on April 19,
2013.)
Amendment No. 1 dated as of September 22, 2014 to the Receivables Purchase
Agreement, dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc.,
as seller, The Bank of Tokyo-Mitsubishi UFJ, LTD., New York Branch, as agent
and the various purchaser groups from time to time party thereto. (Incorporated by
reference to Exhibit 10.2 to our Current Report on Form 8-K filed on September
26, 2014.)
Amendment No. 2 dated as of April 17, 2015 to Receivables Purchase Agreement,
dated as of April 17, 2013, by and among us, as performance guarantor, HSFR,
Inc., as seller, The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as
agent and the various purchaser groups party thereto. (Incorporated by reference to
Exhibit 10.1 to our Quarterly Report on Form 10-Q for the fiscal quarter ended
June 25, 2016 filed on August 4, 2016.)
Amendment No. 3 dated as of June 1, 2016 to Receivables Purchase Agreement,
dated as of April 17, 2013, by and among us, as performance guarantor, HSFR,
Inc., as seller, The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as
agent and the various purchaser groups party thereto. (Incorporated by reference to
Exhibit 10.2 to our Quarterly Report on Form 10-Q for the fiscal quarter ended
June 25, 2016 filed on August 4, 2016.)
Amendment No. 4 dated as of July 6, 2017 to Receivables Purchase Agreement,
dated as of April 17, 2013, by and among us, as performance guarantor, HSFR,
Inc., as seller, The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as
agent and the various purchaser groups party thereto. (Incorporated by reference to
Exhibit 10.1 to our Quarterly Report on Form 10-Q for the fiscal quarter ended
September 30, 2017 filed on November 6, 2017.)
Amendment No. 5 dated as of May 13, 2019 to Receivables Purchase Agreement,
dated as of April 17, 2013, by and among us, as performance guarantor, HSFR,
Inc., as seller, The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as
agent and the various purchaser groups party thereto. (Incorporated by reference to
Exhibit 10.1 to our Quarterly Report on Form 10-Q for the fiscal quarter ended
June 29, 2019 filed on August 6, 2019.)
125
10.42
10.43
10.44
10.45
10.46
10.47
Limited Waiver dated as of May 22, 2020 to Receivables Purchase Agreement,
dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc., as seller,
lender, as agent and the various purchaser groups from time to time party thereto,
as amended. (Incorporated by reference to Exhibit 10.7 to our Quarterly Report on
Form 10-Q for the fiscal quarter ended June 27, 2020 filed on August 4, 2020.)
Amendment No. 6 dated as of June 22, 2020 to the Receivables Purchase
Agreement, dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc.,
as seller, lender, as agent and the various purchaser groups from time to time party
thereto. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form
8-K filed on June 25, 2020.)
Amendment No. 7 dated as of October 20, 2021 to Receivables Purchase
Agreement, dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc.,
as seller, lender, as agent and the various purchaser groups from time to time party
thereto. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form
8-K filed on October 21, 2021.)
Amendment No. 8 dated as of December 15, 2022 to Receivables Purchase
Agreement, dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc.,
as seller, lender, as agent and the various purchaser groups from time to time party
thereto.*+
Omnibus Amendment No. 1, dated July 22, 2013, to Receivables Purchase
Agreement dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc., as
seller, The Bank of Tokyo-Mitsubishi UFJ, Ltd., as agent, and the various
purchaser groups from time to time party thereto and Receivables Sales Agreement,
dated as of April 17, 2013, by and among us, certain of our wholly-owned
subsidiaries and HSFR, Inc., as buyer. (Incorporated by reference to Exhibit 10.5
to our Quarterly Report on Form 10-Q for the fiscal quarter ended June 29, 2013
filed on August 6, 2013.)
Omnibus Amendment No. 2, dated April 21, 2014, to Receivables Purchase
Agreement dated as of April 17, 2013, as amended, by and among us, as servicer,
HSFR, Inc., as seller, The Bank of Tokyo-Mitsubishi UFJ, Ltd., as agent, and the
various purchaser groups from time to time party thereto and Receivables Sales
Agreement, dated as of April 17, 2013, by and among us, certain of our wholly-
owned subsidiaries and HSFR, Inc., as buyer. (Incorporated by reference to Exhibit
10.8 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 29,
2014 filed on May 6, 2014.)
10.48
Receivables Sale Agreement, dated as of April 17, 2013, by and among us, certain
of our wholly-owned subsidiaries and HSFR, Inc., as buyer. (Incorporated by
reference to Exhibit 10.2 to our Current Report on Form 8-K filed on April 19,
2013.)
21.1
List of our Subsidiaries.+
23.1
Consent of BDO USA, LLP.+
126
31.1
31.2
32.1
Certification of our Chief Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.+
Certification of our Chief Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.+
Certification of our Chief Executive Officer and Chief Financial Officer pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002.+
101.INS
Inline XBRL Instance Document - the instance document does not
appear in the Interactive Data File because its XBRL tags are embedded
within the Inline XBRL document.+
Inline XBRL Taxonomy Extension Schema Document+
101.SCH
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document+
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document+
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document+
101.PRE
104
Inline XBRL Taxonomy Extension Presentation Linkbase Document+
The cover page of Henry Schein, Inc.’s Annual Report on Form 10-K
for the year ended December 31, 2022, formatted in Inline XBRL
(included within Exhibit 101 attachments).+
_________
+ Filed or furnished herewith.
* Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company
hereby agrees to furnish supplementally a copy of any of the omitted schedules and exhibits upon request
by the U.S. Securities and Exchange Commission.
** Indicates management contract or compensatory plan or agreement.
# Certain identified information has been excluded from the exhibit because it is both not material and is
the type that the registrant treats as private or confidential.
ITEM 16. Form 10-K Summary
None.
127
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SIGNATURES
Henry Schein, Inc.
By: /s/ STANLEY M. BERGMAN
Stanley M. Bergman
Chairman and Chief Executive Officer
February 21, 2023
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the
following persons on behalf of the Registrant and in the capacities and on the dates indicated.
Signature
Capacity
/s/ STANLEY M. BERGMAN
Stanley M. Bergman
Chairman, Chief Executive Officer
and Director (principal executive officer)
Senior Vice President, Chief Financial Officer
(principal financial and accounting officer)
Vice Chairman, President and Director
February 21, 2023
Date
February 21, 2023
February 21, 2023
February 21, 2023
February 21, 2023
February 21, 2023
February 21, 2023
February 21, 2023
February 21, 2023
February 21, 2023
February 21, 2023
February 21, 2023
February 21, 2023
February 21, 2023
February 21, 2023
/s/ RONALD N. SOUTH
Ronald N. South
/s/ JAMES P. BRESLAWSKI
James P. Breslawski
/s/ MARK E. MLOTEK
Mark E. Mlotek
/s/ MOHAMAD ALI
Mohamad Ali
/s/ DEBORAH DERBY
Deborah Derby
/s/ JOSEPH L. HERRING
Joseph L. Herring
/s/ KURT P. KUEHN
Kurt P. Kuehn
/s/ PHILIP A. LASKAWY
Philip A. Laskawy
/s/ ANNE H. MARGULIES
Anne H. Margulies
/s/ STEVEN PALADINO
Steven Paladino
/s/ CAROL RAPHAEL
Carol Raphael
/s/ SCOTT SEROTA
Scott Serota
/s/ BRADLEY T. SHEARES, PH. D.
Bradley T. Sheares, Ph. D.
Director
Director
Director
Director
Director
Director
Director
Director
Director
Director
Director
/s/ REED V. TUCKSON, M.D., FACP
Reed V. Tuckson, M.D., FACP
Director
128
FOLLOW HENRY SCHEIN ON
Facebook: http://www.facebook.com/henryschein
Twitter: http://twitter.com/henryschein
Instagram: http://instagram.com/henryschein
LinkedIn: http://www.linkedin.com/company/henry-schein
You Tube: http://www.youtube.com/user/henryscheininc
Henry Schein, Inc.
135 Duryea Road
Melville, New York 11747
U.S.A.
(631) 843-5500
www.henryschein.com
12
23KS6549